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Congenital heart disease is the most common congenital anomaly, affecting 
approximately 1% of all live births each year. Although clinical interventions are 
improving, many affected infants do not survive to adulthood. Congenital cardiac 
defects originate from disturbances during development, making the study of 
mammalian cardiogenesis critical to improving outcomes for infants with 
congenital heart disease. Development of the mammalian heart involves 
epigenetically-driven specification and commitment of a diverse landscape of 
cardiac progenitors. Recent studies determined that chromatin modifying enzymes 
play a previously underappreciated role in the pathogenesis of congenital heart 
defects. This thesis investigates the functions of Hdac1 and Hdac2, highly 
homologous Class I histone deacetylases, during early murine cardiac 
development. We establish that Hdac1 and Hdac2 cooperatively regulate 
cardiogenesis in the first heart field, the second heart field, and the cardiac neural 
crest. Genetic ablation of both Hdac1 and Hdac2 within first heart field progenitors 
antagonizes a critical cardiometabolic transition causing thinned compact 
myocardium, contractile network fragmentation, reduced mitochondrial mass, and 
cytosolic lipid accumulation. In first heart field progenitors, Hdac1 and Hdac2 
redundantly facilitate expression of oxidative metabolic gene programs by 
enforcing chromatin homeostasis and suppressing non-productive mRNA 




early in embryogenesis owing to progenitor depletion. Interestingly, a single allele 
of Hdac1 or Hdac2 rescues this defect but exposes a role for Hdac1 and Hdac2 in 
outflow tract septation. Mice with a single allele of Hdac1 or Hdac2 in the posterior 
second heart field die shortly after birth owing to persistent truncus arteriosus, 
interrupted aortic arch, and ventricular septal defect. Normally, Hdac1 and Hdac2 
cooperatively facilitate receptivity of the second heart field to critical signaling 
pathways. Disruption of Hdac1/Hdac2 results in a shortened outflow tract early in 
development, eventually leading to persistent truncus arteriosus at birth. Deletion 
of both Hdac1 and Hdac2 in neural crest progenitor cells reduces proliferation, 
increases apoptosis, and disrupts patterning of the embryonic pharyngeal 
vasculature, leading to mid-gestation lethality. Reintroduction of a single allele of 
either Hdac1 or Hdac2 sustains embryos to birth, however they shortly succumb 
to currently unknown defects. Together, our findings demonstrate that Hdac1 and 
Hdac2 are critical mediators of the earliest stages of mammalian cardiogenesis 
through a variety of spatiotemporally specific, redundant, and dose-sensitive roles 
and indicate they may play important roles in the pathogenesis of human 
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CHAPTER I – Introduction 
 
Congenital Heart Disease – Incidence and Impact 
 
Congenital heart disease is defined as a defect in the structure or function 
of the heart, present at birth[1, 2]. Each year, approximately 40,000 infants are born 
with congenital heart disease in the United States[3, 4]. This constitutes almost 1% 
of all live births, making congenital heart disease the most common congenital 
anomaly[4, 5]. Unfortunately, congenital heart disease is one of the largest causes 
of childhood mortality, with the majority of deaths occurring in the first 28 days of 
life[6]. Roughly 25% of infants born with heart defects are clinically classified as 
“critical” congenital heart disease and require clinical intervention within the first 
year of life[7]. Prognosis for children with critical defects is poor, with approximately 
69% surviving to adulthood[7]. In contrast, 97% of children born with non-critical 
defects live to adulthood, although they also face a shortened life expectancy, as 
the median age of death for an adult with a congenital cardiac anomaly is just 48.8 
years[7, 8]. Although cardiac defects are the most common congenital abnormalities 
at birth, they are even more common in embryonic populations and account for a 
significant fraction of preterm fetal loss[9-12]. 
The incidence of congenital heart disease does not vary with parental age, 
socioeconomic status, country of birth, or most other parental factors (beyond 




perturbations of normal developmental processes secondary to genetic, 
epigenetic, or environmental insult[11, 12]. Thus, prevalence and burden are 
increased in populations with high fertility rates[13]. Oftentimes countries with high 
fertility rates also have low incomes per capita, making the increased prevalence 
of congenital heart disease in these situations a serious societal burden and 
increasing health inequality[13]. While survival and clinical care for patients with 
congenital heart disease are improving, continued progress and improved clinical 
outcomes rely on understanding the origins of heart defects during cardiogenesis. 
Figure 1.1 – Adult Cardiac Anatomy. External (a) and internal (b) adult human 
cardiac (anterior aspect). Blood returns from the caval veins to the right atrium 
(RA), through the tricuspid valve, and into the right ventricle (RV). The RV pumps 
blood through the pulmonary valve into the pulmonary artery, lungs, and into the 
left atrium (LA). From the LA, blood enters the left ventricle (LV), via the mitral 
valve, where it is pumped through the aortic valve, into the aorta, and on to the 
systemic circulation. The sinoatrial node, atrioventricular node (AVN), and bundle 
branches/Purkinje fibers distribute contractile impulses. Chordae tendinea (CT) 
connect papillary muscles to tricuspid/mitral valves. R, right; L, left; Cr, cranial; Ca, 
caudal. This figure was originally published in Harvey, Richard P. 2002. “Patterning 
the Vertebrate Heart.” Nature Reviews. Genetics 3 (7): 544–56 and is adapted 




Cardiovascular Anatomy and Evolution 
 
The Vertebrate Heart 
 Although complexity and specific anatomy varies, all vertebrate organisms 
have a circulatory system that transports fluid through the body for the purpose of 
oxygenation and nutrient exchange[14-16]. Driving this system is the heart, a 
muscularized vessel that provides the mechanical force required to drive fluid 
through the circulatory system[17]. While smaller invertebrate organisms have a 
simple, linear, vessel-like tubular heart, vertebrates have a more complex, 
muscular, multi-chambered heart[18]. 
Zebrafish, a common model organism for vascular development, have a 
two-chambered heart (one atrium, one ventricle) that circulates blood to the gills 
for oxygenation, and then to the body for oxygen, nutrient, and waste exchange[19]. 
Amphibians have a three-chambered heart composed of a right and left atrium 
connected to a common ventricle[20]. Blood from the lungs and systemic circulation 
feed into separate atria before mixing in the common ventricle. The ventricle sends 
blood to the lungs, via the pulmonary arteries, and systemic circulation, through 
paired aortic arches. Incomplete partitioning of the pulmonary and systemic 
circulation results in mixing of oxygenated and deoxygenated blood and perfusion 






The Mammalian Heart 
In contrast, the mammalian heart partitions the oxygen-poor pulmonary and 
oxygen-rich systemic circulations (Figure 1.1)[14]. Deoxygenated blood from the 
systemic venous circulation returns to the right atrium through the inferior and 
superior vena cava. From there, blood passes through the tricuspid valve into the 
right ventricle where it is pumped through the pulmonic valve into the pulmonary 
artery and on to the lungs. Oxygen and carbon dioxide are exchanged within the 
lungs and oxygen-saturated blood returns, via the pulmonary veins, to the left 
atrium. Left atrial blood passes through the mitral valve into the left ventricle, the 
strongest pumping chamber of the heart, which propels oxygenated blood through 
the aortic valve, into the aortic root, and on to the systemic circulation. Complete 
segregation of oxygenated and deoxygenated blood ensures efficient systemic 
oxygenation and maximal pulmonary gas exchange. While all mammalian hearts 
share this basic architecture, subtle differences exist between different species in 
this taxonomic class. Unlike their human counterparts, mice possess bilateral vena 
cava, slightly different atrial appendages, and single pulmonary veins carrying 
oxygenated blood from the lung to the left atrium[21, 22]. Despite this, murine and 
human cardiac anatomy, function, and development are strikingly similar. 
Consequently, murine hearts are frequently used as a model to study human 
cardiac pathology and cardiac development[23]. 
The mammalian heart contains cardiomyocytes, cardiac conduction cells, 




cells[24, 25]. Cardiomyocytes, specialized heart muscle, are the most abundant cell 
type in the heart, constituting upwards of 30% of all cells and occupying over 70% 
of total cardiac area[26-30]. Each cardiomyocyte contains myofibrils, a contractile 
organelle made up of interconnected sarcomeres, which generate the mechanical 
force required to circulate blood[14]. Cardiomyocytes are packed with mitochondria, 
occupying upwards of 25% of their cytoplasm, which generate ATP primarily via 
fatty acid beta-oxidation to sustain the hearts vital pumping action[31]. Although the 
heart constitutes under 1% of total body weight, it consumes approximately 8% of 
all ATP produced every day, making it one of the most energy intensive organs[32]. 
In order to maximize space for contractile myofibrils, the heart is incapable of 
storing energy instead dynamically matching energy production to energy 
consumption[33]. Consequently, disruptions of energy production, by genetic or 
ischemic insult, have devastating effects on cardiac function. 
Cardiomyocytes are electrically coupled through intercellular gap junctions 
to facilitate coordinated contraction and proper blood flow[14]. Cardiac contraction 
is initiated by specialized cardiomyocytes at the atrioventricular (AV) and sinoatrial 
(SA) nodes that direct contraction of the atria and ventricles, respectively. The 
electrical signals generated at these nodes are distributed through the His-Purkinje 
conduction system. Disruption of this network is seen in congenital conditions such 
as Wolf Parkinson White and in acquired pathologies like atrial fibrillation[34, 35]. 
Endothelial cells, including the specialized endocardium which lines the heart 




Pathologies involving the endocardium primarily include infective endocarditis[37]. 
Remaining cell types include hematopoietic cells, cardiac fibroblasts, and 
perivascular cells. Although there is physiology and pathology affecting these cells, 
they do not commonly contribute to congenital heart disease and will not be 







Figure 1.2 – Structural Events in Mammalian Cardiac Development. (a) 
Overall embryo morphology at E7.75 with the cardiac crescent (red) at the midline 
of the developing embryo. (b) Representative transverse section of E7.75 embryos 
depicting bilateral pools of heart progenitors (red) on the ventral surface of the 
embryo. (c) Overall embryo morphology at E8.25 with the newly formed primitive 
heart tube (red) at the midline of the ventral face of the developing mammalian 
embryo. (d) Representative E8.25 transverse section showing bi-layered 
(myocardium, endocardium) primitive heart tube tethered posteriorly to the dorsal 
pericardial mesoderm. (e) Primitive heart tube morphology during looping, at 
E10.5. (f) Representative frontal section showing the primitive right and left 
ventricle (divided by a nascent interventricular septum), endocardial cushions (EC) 
that will form the valves of the mammalian heart, common atrium, and outflow tract 
in addition to contributing to septation of the outflow tract into the aorta and 
pulmonary artery. Primitive trabeculae (T) begin forming at this stage. (g) 
Remodeling heart anatomy at E12.5 as the heart loops, rotates, and septates to 
achieve its final four chamber anatomy (RA, right atrium; LA, left atrium; RV, right 
ventricle; LV, left ventricle). Primitive chambers are divided by immature valve-like 
structures derived from the endocardial cushion (EC). Murine developmental times 
are used for reference in this figure. This figure was originally published in Harvey, 
Richard P. 2002. “Patterning the Vertebrate Heart.” Nature Reviews. Genetics 3 









Mammalian Cardiac Development 
 
Congenital heart defects arise from perturbations of normal cardiac 
development[11, 38-42]. Thus, to diagnose and treat congenital defects in patients, it 
is important to understand normal mammalian cardiogenesis. The mammalian 
heart is the first embryonic organ to form during development and from its inception 
pumps continually to circulate oxygen and nutrients throughout the developing 
embryo (Figure 1.2)[16]. Broadly, cardiac development begins with the specification 
of the cardiogenic mesoderm, a major pool of cardiac progenitors arising from 
gastrulation between day 18-19 in humans and embryonic day 6.5 (E6.5) in the 
mouse[16, 43-45]. Shortly thereafter (~E7.5 in the mouse and day 20 in humans), the 
first identifiable cardiac structure, the cardiac crescent, is formed[46]. The cardiac 
crescent fuses at the midline of the embryo around day 21-22 (~E8.0 in mice), 
forming a thin, linear, heart tube that extends off the ventral surface of the 
embryo[47-49]. Once closed, the primitive heart tube begins contracting, circulating 
blood through the forming embryonic vasculature. Over the next several weeks 
(approximately one week in mice), the primitive heart tube undergoes outflow tract 
elongation, rightward looping, and alignment of the outflow and inflow tracts 
(Figure 1.3)[16]. Once aligned, septation creates four distinct chambers, two 
independent inlets, and two partitioned outlets. In humans, the heart is mostly 
developed by the 9th week of development (E14.5 in mice), however the pulmonary 




ductus arteriosus shortly after birth[50]. In parallel, cellular and functional maturation 
of the developing heart also occurs[51]. Disruption of cardiac physiology at any of 
these developmental stages can cause defective cardiogenesis, resulting in 
congenital heart disease or preterm fetal loss. 
 
Outflow Tract Development 
Outflow tract development is a complex process particularly susceptible to 
disruption, with approximately one third of all congenital cardiac defects involving 
the outflow tract[52]. Here we will discuss the generation of a mature outflow tract 
while outflow tract pathologies will be discussed later. Anatomically, the outflow 
tract is divided into the aorta and pulmonary artery. The aorta arises posteriorly 
from the left ventricle, coursing over the pulmonary artery, transitioning into the 
aortic arch, and descending into the body as the thoracic aorta. Vessels supplying 
the upper limbs, neck, and head branch from the aortic arch as it passes over the 
pulmonary artery. The pulmonary artery arises anteriorly from the right ventricle 
before passing posteriorly, bifurcating into right and left segments and supplying 
blood to the lungs. This complex anatomy ensures partitioning of oxygen-rich 
systemic circulation and oxygen-depleted pulmonary vasculature. 
The mammalian heart first arises as a linear tube with a common outflow 
termed the truncus arteriosus (Figure 1.3, 1.4)[53, 54]. At distal end of the primitive 
heart tube, the truncus arteriosus interfaces with the aortic sac, a vascular 




(Figure 1.3, 1.4)[55, 56]. The pharyngeal arch arteries and aortic sac eventually 
remodel to form the distal portion of the aortic arch and most proximal arterial 
vessels supplying the head, neck, and upper limbs[57]. Developmentally, the aorta 
and pulmonary artery arise from septation of the truncus arteriosus, between E9.5 
and E14.5 in the mouse[56, 58-61]. 
At E9.5, the outflow tract elongates, facilitating rotation and looping of the 
primitive heart tube. While this occurs, two pairs of acellular swellings, termed 
endocardial cushions, arise within the lumen of the truncus arteriosus[56, 62]. An 
influx of cells colonizes these endocardial cushions between E9.5 and E10.5[62-64]. 
The proximal pair of cushions, the valvular endocardial cushions, eventually form 
the semilunar valves (aortic and pulmonary valves) while the distal endocardial 
cushions facilitate outflow tract septation[61]. Septation begins when the distal 
endocardial cushions elongate towards the junction of the truncus arteriosus and 
aortic sac[50]. Once elongated, around E11.5, distal fusion occurs. Fusion proceeds 
proximally, leaving in its wake a spiral septum dividing the truncus arteriosus[54, 58]. 
In parallel, the aorticopulmonary septum bifurcates the aortic sac, joining with the 
distal endocardial septum[58]. The now separate aorta and pulmonary artery finally 
undergo rotation, remodeling, and maturation to form the partitioned mammalian 
outflow tract. The pulmonary circulation sees relatively little perfusion until after 
birth, owing to high pulmonary vasculature resistance[65]. Instead, blood leaving 
the right ventricle passes through the ductus arteriosus into the aorta and on to the 




birth, the ductus arteriosus to close, eventually forming the ligamentum arteriosum 
between the aortic arch and pulmonary artery[66]. 
 
Development of Cardiac Function 
Concomitant with structural aspects of mammalian cardiogenesis, cells 
populating the embryonic heart undergo functional and metabolic maturation. 
Initially, the primitive heart tube is populated by immature cardiomyocytes and 
endocardium[59]. As development progresses, cellular complexity increases with 
the heart eventually containing precursors of all mature cardiac lineages. As the 
embryos grows, immature cardiomyocytes develop contractile and metabolic 
infrastructure to meet increasing demand[67]. Initially, cardiomyocytes of the 
primitive heart tube sustain contraction with anaerobic, glycolytic energy 
production[68-72]. Mature cardiomyocytes subsist primarily on fatty acid beta-
oxidation, an aerobic process requiring competent mitochondrial enzymes and a 
fully functional electron transport chain[70, 72, 73]. 
The switch from anaerobic metabolism was originally postulated to occur 
sharply at birth when the neonate is thrust into an oxygen-rich environment[74]. 
However, more recent studies demonstrated this switch occurs gradually[68, 69, 75]. 
Studies of human fetal cardiac tissue indicate that between early embryonic 
development and mid embryonic development there is a doubling of contractile 
and metabolic gene program expression[75]. This is mirrored by another doubling 




mitochondrial permeability transition pore (mPTP) is open, preventing the 
development of an electrochemical gradient and oxidative metabolism[76]. Shortly 
thereafter, at E11.5, the mPTP is closed and cardiomyocytes are producing energy 
via oxidative phosphorylation[77]. This study found that at E10.5 mitochondrial 
metabolism was coupled in some samples and uncoupled in others, positioning 
E10.5 as a critical checkpoint of metabolic maturity. Consistent with this, disruption 
of embryonic oxidative metabolism in murine models consistently cause lethality 
around this time point[78-82]. Importantly, there is an emerging link between 
cardiomyocyte metabolic maturity and contractile development. Specifically, 
murine models suggest closure of the mPTP is necessary and sufficient to drive 
cardiomyocyte differentiation[76]. Overall, these results inexorably link functional 
and metabolic cardiac maturation. Importantly, disruption of cardiac development 
at any of these structural or functional stages can cause defective cardiogenesis, 










Figure 1.3 – Mammalian Cardiac Progenitor Populations. (A) Schematic 
showing the relative positions of the first heart field (red) and second heart field 
(blue). The first heart field forms the majority of the primitive heart tube at E8.25 
which is subsequently lengthened by addition of second heart field progenitor cells 
to the arterial and venous poles of the heart. (B) Spatiotemporal events in 
mammalian cardiogenesis depicting interaction between cardiac progenitor 
populations. The cardiogenic mesoderm (yellow) arises within the posterior streak 
at E6.5, eventually forming the cardiac crescent at E7.5. The cardiac crescent 
contains the first heart field (orange) and second heart field (blue). Between E7.5 
to E8.5 the cardiac crescent fuses at the midline to form the primitive heart tube. 
First heart field progenitors form the bulk of the primitive ventricle at E8.5 and will 
go on to form the left ventricle while the second heart field forms the outflow tract 
and right ventricle. Around E9.5 cardiac neural crest cells migrate and contribute 
to the elongation and septation of the developing outflow tract. (C) Network 
depicting the clonal and molecular interrelationship between various cardiac 
progenitor populations and their end cardiac derivatives. Mesp1 expression marks 
the cardiogenic mesoderm while Nkx2.5 expression delineates first heart field 
cells. Isl1 expression is found in second heart field while Mef2C expression is 
restricted to anterior division of the second heart field. Critical signaling pathways, 
including Wnt signaling, FGF signaling, and BMP signaling all contribute to 
mammalian cardiogenesis. Non-canonical Wnt signaling promotes differentiation 
of the cardiogenic mesoderm, while Wnt/β-Catenin signaling antagonizes 
differentiation. BMP signaling drives specification of the first heart field while the 
cooperative efforts of FGF and Wnt/β-Catenin promote second heart field 
specification. Cr, cranial; Ca, caudal; R, right; L, left; ICM, inner cell mass; PS, 
primitive streak; CM, cardiogenic mesoderm; FHF, first heart field; SHF, second 
heart field; ML, midline; OFT, outflow tract; PHT, primitive heart tube; PM, posterior 
mesoderm; VP, venous poles; CNCCs, cardiac neural crest cells; PEO, 
proepicardial organ; SVC, superior vena cava; IVC, inferior vena cava; AO, aorta; 
PT, pulmonary trunk; RA, right atrium; LA, left atrium; RV, right ventricle; LV, left 
ventricle; EPC, epicardium. (A) was originally published in “Harvey, Richard P. 
2002. “Patterning the Vertebrate Heart.” Nature Reviews. Genetics 3 (7): 544–56.” 
and is reproduced here with permission. (B-C) were originally published in “Später, 
Daniela, Emil M. Hansson, Lior Zangi, and Kenneth R. Chien. 2014. “How to Make 







Mammalian Cardiac Development - Cardiac Progenitor Populations 
 
 Like all organs, the mammalian heart contains many different cell types with 
separate functions and clonal origins (Figure 1.3). Throughout development, 
several cardiac progenitor populations cooperate to form the mature heart and the 
various end cardiac lineages it requires[51]. The earliest structure containing cells 
destined for cardiac specification is the cardiogenic mesoderm (Figure 1.3)[46]. 
Marked by Mesoderm Posterior BHLH Transcription Factor 3 (MESP1) expression, 
the cardiogenic mesoderm arises from the anterior edge of the primitive streak 
during gastrulation, around E6.5 in mouse development[47, 83-87]. Subsequently, the 
cardiogenic mesoderm migrates bilaterally under the head folds before fusing at 
the midline[88-91]. It was originally thought that the cardiac crescent contained a 
single clonal population termed the first heart field, however this was refuted with 
the identification of an independent, second heart field that independently 
contributes to the developing heart[92-95]. Now we understand there are two distinct 
progenitor pools in the cardiac crescent: the first heart field, marked by NK2 
Homeobox 5 (NKX2-5 or NKX2.5) expression, and the second heart field, marked 
by expression of insulin gene enhancer protein ISL-1 (ISL1)[87, 96-98]. 
Several other progenitor pools contribute to mammalian cardiogenesis 
including the cardiac neural crest (identified by expression of Wnt family member 
1 [WNT1]), proepicardium (expressing Wilms tumor 1 [WT1]), and vascular 




Here I will discuss how some of the major progenitor populations, primarily the first 
heart field, the second heart field (and its two sub-division), and the cardiac neural 
crest, contribute to heart development as they are most often involved in congenital 
defects. 
 
The First Heart Field 
The first heart field was one of the first observed cardiac progenitor 
populations. Identified by expression of myocardial transcription factors and 
markers including NKX2-5, GATA binding protein 4 (GATA4), and T-box 
transcription factor 5 (TBX5), this population occupies the anterior portion of the 
cardiac crescent at E7.5 (Figure 1.3B-C)[97, 101-104]. At E8.5, first heart field 
progenitors coalesce at the midline of the embryo and detach from the dorsal 
pericardial wall, forming the primitive heart tube. First heart field derivatives form 
most left ventricular cardiomyocytes, minor portions of the atrial muscle, and some 
of the cardiac conduction system[105, 106]. Additionally, the first heart field makes 
minor contributions to smooth muscle and endothelial lineages. Broadly, first heart 
field differentiation and specification are positively regulated by bone 
morphogenetic protein (BMP) and fibroblast growth factor (FGF) signaling while 
negatively regulated by wingless/integrated (WNT) signaling from the adjacent 
dorsal neural tube[86, 107-113]. 
Mirroring its heavy contribution to the left ventricle, pathologies involving the 




resulting from first heart field dysfunction invariably result in embryonic lethality 
and are not observed in human populations[10]. Less severe defects include 
disruptions in left ventricular myocardium (hypoplastic left heart syndrome, 
congenital cardiomyopathy, left ventricular noncompaction) or failure to establish 
a distinct left ventricle (ventricular septal defect)[12, 115-120]. 
Molecularly, numerous transcription factors and co-factors regulate first 
heart field morphogenesis in both mice and humans[59, 102, 121-126]. In mice, 
expression of the prototypical first heart field marker Nkx2.5 is required for cardiac 
morphogenesis, with inactivation of Nkx2.5 causing a breakdown of ventricular 
morphology and embryonic lethality[127-129]. Reinforcing its role as a modulator of 
mammalian cardiogenesis, mutations in NKX2.5 have been identified in human 
congenital heart disease, with murine haploinsufficiency of Nkx2-5 phenocopying 
these defects[130-132]. In murine models, disruption of Gata4 leads to abnormal, 
bilateral heart tubes (cardia bifidia), while in humans GATA4 mutations are 
associated with numerous congenital cardiac defects[133, 134]. Additionally, 
disruption of other first heart field markers (including Tbx5, Hand1, and Tbx20) 
lead to developmental cardiac defects in mice and are associated with congenital 
heart disease in humans[135-140]. Together, these results establish both the critical 
role of the first heart field during mammalian cardiogenesis and the remarkable 





The Second Heart Field 
The second heart field, first described in 2001, occupies the posterior 
portion of the cardiac crescent and is canonically marked by expression of ISL1[93, 
98, 141-143]. Since the identification of this second progenitor pool there has been 
much debate about the clonal origins and relationship between the first and second 
heart fields[92, 144, 145]. Early theories postulated that second heart field progenitors 
were derived from the first heart field shortly after they populate the cardiac 
crescent, however further investigation revealed that the second heart field is an 
independent population which arises in parallel from the cardiogenic mesoderm[43, 
95, 146]. 
Relative to the first heart field, the second heart field’s contributions to 
cardiogenesis are delayed[147]. From its position in the pharyngeal mesoderm and 
dorsal pericardial wall, second heart field progenitors maintain continuity at the 
arterial and venous poles as the primitive heart tube delaminates ventrally. 
Progenitors from the dorsal pericardial wall and pharyngeal mesoderm are 
progressively added to both poles of the developing heart, growing the heart tube, 
enabling rightward looping, and facilitating outflow tract septation (Figure 1.4). As 
their contributions suggest, second heart field progenitors are responsible for 
forming the right ventricle, most of the atria, and the intracardiac (subpulmonary) 
outflow tract. Specific ablation of the second heart field leads to severe outflow 
tract defects similar to tetralogy of Fallot, reinforcing the critical contributions that 




second heart field differentiates into cardiomyocytes, endocardial cells, and 
vascular smooth muscle[149]. 
 Addition of second heart field progenitor cells to the primitive heart tube is 
a gradual and highly controlled process requiring a balance of proliferation and 
differentiation. To achieve this control, the second heart field is divided into an 
anterior portion, expressing myocardial factors including myocyte enhancer factor 
2C (MEF2C) and fibroblast growth factor 10 (FGF10), and a posterior segment 
marked by T-box transcription factor 1 (TBX1)[59, 123, 124, 126, 143, 147, 150-152]. The 
anterior second heart field contains the cells of the developing outflow tract, the 
arterial pole, and cranial dorsal pericardial wall. The posterior segment comprises 
cardiac progenitors adjacent to the venous pole. Broadly, cardiac progenitors 
proliferate in the posterior second heart field before migrating into the anterior 
second heart field and joining the primitive heart tube[59]. As these progenitors 
migrate, they are exposed to signaling gradients, promoting specification and 








Figure 1.4 – Mammalian Outflow Tract Development. (A) Schematic showing 
cellular and structural contributions to outflow tract (OFT) septation. Two pairs of 
endocardial cushions arise in the common arterial outflow, the truncus arteriosus. 
Between E9.5 and E10.5, they are populated by a combination of second heart 
field progenitors (blue), cardiac neural crest progenitors (green), and 
mesenchymal cells via endothelial-mesenchymal transition. As development 
continues, the distal cushion fuses with its opposing proximal cushion, creating a 
putative spiral septum in the developing OFT. The two edges of this septum fuse, 
partitioning the truncus arteriosus into the pulmonary artery (PA) and aorta (AO) 
before the OFT rotates, aligning the AO over the left ventricle (LV) and PA over 
the right ventricle (RV). (B) A diagram showing the spectrum of OFT defects that 
can arise from disrupted septation, rotation, or positioning of the truncus arteriosus 
during development. Normal - the AO arising posteriorly from the LV and the PA 
arising from the RV. PTA – Persistent truncus arteriosus; There is a failure to 
properly divide the embryonic outflow tract into the AO and PA resulting in a 
common arterial outflow present at birth, often associated with a ventricular septal 
defect (VSD). DORV – double outlet RV; Due to malpositioning of the outflow tract, 
the AO and PA arise from the RV; Dependent on presence of a VSD for survival. 
TGA – transposition of the great arteries; the origin of the AO and PA are swapped. 
OA – overriding AO; The AO is inappropriately positioned over the interventricular 
septum, receiving blood flow from both the RV and LV. (C) Diagram depicting 
cardiac neural crest (blue), second heart field (red), and endothelial-mesenchymal 
transition cellular contributions to the developing outflow tract. The cardiac neural 
crest contributes primarily to the distal (truncal) cushions and putative 
aorticopulmonary septum in the aortic sac (AS). The second heart field contributes 
to the RV myocardium and the OFT. The proximal (conal) endocardial cushion is 
primarily populated by endothelial-mesenchymal transition. (B) was originally 
published in “Laugwitz, Karl-Ludwig, Alessandra Moretti, Leslie Caron, Atsushi 
Nakano, and Kenneth R. Chien. 2008. “Islet1 Cardiovascular Progenitors: A Single 
Source for Heart Lineages?” Development 135 (2): 193–205.” and are adapted 
here with permission. (C) was originally published in “Neeb, Zachary, Jacquelyn 
D. Lajiness, Esther Bolanis, and Simon J. Conway. 2013. “Cardiac Outflow Tract 
Anomalies.” Wiley Interdisciplinary Reviews: Developmental Biology 2 (4): 499–




 Molecularly, both segments of the second heart field are regulated by WNT, 
FGF, and Hedgehog signaling, among others[145, 153, 154]. Throughout the dorsal 
pericardial wall FGF signaling drives proliferation. As these cells migrate to the 
developing heart, BMP signaling from the cardiac neural crest antagonizes 
proliferative FGF signals, stimulating differentiation and functional specification. 
Consequently, neural crest ablation inhibits BMP signaling, resulting in increased 
proliferation of second heart field progenitors and a failure to differentiate into end-
cardiac lineages. Similarly, at the venous pole of the heart WNT, Hedgehog, and 
BMP signaling regulate progenitor cell contribution to the forming atria. TBX1 
expression in the posterior second heart field delays differentiation and maintains 
proliferation by suppressing serum response factor (SRF), negatively regulating 
MEF2C, and disrupting BMP signaling[124, 126, 155, 156]. Differentiation in the anterior 
heart field is driven by BMP signaling which lowers expression of ISL1 and TBX1, 
loosening their repressive hold on the second heart field and facilitating expression 
of cardiogenic transcription factors[156-158]. 
The interplay between proliferation, differentiation, and apoptosis in the 
second heart field is of particular interest in the study of congenital heart disease 
as the outflow tract, the major structure formed by the second heart field, is 
disrupted in almost one third of all cases of congenital heart disease[52]. DiGeorge 
syndrome (22q11.2 microdeletion) is characterized, in part, by outflow tract 
anomalies[159]. Interestingly, TBX1 lies in the middle of the typically deleted region, 




syndrome[126, 155, 159, 160]. Studies in mice have shown that disruption of Tbx1 
specifically within the posterior second heart field recapitulates some of the outflow 
tract abnormalities observed in patients[152, 161]. Furthermore, disruption of 
fibroblast growth factor 8 (Fgf8), another gene thought to be involved in the 
pathogenesis of DiGeorge syndrome, inhibits second heart field proliferation[154, 
162, 163]. Another important factor in balancing second heart field contributions to the 
developing outflow tract is the prototypical second heart field marker, Isl1[98, 164]. 
Loss of Isl1 reduces second heart field progenitor proliferation, resulting in a 
depletion of the progenitor pool and abnormal outflow tract morphology[98, 165, 166]. 
An emerging trend in the second heart field is that even small disturbances in 
proliferation or differentiation, morphologically presenting as a failure to properly 
elongate the primitive outflow tract, can manifest into severe outflow tract 
defects[52, 124, 167-170]. All of these observations indicate that, although relatively 
newly identified, the second heart field makes critical contributions to 
cardiogenesis with a specific emphasis on outflow tract development. 
 
The Cardiac Neural Crest 
 A final major cardiac progenitor pool is the cardiac neural crest[46, 171, 172]. 
The neural crest is a developmental structure that separates from the neural plate 
during neural tube closure, extending rostrocaudally along the dorsum of the 
embryo[173-176]. There are several distinct subdivisions of the neural crest including 




neural crest populates the third, fourth, and sixth pharyngeal arches, contributing 
to the distal portions of the outflow tract, aortic sac, and structures that will divide 
the outflow tract into the aorta and pulmonary artery (Figure 1.4)[14, 47, 182-184]. The 
cardiac neural crest arises between embryonic day 21-23 in humans (~E8.5 in 
mice) and migrates ventrally through the aortic sac to populate the outflow tract 
and pharyngeal arches between E9-E11. Induction, migration, and differentiation 
of cardiac neural crest progenitor cells relies upon BMP, FGF, Notch, retinoic acid, 
and WNT signaling[52]. Induction is defined by expression of a group of “border 
specification genes” including Msx1, Msx2, Pax3, and Zic1[52, 184-186]. These, along 
with the aforementioned signaling molecules drive expression of downstream 
neural crest transcripts including Tfpa2, Foxd3, Crabp1, Snai2, Sox10[52, 187-189]. 
While neural crest cells do not make bulk structural contributions to the developing 
heart (mainly the purview of the first and second heart fields), they play a crucial 
role in coordinating other cardiac progenitors. First and second heart field 
progenitors are responsive to neural crest derived WNT and BMP signaling[157, 190, 
191]. Due to its proximity to the neural crest, WNT signaling delays cardiac 
specification of second heart field progenitors, facilitating proper assembly of the 
developing primitive heart tube. Additionally, BMP signaling within cardiac neural 
crest progenitors residing in the pharyngeal arches drives second heart field 





 The critical function of the cardiac neural crest is best illustrated through a 
plethora of developmental studies. Through this work, the cardiac neural crest has 
been placed at the helm of outflow tract elongation, endocardial cushion formation, 
aorticopulmonary septation, and outflow tract rotation[52, 58, 188, 192-196]. Additionally, 
the cardiac neural crest cooperates with the cranial neural crest division to form 
much the embryonic and mature vasculature of the head and neck[180]. Neural crest 
progenitors form vascular components of the paired pharyngeal arch arteries 
which eventually remodel into many of the offshoots from the aortic arch. 
Delineating areas sensitive to neural crest function, diphtheria toxin mediated 
ablation of the neural crest (via Wnt1-Cre2) results in persistent truncus arteriosus, 
pharyngeal arch artery defects, and pulmonary stenosis[186]. Other studies have 
defined that the neural crest plays an important role in outflow tract alignment, 
septation, and valvular morphogenesis[172]. Molecularly, cardiac neural crest cells 
are marked by expression of transcription factor AP-2 alpha (TFAP2A), WNT1, and 
paired box gene 3 (PAX3)[57, 197, 198]. 
Disruption of neural crest function during development is implicated in an 
array of syndromes including DiGeorge syndrome (22q11.2), and the CHARGE 
syndromes[159, 160, 172, 199]. A common feature of syndromes involving neural crest 
dysfunction is cardiac outflow tract pathologies including persistent truncus 
arteriosus, double outlet right ventricle, overriding aorta, congenital vascular rings, 




crest is an important target in the effort to diagnose and treat congenital cardiac 
defects. 
 
Other Cardiac Progenitors 
 In addition to the major progenitor populations mentioned above, several 
other progenitor pools contribute to the intricate, coordinated process of 
mammalian cardiac development[46]. Among these is the proepicardium, which 
grows outward to cover the developing heart tube, and vascular progenitors that 
form the endocardium, the endothelial cell layer that forms the interfaces between 
myocardium and blood. During development, the endocardium interfaces with the 
primitive heart tube to promote myocardial proliferation, specification, and 
maturation[200]. Although they will not be extensively discussed here, these 
progenitor pools all make critical contributions to cardiogenesis and their disruption 
or dysfunction can likewise have devastating effects on development or result in 
congenital defects.  
 
Mammalian Cardiac Development - Origins of Congenital Heart Defects 
 
Congenital heart defects arise from perturbations in normal cardiac 
development[39-41]. Consequently, understanding the cellular, molecular, genetic, 
and epigenetic dynamics of cardiac progenitors in development and disease is 




valvular, outflow, metabolic, and functional pathologies. Ventricular pathologies 
encompass structural defects such as ventricular septal defects, double outlet right 
ventricle, and hypertrophic cardiomyopathy[12, 117, 201]. Valvular pathologies include 
narrowing of a valve orifice (stenosis), incomplete valve formation (atresia), or 
abnormal number of leaflets (bicuspid aortic or pulmonic valves)[202]. Outflow tract 
pathologies involve abnormal positioning (transposition of the great arteries, 
overriding aorta), incomplete separation (persistent truncus arteriosus), abnormal 
course (interrupted aortic arch), stenosis, and dilation of the aorta and pulmonary 
artery[52]. Beyond structural defects, disrupted cardiovascular metabolism and 
cardiac conduction can also result in congenital heart disease, most often 
presenting with congenital cardiomyopathy[203]. 
 Clinically, these defects often occur together as syndromes, one of the most 
severe syndromes being termed tetralogy of Fallot[114, 204, 205]. Characterized by 
right ventricular outflow obstruction, ventricular septal defects, rightward deviation 
of the aorta, and subsequent right ventricular hypertrophy, tetralogy of Fallot 
accounts for approximately 10% of all congenital heart disease and almost 
invariably requires clinical intervention within the first year of life[4, 206]. 
 Owing to the complex, interconnected nature of mammalian heart 
development, even small genetic and epigenetic perturbations can result in cardiac 
defects. There is a long list of autosomal dominant single gene disorders with 
cardiac involvement, including CHARGE syndrome (CHD7)[199], Treacher Collins 




and Holt-Oram syndrome (TBX5)[102, 122], indicating how sensitive cardiac 
progenitors are to small variations in expression of critical signaling and structural 
genes. Additionally, varied cardiac defects are often observed in chromosomal 
syndromes including Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 
18), Patau syndrome (Trisomy 13), Turner syndrome (45XO), and DiGeorge 
syndrome (22q11.2 microdeletion)[159, 160, 210-216]. Adding to this, chromosomal 
abnormalities are often found in embryos with severe, non-viable congenital heart 
defects in fetal necropsy studies[10, 217-219]. 
 While there has been substantial progress in elucidating the genetics of 
congenital heart disease, the role of epigenetics is less defined[220, 221]. Epigenetics 
involves changes in gene expression without changes in the genome and has been 
identified as a critical player in both development and disease[222]. Recently, 
mutations in histone modifying enzymes, enzymes that control chromatin structure 
and DNA compaction, were found to be enriched in de novo cases of congenital 
heart disease[223]. Consistent with genetic experiments, this suggests that tight 
control of gene expression and chromatin structure is critical for successful 
cardiogenesis. While this area is relatively less explored, evidence exists 
supporting the role of chromatin modifying enzymes in cardiogenesis. The class I 
histone deacetylase 8 (HDAC8) has recently been associated with Cornelia de 
Lange syndrome[224, 225]. Additionally, a de novo HDAC2 variant was recently 
identified in a syndrome with similarities to Cornelia de Lange syndrome, 




1p35, a genomic region containing another class I histone deacetylase, HDAC1, 
presents with cardiac involvement[227]. Microdeletion at 6q21-22, containing 
HDAC2, also presents with cardiac symptoms[228]. Finally, treatment during 
pregnancy with compounds that disrupt chromatin modifying enzymes, including 
the HDAC inhibitors trichostatin A[229] or valproic acid[230-232] and the DNA 
Methyltransferase inhibitors azacitidine[233] or decitabine[234], can cause congenital 
heart defects and fetal harm. Together, these observations are consistent with 
findings that tight regulation of the epigenome and chromatin conformation is 




 Epigenetics, the study of phenotypes arising from heritable changes in gene 
expression rather than genotype, was first defined by C.H. Waddington in 1942[235, 
236]. Since then, there has been extensive investigation into how gene expression 
is controlled at various levels and how alterations affect behavior, development, 
and disease[237]. Complex organisms arise from a singular progenitor pool, raising 
an obvious question: how does such complexity arise out of a population of cells 
with a single set of instructions? Far from being a linear set of instructions read 
from start to finish, the mammalian genome is a complex, multidimensional manual 
that is regulated at multiple levels and by a diverse array of interactions[238]. The 




systems including the growing fields of small RNAs and covalent chromatin 
modifications[239, 240]. Despite this, much remains unknown about how this diversity 
is achieved through development. Here we will focus on chromatin dynamics and 
their role in mammalian cardiac development. 
 Chromatin is a complex structure built from DNA, RNA, and proteins that 
dynamically packages a cell’s genome into distinct functional units preventing DNA 
damage, mediating chromosome localization, regulating gene expression, 
facilitating DNA replication, and modulating cellular replication[239, 241, 242]. The 
basic structure of DNA compaction was first recognized over 100 years ago[243-245]. 
Cytologic examination revealed two states of DNA in the nucleus: dense 
compacted heterochromatin and less-dense euchromatin[243]. Despite this early 
insight into how DNA is stored within nuclei, it was not until 1974 that the structure 
of the nucleosome, the base chromatin unit, was characterized as a repeating unit 
of ~200 base pairs of DNA wound around proteins (histone)[246, 247]. The regulatory 
potential of DNA compaction and the nucleosome was quickly theorized, 
experimentally tested, and confirmed. Early studies demonstrated that DNA 
compaction could impede transcription, providing a mechanism by which DNA 
packaging alters gene expression and promotes cellular heterogeneity[248, 249]. 
Additionally, further studies identified that the proteins that make up the histone 
core are subjected to modifications that modulate gene expression[250, 251]. 
 Through the years, we have gained more insight into the structure and 




repeating unit of ~146 base pairs of double-stranded DNA wound around an 
octamer of histone proteins with each octamer holding 1.67 leftward superhelical 
wraps of DNA[252]. Histone octamers are made up of pairs of each of the four core 
histones: H2A, H2B, H3, and H4[253]. Additionally, histone variants, including H3.3 
and H2AZ, mediate distinct and unique functions[254, 255]. Histones are 
characterized by C-terminal globular domains and N-terminal flexible tail 
domains[253]. The interaction between coiled DNA and histones is stabilized at 
numerous contact points, including interactions between the positively-charged tail 
domains and DNA’s negatively charged phosphate backbone. Nucleosome 
subunits are assembled into condensed fibers and eventually chromosomes, 
facilitating compaction and segregation of distinct units of DNA. Recently, higher 
level chromatin organization with varied regulatory roles have been described 
including topologically associating domains, lamina-associated domains, and 
nucleolus-associated domains[256-259]. 
Early studies identified the regulatory potential of histone modifications, as 
they altered nucleosome structure and gene expression[260]. Some of the first 
covalent modifications identified were lysine methylation and acetylation[260, 261]. 
Since then, a broad range of modifications, of both the globular and tail domains, 
have been identified with distinct residue affinities and varied functions[239]. Some 
of these modifications include the lysine or arginine mono/di/tri-methylation, 
acetylation, ubiquitylation, sumoylation, diminiation, phosphorylation, ADP 




discuss histone acetylation and methylation as they are the most studied and have 
the best-defined roles in development and disease.  
Acetylation at lysine residues of H3 or H4 neutralizes lysine’s positive 
charge, weakening electrostatic interactions with the negatively charge phosphate 
backbone of coiled DNA, and loosening chromatin compaction[263]. Methylation 
does not alter histone charge, instead regulating interaction with chromatin binding 
domains such as the Tudor domain, chromodomain, or PHD domain[253]. The rise 
of genome-wide techniques to profile histone modifications, such as ChIP-seq, 
facilitated mapping covalent histone modifications and correlation with gene 
expression. The original studies that defined the genome-wide residency of histone 
acetylation marks found acetylation and methylation generally aligned with their 
biochemical functions. Consistent with earlier studies showing histone occupancy 
impedes transcription and nucleosome eviction is required for elongation, 
occupancy was localized to gene bodies, with low residency in canonical promoter 
regions[264, 265]. Acetylation at H3 and H4 were generally localized to promoter and 
5’ORF regions, consistent with their role as charge-neutralizers and in agreement 
with studies showing acetylation increases chromatin accessibility and 
transcription. Methylation levels and distributions are more varied than acetylation. 
H3K4 mono-methylation (H3K4me) is enriched towards the 3’ ends of genes, 
potentially representing a basal chromatin state for the formation of di- and tri-
methylation marks. Consistent with this theory, H3K4 dimethylation (H3K4me2) 




transcription and resides around transcriptional start sites. Additionally, 
trimethylation of H3K36 and H3K79 were generally found within the coding regions 
of actively transcribed genes. Given these relationships, the original role of the 
nucleosome, histones, and covalent histone modifications were considered to be 
binary: pro-euchromatin modifications (H3/H4 acetylation, trimethylation) loosened 
interactions between DNA and histones, enabling the recruitment of transcriptional 
enzymes and facilitating gene expression while their absence or removal promoted 
the formation of heterochromatin and transcriptional repression[266].  
 
Maintaining and Modifying the Epigenome 
 
 Since covalent histone modifications are important regulators of gene 
expression, it follows that there are systems in-place to maintain and modify these 
modifications. Shortly after the discovery of histones and covalent histone 
modifications, enzymes that add and remove these modifications were identified 
and the study of epigenetics was truly launched. Here we will briefly discuss the 
enzymes and control mechanisms that regulate histone acetylation and histone 
methylation. 
 Histone methylation is controlled by the balance between writing and 
erasing lysine or arginine methylation by histone methyltransferases and histone 
demethylases[267-271]. As mentioned previously, methylation does not alter histone 




factor recruitment, and genome regulation. Histone methyltransferases catalyze 
the addition of methyl groups to lysine or arginine residues of histone proteins. 
Primarily, histone methyltransferases modify specific H3 and H4 residues to impart 
residue and modification dependent functions. These modifications are deposited 
by numerous histone methyltransferases, such as SET2 and EZH2, with distinct 
substrate specificities and regulatory networks. Consequently, histone methylation 
plays a varied role in numerous physiologic and pathologic states. Histone 
methylation is antagonized by histone demethylases, such as LSD1, that also 
display independent substrate preference and varied effects. 
 Similarly, histone acetylation is controlled by the balance between two 
opposing groups of histone modifying enzymes: histone acetyltransferases (HATs) 
and histone deacetylases (HDACs)[261, 263]. HATs use acetyl-CoA as a co-factor to 
catalyze the transfer of an acetyl-motif to the ε-amino groups of lysine residues 
primarily on H3/H4 histone tails, although they can also target non-histone 
proteins. Acetylation neutralizes the net-positive charge of lysine, weakening 
interactions between DNA and nucleosomes. Consequently, HATs are considered 
transcriptional activators and mediators of a euchromatic state. Type A HATs are 
a diverse group of nuclear enzymes which target nucleosomal histones across the 
genome[263, 272]. Major groups, based on homology to Saccharomyces cerevisiae 
histone acetyltransferases, include GNAT, MYST, and CBP/p300. Type B HATs 




272]. These enzymes reside primarily within the cytoplasm, potentially targeting 
free-histones and non-histone proteins for acetylation. 
 Acetylation of histone tails is antagonized by HDACs[273]. While the first 
HDAC was identified over 50 years ago, it was not until 1996 that the first 
mammalian HDAC was isolated[274]. Since then, 18 mammalian deacetylases have 
been identified and classified into four groups based on their homology to 
Saccharomyces cerevisiae deacetylases (Figure 1.5)[275]. These enzymes were 
originally considered to be repressive, owing to their mechanism of action, 
however recent studies challenge this assertion[276, 277]. 
Class I histone deacetylases, homologous to Saccharomyces cerveisiae 
Rpd3, include HDACs 1/2/3/8[278]. HDAC1 was the first deacetylase identified in 
1996 and its discovery was shortly followed by independent identification of 
HDAC2[274, 279]. HDAC3 was defined in 1997 based on its homology to HDAC1 and 
HDAC2 while HDAC8 was defined in 2000[280, 281]. Class I histone deacetylases 
are ubiquitously expressed and exhibit robust enzymatic activity towards 
nucleosome-associated histone substrates, although more recent evidence 
(discussed below) introduces nuances to this understanding[282]. These four 
HDACs have a relatively simple structure, consisting a highly-conserved 
deacetylase domain and short amino- or carboxy- terminal extensions (Figure 
1.5). HDAC1 and HDAC2 are the most related, with upwards of 85% amino acid 
identity in both mice and humans[283]. HDAC3 shares ~60% identity with 




HDAC2 contain N-terminal nuclear localization sequences, although cytosolic and 
mitochondrial residency has been described[284, 285]. HDAC3 has both a nuclear 
localization sequence and nuclear export signal on its C-terminus, suggesting 
ability to function in both compartments[286, 287]. HDAC8 localizes to the nucleus 
owing to a nuclear localization sequence within its catalytic domain, although 
cytosolic localization has been demonstrated[281, 288, 289]. Interestingly, these potent 
epigenetic regulators have no intrinsic DNA binding capability. Instead, association 
with large multi-subunit chromatin remodeling complexes provides DNA binding 
ability[290]. HDAC1 and HDAC2 are highly homologous histone deacetylases that 
are found as homo- or hetero-dimers in multiple traditionally ‘co-repressive’ 
complexes including the SIN3, nucleosome remodeling deacetylase (NuRD), and 
CoREST complexes (Figure 1.6)[283, 291-298]. HDAC1/HDAC2 along with Rbbp4/7 
constitute the deacetylase core of these complexes while peripheral members 
contribute specificity and other chromatin remodeling functions[290]. The NuRD 
complex is a combined helicase-demethylase, while CoREST is a demethylase-
deacetylase. More recently, HDAC1 and HDAC2 have been found to assemble 
into the Nanog and Oct4 associated deacetylase complex (NODE) in embryonic 
stem cells, the SHIP complex during spermatogenesis, and the MiDAC complex 
during mitosis[299-301]. HDAC3 homo-oligomerizes in the N-CoR/SMRT complex, 
while no mammalian complex has been defined for HDAC8, despite its 




purified lack enzymatic activity, HDAC8 has shown the ability to act independent 
of any complex[283, 296, 302, 303, 306-309]. 
Class II HDACs, homologous to the Saccharomyces cerevisiae Hda1 
enzyme, are divided into two groups: IIa (HDACs 4/5/7/9) and IIb (HDACs 
6/10)[310]. Class IIa HDACs are characterized by their large N-terminal domains 
relative to the HDACs in class I (Figure 1.5). These domains contain binding sites 
for MEF2 and 14-3-3, making these HDACs able to respond to various cellular 
signals[311-314]. Additionally, Class IIa HDACs exhibit tissue-specific expression 
patterns and functions. HDAC5 & 9 are expressed in muscle, heart, and brain[315, 
316]. HDAC4 is found in the brain and skeletal growth plates while HDAC7 is 
enriched in endothelial cells and thymocytes[317, 318]. Purified class IIa HDACs have 
only minimal enzymatic activity towards histone substrates as a tyrosine, which 
acts as a transition-state stabilizer in class I HDACs, is replaced by a histidine[319-
324]. Confirming this, the deacetylase domain is dispensable for almost all class IIa 
HDAC functions[325-327]. Class IIb HDACs are less well defined, although HDAC6 
has been identified as the main cytoplasmic deacetylase[328]. 
Class III HDACs, also known as the sirtuins, are NAD+ dependent 
deacetylases with homology to Saccharomyces cerevisiae Sir2[329-333]. This class 
works through a different mechanism than the other HDAC classes, leading to their 
exclusion from most studies examining HDAC function[275, 282]. The seven known 
sirtuins show distinct subcellular distributions[334]. SIRT1/2 are localized to the 




SIRT4/5 are restricted to mitochondria. SIRT6 is wholly nuclear while SIRT7 
localizes to the nucleolus. Because they use NAD+ as a co-factor and some 
localize in mitochondria, the sirtuins are thought to link metabolism and acetylation. 
HDAC11, with homology to both class I and class II histone deacetylases, 
is the only known Class IV deacetylase and is relatively less studied[335]. HDAC11 
is highly conserved and enriched in various tissues including the brain, heart, 
muscle, kidneys, and gonads[336]. Initial studies identified that HDAC11 is involved 
in cytokine production and as is a potential target for immune anti-cancer 
therapy[337, 338]. A developmental role for HDAC11 has not been identified. 
  
Figure 1.5 – Mammalian Histone Deacetylases. The 11 mammalian histone 
deacetylates, structure, knockout lethality/phenotype, and Class. Green, 
conserved HDAC domain. Numbers, amino acids. For Class II HDACs, myocyte 
enhancer factor 2 (MEF2) binding sites are blue, and 14-3-3 binding sites ares 
shown. ND, not determined; S, serine phosphorylation site; ZnF, zinc finger. This 
figure was originally published in “Haberland, Michael, Rusty L. Montgomery, and 
Eric N. Olson. 2009. “The Many Roles of Histone Deacetylases in Development 
and Physiology: Implications for Disease and Therapy.” Nature Reviews. Genetics 





Figure 1.6 – Mammalian Histone Deacetylase 1/2 Complexes. The three main 
HDAC1/HDAC2 containing complexes (Sin3, NuRD, and CoREST). These 
complexes contain either hetero- or homo-dimers of HDAC1/HDAC2 as a catalytic 
core and a variety of other subcomponents with numerous DNA binding domains. 
NuRD combines helicase-demethylase function while CoREST combines 
demethylase-deacetylase functions. This figure was originally published in “The 
Physiological Roles of Histone Deacetylase (HDAC) 1 and 2: Complex Co-Stars 
with Multiple Leading Parts.” Biochemical Society Transactions 41 (3): 741–49. 




Class I Histone Deacetylases – Roles in Development and Disease 
 
Class I histone deacetylases are implicated in the pathogenesis of a wide 
range of human diseases, including many adult pathologies[275, 276, 278, 283, 339-342]. 
HDAC dysfunction is associated with metabolic syndrome, neurodegenerative 
conditions, cardiac pathologies, developmental syndromes, and malignancy[342-
344]. While copy number variation at the chromosomal regions containing HDAC1 
(1p35) or HDAC2 (6q21-22) have been associated with congenital anomalies and 
preliminary evidence suggests HDAC2 may be involved in pathogenesis of 
Cornelia de Lange syndrome, no causal link has been identified in humans[226-228, 
345]. HDAC1 overexpression has been observed in several neoplastic conditions 
including prostate cancer, gastric cancer, ovarian cancer, and Hodgkin’s 
Lymphoma[346-349]. Increased HDAC1 is thought to drive inappropriate proliferation, 
fueling malignant transformation. Similarly, alterations in HDAC2 are thought to 
promote proliferation in cases of colonic, gastric, endometrial, and ovarian 
cancers[350-353]. Mirroring HDAC1 and HDAC2, HDAC3 and HDAC8 dysfunction 
has been associated with cancer in human studies[354-356]. Additionally, mouse 
models suggest that class I HDACs regulate mature cardiac function. Hdac2-null 
mice were resistant to hypertrophic stimuli, while mice overexpressing Hdac2 
displayed cardiac hypertrophy[357]. Overexpression of Hdac3 in mice leads to 
increased cardiomyocyte proliferation, while ablation results in cardiac 




in adult mice[359]. A common feature to many of these conditions, mirroring their 
presumed role in cancer, is class I HDAC control of cell cycle progression and 
proliferation[341]. In both mouse and human studies, class I HDACs generally 
promote proliferation while their ablation decreases proliferation, increases 
apoptosis, or promotes precocious differentiation. 
Currently, there are several HDAC inhibitors with FDA approved indications 
and many more undergoing clinical trials[360, 361]. HDAC inhibitors antagonize Class 
I, II, and IV histone deacetylases through binding to the catalytic HDAC domain. 
First generation of HDAC inhibitors function as pan-HDAC inhibitors while more 
specific second generation inhibitors are being developed and tested[362]. 
Approved HDAC inhibitors include vorinostat, romidepsin, belinostat, 
panobinostat, valproic acid, and etinostat. Approved uses generally revolve around 
the anti-proliferative effects observed with loss of class I HDACs in vitro and in 
vivo. Current indications include cutaneous T-cell lymphoma, peripheral T-cell 
lymphoma, and multiple myeloma. Valproic acid, originally used as a mood 
stabilizer, is still commonly used as an anti-epileptic drug. Overall, the role of 
HDAC inhibitors growing as the relationship between HDACs and pathophysiology 
is elucidated. 
Class I histone deacetylase function is not restricted to adult physiology. A 
body of work unsurprisingly positions these as potent regulators of the epigenome 
in both normal and aberrant development. Development of complex organisms 




of multipotent transcriptional progenitor cells to form the diverse landscape of cell 
types required for survival. During this process, continual refinement of gene 
program expression is mediated by epigenetic remodeling of chromatin. Central to 
this process are the Class I histone deacetylases, owing to their high enzymatic 
activity at histones contained within nucleosomes[342]. Mutation or inactivation of 
these critical epigenetic mediators has broad implications for normal and abnormal 
physiology during development. Consistent with this, animal studies have shown 
that loss of function of any of the class I histone deacetylases results in embryonic 
or perinatal lethality[275]. 
Global inactivation of Hdac8 in mice is lethal shortly after delivery due to 
skull instability[363]. In humans, mutations of HDAC8 are associated with Cornelia 
de Lange Syndrome[225], an autosomal dominant genetic disorder. In this context, 
loss of HDAC8 results in hyperacetylation of SMC3, a cohesin involved in 
segregation of sister chromatids, inhibiting its function during prophase and 
anaphase, potentially driving clinical features of the syndrome. To date, there are 
no other identified developmental roles for HDAC8 in either murine or human 
systems. 
 Total ablation of Hdac3 results in lethality before E9.5 due to broad 
gastrulation defects early in development[359, 364-366]. So far, no studies directly link 
HDAC3 to human congenital anomalies, however a copy number variation 
syndrome termed 5q31.1q35.1, a region which includes Hdac3, is associated with 




for Hdac3 in murine development, with potential applications to humans. 
Interestingly, some of these roles for Hdac3 are independent of deacetylase 
activity, suggesting that it may not be a potent modifier of the epigenome[368, 369]. 
In muscle, Hdac3 antagonizes myogenesis by deacetylating Mef2[370]. Mice lacking 
Hdac3 in mature cardiomyocytes present with cardiac hypertrophy and lethality a 
few months after birth. Mechanistically, loss of Hdac3 disrupts cardiac metabolism, 
seen by dysregulation of fatty acid metabolism and increased ligand-induced lipid 
storage, resulting in cardiac dysfunction[359]. Interestingly, this phenotype is not 
recapitulated with postnatal inactivation of Hdac3, suggesting that this is a 
developmentally specific role[371]. Additionally, increased Hdac3 expression is 
associated with cardiomyocyte hyperplasia due to increased myocyte 
proliferation[366]. Specifically, Hdac3 controls cardiomyocyte proliferation via 
suppression of Cdkn1a. Expanding the role of Hdac3 in the heart, Hdac3 
modulates expression of Nkx2-5, whose dysfunction is associated with human 
congenital defects, in adult murine models[132]. 
Ablation of Hdac3 in cardiac progenitor cell populations disrupts heart 
development, seen by embryonic or neonatal lethality. Within the first heart field, 
loss of Hdac3 via Nkx2.5-Cre leads to complete embryonic lethality due to 
ventricular wall hypoplasia[358]. Mechanistically, Hdac3 represses Tbx5-dependent 
activation of cardiomyocyte lineage genes in a deacetylase-dependent but 
chromatin-independent manner, with loss of Hdac3 leading to precocious 




deacetylase-independent manner within second heart field progenitors to facilitate 
normal outflow tract morphogenesis[372]. Inactivation of Hdac3 in Isl1-expressing 
progenitors (using Isl1-Cre) leads to an array of outflow tract defects including 
aortic dilation, malrotation, overriding aorta, double-outlet right ventricle, and 
abnormal valve development that culminate with lethality around E18.5[372]. 
Specifically, Hdac3 functions independently of its deacetylase activity to silence 
expression of Tgfβ1 by recruiting members of the Prc2 complex. Loss of Hdac3 
activates Tgfβ signaling, aberrant endothelial-to-mesenchymal transition, and 
causes alterations in extracellular matrix homeostasis that disrupt normal outflow 
tract formation. Finally, within vascular progenitor cells, Hdac3 drives maturation 
and maintenance of the lymphovenous valves in a chromatin-dependent, but 
deacetylase-dependent manner[373]. Ablation of Hdac3 in vascular progenitors 
results in perinatal (Cdh5-Cre) or embryonic (Tie2-Cre, Lyve1-Cre) lethality, most 
likely due to failure of blood-lymph separation. Phenotypically, Hdac3 deficient 
mice exhibit edematous blood-filled lymphatics, an incompetent lymphovenous 
valve, and absent lymphatic valves. Mechanistically, Hdac3 interacts with Tal1, 
Gata2, and Ets1/2 in a flow-dependent manner to regulate a conserved, intragenic 
enhancer element of Gata2, a transcription factor required for proper lymphatic 
morphogenesis. Breakdown of this interaction lowers Gata2 expression and 
disrupts lymphatic development. Overall, these studies position HDAC3 as a 
critical regulator of mammalian cardiogenesis. Identification of deacetylase-




chromatin-dependent roles for HDAC8 suggest that HDAC1 and HDAC2 are the 
major regulators of mammalian histone deacetylation. Suggesting major roles in 
chromatin regulation, ablation of HDAC1 and HDAC2 reduces cellular deacetylase 
activity by 50%[374, 375]. 
Ablation of either Hdac1 or Hdac2 in embryonic stem cells does not affect 
proliferation[376]. However, loss of Hdac1, but not Hdac2, in embryoid bodies 
enhanced morphologic differentiation, increases contractility, and better-defined 
cellular organization. This suggests that, despite their homology, Hdac1 and 
Hdac2 have only partially overlapping functions. Loss of Hdac1, but not Hdac2, in 
embryonic stem cells increases H3K56 acetylation and expression of 
cardiomyocyte, muscle, and neuronal markers, mirroring experiments with HDAC 
inhibition, suggesting that the deacetylase function of Hdac1 is required for ordered 
stem cell differentiation[377]. Hdac1-null embryonic stem cells also exhibited 
upregulation of pluripotency genes yet HDAC inhibition with trichostatin A 
downregulated these same genes , consistent with a previous study[378]. 
Interestingly, Hdac1 preferentially associates with actively transcribed loci in 
embryonic stem cells[379], challenging the presumed sole role of HDACs as 
transcriptional co-repressors. HDAC inhibition enhances neuronal differentiation of 
in vitro, highlighting the pleiomorphic effects of HDACs on proliferation[380]. These 
in vitro studies are mixed, indicating Hdac1 and Hdac2 exercise varied control of 




Numerous studies have also elucidated the roles of for Hdac1/Hdac2 in 
vivo. A very recent study drew a link between a de novo HDAC2 variant and 
Cornelia de Lange-like phenotype, however no causal link has been elucidated[226]. 
No homozygous, monogenic, germline mutations of HDAC1 or HDAC2 have been 
described in humans, suggesting that their mutation likely results in embryonic 
lethality. Supporting this, targeted disruption of both alleles of Hdac1 in mice 
results in early lethality[381-383]. While the original study reports lethality of Hdac1-
null embryos E10.5 from severe proliferative defects, data suggests that Hdac1-
null embryos arrest closer to E7.5. Mechanistically, Hdac1 suppress the cyclin-
dependent kinase inhibitors Cdkn1a and Cdkn1b. Transcriptional analysis 
revealed both up and down-regulated genes, suggesting HDACs may not adhere 
to the binary model of chromatin function. Global inactivation of Hdac2 results in 
background-dependent defects[25, 357, 382, 384]. Germline ablation of Hdac2 (by CAG-
Cre) causes obliteration of the right ventricular lumen, cardiomyocyte hyperplasia, 
increased cardiomyocyte apoptosis, and perinatal lethality[382]. Mice homozygous 
for a Hdac2 LacZ gene-trap allele were viable, but showed decreased cardiac 
hypertrophy following hypertrophic insult[357]. This discrepancy suggested the LacZ 
gene-trap strategy produced a hypomorphic allele[275]. 
While germline ablation of Hdac1 or Hdac2 causes developmental defects, 
published reports consistent with results from our lab found that loss of Hdac1 or 
Hdac2 in a wide range of tissues and progenitor cells including mature 




fibroblasts, first heart field progenitors, and second heart field progenitors, does 
not drastically alter embryonic development or adult functions[25, 375, 376, 381-383, 385-
390]. Despite this, disruption of the Sin3, NuRD, or CoREST complex is 
embryonically lethal, reinforcing the critical developmental roles of Hdac1/Hdac2 
within these complexes[391-393]. Early studies explained this by postulating that 
Hdac1 and Hdac2 served overlapping and redundant functions past the earliest 
stages of development[375]. Consistent with this theory, expression of Hdac1 or 
Hdac2 is induced following ablation of its paralog and, in many cases, loss of both 
alleles of Hdac1 and Hdac2 are required to observe any abnormalities.  
Recently, studies have shown Hdac1 and Hdac2 have a mix of redundant, 
semi-independent, and independent roles during development and beyond. Loss 
of Hdac1/Hdac2 in fibroblasts and B-cells blocks cell cycle progression at the G1-
S checkpoint, causing apoptosis[383]. Hdac1 and Hdac2 redundantly regulate 
neural progenitor differentiation, with ablation again causing apoptosis[394]. Genetic 
ablation of Hdac1 and Hdac2 in epidermal cells dysregulated p53/p63 signaling, 
leading to apoptosis[386]. In the lung, disruption of Hdac1/Hdac2 de-repress Bmp4 
and Rb1[395]. Deletion in oligodendrocytes, via Olig1-Cre, results in inappropriate 
Wnt and β-catenin signaling causing tremor and lethality by the second week of 
life[396]. Similarly, mice lacking Hdac1 and Hdac2 in the peripheral nervous system, 
via Dhh-Cre, exhibit tremors, hindlimb motility defects, and lethality by the third 
week of life[389, 397]. Specifically, loss of Hdac1 and Hdac2 in Schwann cells causes 




within thymocytes impairs T-cell receptor function and induces apoptosis. Hdac1 
and Hdac2 mediate proliferation and apoptosis in megakaryocytes with ablation 
shifting the balance towards apoptosis[383, 398]. Within oocytes, lack of 
Hdac1/Hdac2 leads to TRP53 hyperacetylation and apoptosis[399]. Additionally, 
Hdac1 and Hdac2 mediate mitosis in hepatocytes and autophagy in skeletal 
muscle[400, 401]. In cardiac physiology, Hdac1/Hdac2 redundantly regulate cardiac 
growth and development[382]. Deletion in mature myocytes, by αMHC-Cre, causes 
arrythmia, cardiomyopathy, upregulation of “cardiac stress markers”, upregulation 
of calcium channel genes, upregulation of skeletal muscle genes, and lethality 
within two weeks of birth. 
Normally, deletion of both alleles of Hdac1/Hdac2 is required to cause 
defects, however in certain cases a single allele is unable to fully rescue the double 
defects. The mechanism has not been fully elucidated, although there is evidence 
of haploinsufficiency of Hdac1/Hdac2 following paralog loss[375]. Approximately 
40% of Hdac1 is not associated with Hdac2, and homo- and hetero-dimer complex 
ratios vary from cell type to cell type[383], again suggesting independent functions. 
Numerous studies both in cell lines and mammalian models identified a mix of 
redundant and dose-dependent functions for Hdac1/Hdac2. Oocytes expressing a 
single allele of Hdac1 in an Hdac2-knockout background exhibit chromosomal 
segregation and kinetochore formation defects[402]. Other studies, including in T-
cells and the epidermis demonstrated that reintroduction of a single allele of 




Another study demonstrated a single allele of Hdac2, but not Hdac1, rescued loss 
of both Hdac1/Hdac2 in the brain[404]. These studies suggest Hdac1 and Hdac2 
have a spatiotemporally specific hierarchy and range of redundant, dose-sensitive, 
and independent functions.  
Although evidence points to HDAC1 and HDAC2 providing most nuclear 
deacetylase activity in mammals, it is unclear if they, like other mammalian 
HDACs, have deacetylase-independent functions. Enzymatic activity of Hdac1 and 
Hdac2 depends on a key histidine residue, H141 in Hdac1 and H142 in Hdac2, 
with mutation to alanine (H141A, H142A) decreasing deacetylase activity and 
globally increasing acetylation[298]. Deacetylase independent roles for HDAC1 and 
HDAC2 have been shown in vitro, but only recently a study introduced conditional 
deacetylase-deficient Hdac1 (Hdac1-H141A) and Hdac2 (Hdac2-H142A) alleles to 
help elucidate their in vivo enzymatic function[405, 406]. Interestingly, mice 
homozygous for deacetylase-deficient Hdac1 exhibit complete embryonic lethality, 
mirroring the lethality observed with germline ablation of Hdac1[406]. Unfortunately, 
the report provides limited information on the phenotype of Hdac1H141A/H141A 
embryos. Despite the limited information, these data suggest Hdac1’s enzymatic 
activity is required during early mammalian development. Unexpectedly, 
Hdac2H141A/+ exhibit perinatal lethality without the cardiac defects seen in Hdac2-
null embryos. Instead, Hdac2H142A/+ mice display abnormal brain architecture and 




due to a dominant-negative effect of Hdac2H142A. This study is consistent with 
Hdac1 and Hdac2 having major deacetylase-dependent roles during development. 
Genome-wide residency assays found HDAC1 and HDAC2 preferentially 
associate with coding regions of actively transcribed genes, calling into question 
their label as transcriptional repressors[407]. Additionally, transcriptome analysis of 
double-knockout tissue reveals a mixed transcriptional signature[275, 378, 407]. 
Interestingly, Rpd3, the saccharomyces cerevisiae HDAC, is an established 
transcriptional activator[408]. Rpd3 promotes transcription as part of the Rpd3s 
complex, orthologous to mammalian Sin3, in cooperation with the histone 
methyltransferase Set2[409-415]. Set2 deposits H3K36 trimethylation in the wake of 
elongating RNA Polymerase II which directs Rpd3s, via the chromodomain of Eaf2, 
to deacetylate nucleosomes within actively transcribed loci, restoring basal 
chromatin architecture and enabling successive rounds of “productive” mRNA 
synthesis. Breakdown of this pathway, demonstrated by ablation and inhibitor 
studies, causes hyperacetylation of coding regions and a persistent state of non-
productive mRNA synthesis characterized by aberrant initiation at exonic 
alternative transcription start sites termed cryptic transcription[411]. It has been 
hypothesized that HDAC1/HDAC2 activate transcription through a similar 
conserved mechanism in mammals, however this hypothesis is untested.  
Through all of these studies, it is clear that lysine acetylation plays an 
important role in a vast array of different physiologic and pathologic states. As the 




modulate mammalian development. Despite this literature, the specific roles of 
HDAC1 and HDAC2 in early cardiac progenitors remains undefined.  
 
Aims of this Work 
 
 HDAC1 and HDAC2 have established roles in mammalian development 
and physiology, however their role in early cardiac progenitor cells remains 
undefined. This thesis examines the independent, redundant, and dose-sensitive 
roles of Hdac1 and Hdac2 in three major cardiac progenitor populations: the first 
heart field, the second heart field, and the cardiac neural crest. This work touches 
upon many previously established themes involving Hdac1 and Hdac2 including 
their role in cell cycle regulation, lineage commitment, proliferation, and apoptosis. 
Additionally, this thesis defines novel dose-sensitive roles for Hdac1 and Hdac2 in 
mammalian cardiogenesis. Finally, this work explores the role of histone 
modifications as they relate to epigenetic homeostasis and ordered transcription 




CHAPTER II – Histone deacetylase 1 and 2 silence cryptic transcription to 
promote mitochondrial function during cardiogenesis 
Chapter II is adapted from a manuscript in preparation and included with 
permission not required. 
 
Author Contributions: 
I provided all data shown in all figures except Table 2.2 which was provided by 
Lauren Bourke. Transcriptome assay was performed by the University of 
Massachusetts Microarray Core Facility. Transmission Electron Micrographs were 
generated in collaboration with the University of Massachusetts Electron 
Microscopy Core Facility. 
 
Abstract: 
Cryptic transcription occurs widely across the eukaryotic genome, however 
its regulation during vertebrate development is not understood. Here, we show that 
two class I histone deacetylases (Hdac1 and Hdac2) silence cryptic transcription 
to promote mitochondrial function in developing murine hearts. Cardiac-specific 
loss of Hdac1/Hdac2 in mice disrupts the developmental switch from anaerobic to 
mitochondrial oxidative phosphorylation (OXPHOS), causing severe defects in 
mitochondrial mass, mitochondrial function, and complete embryonic lethality. 




fidelity of metabolic gene programs. Mechanistically, Hdac1/Hdac2 deacetylate 
histone residues including H3K23, H3K14, and H4K16 to suppress cryptic 
transcriptional initiation within the coding regions of actively transcribed metabolic 
genes. Thus, Hdac1/2 mediated epigenetic silencing of cryptic transcription is 





 The mammalian heart forms early during development, requiring constant 
energy to maintain its critical pumping action[72, 416]. During early cardiac 
development, cardiomyocytes switch energy production from anaerobic pathways 
to mitochondrial oxidative phosphorylation (OXPHOS)[417]. Multiple studies link 
defective developmental energy generation and congenital heart disease (CHD), 
with almost every metabolic disruption associated with cardiac symptoms[12, 418]. 
Although recent advances identified the transition to OXPHOS as a checkpoint and 
potential origin for metabolic CHD, the molecular basis for this developmental 
metabolic transition remains elusive[71, 201, 417, 419]. In adult cardiomyopathies and 
metabolic syndrome, pathologic reversal of the anaerobic to OXPHOS switch 
occurs, suggesting epigenetic regulation[33, 221, 420-422]. Concordantly, intracellular 
metabolic transitions, in both development and disease, alter a myriad of lysine 




highlights that intracellular metabolites modulate activity of histone deacetylases 
(HDACs) and histone acetylation in cultured cells[81, 275, 276, 342, 359, 426]. Despite this, 
the roles of HDACs during developmental metabolic transitions remain undefined.  
 
Materials and methods 
Contact for Reagent and Resource Sharing 
Further information and requests for resources should be directed to the Lead 
Contact, Chinmay M. Trivedi (Chinmay.Trivedi@umassmed.edu). 
 
Animals 
Nkx2.5IRES-Cre, R26R-LacZ, Hdac1Flox, and Hdac2Flox mice used in this study have 
been previously described. All animal protocols were approved by the University 
of Massachusetts Medical School Institutional Animal Care and Use Committee 
(IACUC). Embryonic samples were generated via timed mating. Following the 
identification of a vaginal plug, pregnant females were isolated, sacrificed, and 
embryos dissected at the appropriate embryonic time point (ranging from 9.5-11.5 
days post fertilization). Mice were then separated into double knockout and control 
groups according to their genotype and developmental stage. 
 
Antibodies and Reagents 
The following antibodies were utilized in this study: Hdac1 (Abcam), Hdac2 
(Thermo-Fisher), cTnT (DHSB), MYH (Santa Cruz), PHH3 (Cell Signaling, CC3 




(Abcam), H3K23ac (Abcam), H3K14ac (Active Motif), H4K16ac (Abcam), RNA 
Polymerase II (Epigentek), Non-Immune IgG (Epigentek). Eosin Y and Harris 
modified hematoxylin were obtained from Fisher while X-gal was purchased from 
5-Prime. Vectashield permanent mounting medium, Vectashield fluorescent 
mounting medium, Vectashield Elite ABC reagent kit, Vector TrueVIEW 
Autofluorescence Quenching Kit, and DAB Peroxidase Substrate kit were 
purchased from Vector Labs. ProLong Glass Antifade Mounting Medium was 
purchased from Thermo Fisher Scientific. Donkey Serum and Horse Serum were 
obtained from Sigma. RNeasy Plus Micro, QIAquick Gel Extraction, and DNeasy 
Blood and Tissue kits were obtained from Qiagen. Chromaflash High Sensitivity 
ChIP Kit was from Epigentek. SMARTer RACE 5’/3’ kit was from Takara Bio.  
 
Histology 
Tissue samples were collected, fixed in 4% paraformaldehyde in 1X PBS at 4ºC 
overnight, dehydrated through an ethanol gradient, embedded in paraffin, and 
sectioned at 8µm thickness on a Leica fully motorized rotary microtome 
 
Imaging 
Images of dissected embryos were captures on a Leica Mz10 F fluorescence 
stereomicroscopy via a 0.7X C-mount, Achromat 1.0 x 90 mm objective, SOLA 
light engine (Lumencore), DS-Fi1 color camera (Nikon) through NIS-Elements 
Basic Research Software (Nikon). Images of stained sections were captures using 




lenses, SOLA light engine, DS-Fi1 color camera, and NIS-Elements Basic 
Research Software. Confocal microscopy images were acquired using Leica TCS 
SP5 II Laser Scanning Confocal microscope. Alexa Fluor 488 and 568 were 
simultaneously excited at 488 nm and 561 nm with confocal lasers, respectively. 
Emissions were split by an MBS 488/561/633 beam splitter and captured with 2 
detection ranges (ch1: 493–536 nm, ch2: 576–685 nm). For nuclear staining, 
Hoechst was excited using a Chameleon Ti:Sapphire pulse laser (755 nm) 
(Coherent Inc.) and was emission detected at 387 to 486 nm. Image stacks of 
vertical projections were assembled using ImageJ software (NIH). Additional 
confocal images were acquired with a Zeiss LSM800 airyscan confocal scanning 
microscope equipped with a solid-state laser module with 405, 488, 561, 640nm 
beam splitter, Plan-Apochromat objectives with DIC (63x/1.4 Oil, 20x/0.8, and 
10x/0.45) and Zeiss’s Zen 2.5 imaging software. All analysis was performed on at 
least 3 biologically independent samples (n=3). 
 
Hematoxylin and Eosin Staining 
Staining was performed via deparaffinizing sections in xylenes, rehydrating with 
an ethanol gradient, a 30sec stain with 30% Harris modified hematoxylin (in diH2O) 
followed by a 30sec counterstain with eosin Y. Stained slides were rinsed and then 
dehydrated through an ethanol gradient, cleared with xylenes, and mounted using 
Vectashield permanent mounting medium. All analysis was performed on at least 





LacZ (β-gal) staining 
Samples for LacZ (β-gal) staining were quickly dissected in cold PBS and fixed in 
2% paraformaldehyde for 30min at 4ºC. Samples were then washed in PBS at 
room temperature and stained overnight in staining solution (5mM potassium 
ferricyanide, 5mM potassium ferrocyanide, 2mM MgCl2, 0.01% deoxycholic acid, 
0.04% Nonidet P40, 0.1% X-gal, in 1X PBS) in the dark at 37ºC or until staining 
developed. Samples were then washed in 1X PBS and fixed overnight in 4% 
paraformaldehyde in PBS at 4ºC. All analysis was performed on at least 3 
biologically independent samples (n=3). 
 
Immunohistochemistry 
Selected sections were deparaffinized in xylenes, rehydrated through an ethanol 
gradient, pretreated using the Aptum Antigen Retriever 2100 and Aptum R-buffer 
A or Sodium Citrate Buffer (pH 6.0). Sections for immunofluorescent staining were 
blocked with 10% donkey serum/0.3% Triton X-100 in PBS for 1hr at room 
temperature. Sections were then washed with PBS and probed with primary 
antibody (in 10% donkey serum in PBS) overnight at 4ºC. Subsequently, slides 
were washed with PBS and incubated with Alexa Fluro 488/546/568-conjugated 
secondary antibodies (1:500) and Hoechst nuclear counterstain (1:1000) at room 
temperature for 1hr. Following incubation, slides were rinsed, quenched with 
Vector TrueVIEW Autofluroescence quenching kit according to manufacturer 




mounting medium or ProLong Glass Antifade mountant. All analysis was 
performed on at least 3 biologically independent samples (n=3). 
 
Morphometric Analysis 
Quantitative morphologic analysis was performed using ImageJ software to 
measure and record anatomical features of interest. Primitive ventricular thickness 
was estimated by comparing the average of 4 serial measurements on each 
section of interest across 10 independent biologic samples from both genotypes 
of interest (n=10). Raw pixel values were converted to a micron scale according to 
a conversion factor related to the microscope objective/imaging parameters used.  
 
Quantification of Immunohistochemistry/Immunofluorescence 
Cell counting was performed using ImageJ software to measure and record 
staining points of interest. The ImageJ Cell Counter plugin was utilized to record 
the total number of cardiomyocyte nuclei (cTnT+ or MYH+) in each section and the 
number of double positive nuclei (cTnT+ or MYH+ AND CC3+ or PHH3+). The 
number of double positive nuclei per one hundred cardiomyocyte nuclei is 
presented as either apoptotic index (CC3) or proliferative index (PHH3). All 
analysis was performed with 13-16 biologically independent samples (n=13-16). 
Control genotypes include 1++2++, 1FF2FF, Nkx2.5;1Het2Het, and Nkx2.5;1Het2KO. 
 
Transcriptome Analysis 
Primitive heart tubes were isolated from E10.5 mouse embryos and snap-frozen 




20 1FF2FF and Nkx1.5;1KO2KO hearts using a Qiagen RNeasy Plus Micro kit (n=20). 
The Clariom D Pico Assay (Affymetrix) was performed in triplicate (n=3) from 
pooled samples of 20 E10.5 primitive heart tubes by the University of 
Massachusetts Genomics Core Facility. Raw data were analyzed using the 
Affymetrix Transcriptome Analysis Console with a significant cutoff of FDR<0.05. 
Data were further analyzed using DAVID Functional Annotations Bioinformatics 
Microarray Analysis, PANTHER Gene List Analysis, and Broad Institute Gene Set 
Enrichment Analysis (GSEA) using default settings. Spearman hierarchical 
clustering was performed to visualize interrelationships within our data. Lists of 
enriched ontologic categories were generated and used to create heatmaps, 
enrichment plots, and doughnut charts in GraphPad Prism. Heatmaps of were 
generated using GraphPad Prism. Relative transcript expression is reported as the 
log-transformed expression value is normalized to the median across all six 
samples.  
 
Mitochondrial DNA (mtDNA)/Nuclear DNA (nDNA) Quantification 
Primitive heart tubes were isolated from E10.5 mouse embryos and snap-frozen 
in liquid nitrogen before being stored at -80ºC. Total DNA was extracted from a 
pool of 5 biologically independent 1FF2FF and Nkx2.5;1KO2KO hearts (n=5) using a 
Qiagen DNeasy Blood and Tissue kit (n=5). Relative levels of mitochondrial and 
nuclear DNA were quantified by quantitative PCR using SYBR Green Master Mix 
and previously reported primers(below). mtDNA levels were normalized to nDNA 




Primers for mtDNA/nDNA Quantification 
Target Forward (5’ – 3’) Reverse (5’ – 3’) 
mMito CTAGAAACCCCGAAACCAAA CCAGCTATCACCAAGCTCGT 
nDNA ATGGGAAGCCGAACATACTG CAGTCTCAGTGGGGGTGAAT 
Primers taken from: Malik, Afshan N., Anna Czajka, and Phil Cunningham. 2016. 
“Accurate Quantification of Mouse Mitochondrial DNA without Co-Amplification of 
Nuclear Mitochondrial Insertion Sequences.” Mitochondrion 29 (July): 59–64. 
 
Transmission Electron Microscopy 
Primitive heart tubes from E10.5 mouse embryos were dissected in cold 1X PBS 
and immediately immersed in 2.5% glutaraldehyde in 0.1M Sodium Cacodylate 
buffer, pH 7.2 and fixed overnight at 4ºC. Samples were processed and analyzed 
at the University of Massachusetts Medical School Core Electron Microscopy 
Facility according to standard procedures. Briefly, after fixation the samples were 
rinsed 3x in the same fixation buffer and post-fixed with 1% osmium tetroxide for 
1hr at room temperature. Samples were then washed 3x with diH2O for 20min and 
dehydrated through a graded ethanol series of 20% increments, before 2 changes 
in 100% ethanol. The samples were then infiltrated first with 2 changes of 100% 
Propylene Oxide and then with 50%/50% Propylene Oxide/SPI-Pon 812 Resin. 
The following day, 6 changes of fresh 100% SPI-Pon 812 resin were performed 
before samples were polymerized at 68ºC in flat embedding molds. The samples 
were then re-oriented as to obtain cross sections of the heart tubes and one 
micrometer sections were cut and stained with toluidine blue to confirm orientation. 
Approximately 70nm sections of this area were collected and placed on copper 




then examined using a FEI Tecnai 12 TEM with 120Kv accelerating voltage and 
images were captured using a Gatan TEM CCD camera. All analysis was 
performed in triplicate (n=3). 
 
Rapid Amplification of cDNA Ends (RACE) 
5’RACE Experiments were performed using a Takara Bio SMARTer 5’RACE and 
3’RACE Kit according to manufacturer guidelines. Briefly, primitive heart tubes 
were isolated from E10.5 mouse embryos and snap-frozen in liquid nitrogen before 
being stored at -80ºC. 1FF2FF and Nkx2.5;1KO2KO total RNA was isolated using a 
Qiagen RNeasy Plus Micro Kit from pools of 3 biologically independent samples 
(n=3) and first-strand cDNA was synthesized using reagents and protocols 
provided by the kit. Using primers complementary to sequences in distal exons of 
key metabolic genes (below) and reagents provided in the kit, 5’-directed rapid 
amplification of cDNA ends (5’RACE) was performed. Products were resolved in a 
1% TAE/Ethidium Bromide gel, extracted using a QIAquick Gel Extraction Kit 
(Qiagen), and sequenced (Eurofins Genomics). Specificity and alignment of 
sequences was determined using MacVector. 
Primers for 5’RACE 
Target Reverse ((5’ – 3’)) 
CS (Exon 5) GGCTGCAACGCACGGCAGCTTGGCA 
Ndufb9 (Exon 4) TGGGCCGTTCCCGAGGTCTGGTCACA 
 
Chromatin Immunoprecipitation Quantitative PCR (ChIP-qPCR) 
ChIP-qPCR experiments were performed using an Epigentek ChromaFlash High 




1+/+2+/+ (WT) and Nkx2.5;1KO2KO (DKO) primitive heart tubes were isolated from 
E10.5 mouse embryos and snap frozen in liquid nitrogen before storage at -80ºC. 
Biologically independent samples were pooled (n=7-10), briefly fixed in 1% 
formaldehyde in 1X PBS at room temperature for 30min before being quenched 
with glycine for 5min and washed with 1X PBS. Chromatin fragmentation was 
performed in Lysis Buffer (Epigentek) using a Covaris M220 (2 cycles of: Peak 
Power – 50; Duty Factor – 20; Cycles/Burst – 200; Duration – 3min). Proteins were 
immunoprecipitated from 0.75ug-2ug of chromatin in ChIP buffer using Hdac1, 
Hdac2, H3K36me3, H3K23ac, H3K14ac, H4K16ac, RNA Polymerase II, and Non-
Immune IgG antibodies on an orbital shaker (100rpm) at room temperature for 1hr 
before being transferred to 4ºC overnight. Immunoprecipitated antibody-chromatin 
complexes were washed 4x with the provided Wash Buffer, treated with RNase A, 
Proteinase K, and eluted using Elution Buffer. DNA was further purified using the 
included purification columns and protocol. Using purified immunoprecipitated 
DNA, enrichment of the targets at various locations were measured using 
quantitative PCR (qPCR) with SYBR Green Master Mix. All analyses were 
performed in triplicate (n=3). Primer sequences are as follows: 
Primers for ChIP-qPCR Analysis 
Target Forward (5’ – 3’) Reverse (5’ – 3’) 
CS TSSC CCATTTTGGGCCAATGGTCG GGGGAAGGGTAGACAAACCG  














Quantitative Reverse Transcription PCR (RT-qPCR) 
Primitive heart tubes were isolated from E10.5 mouse embryos and snap-frozen 
in liquid nitrogen before being stored at -80ºC. Total RNA was isolated from pools 
of 10 biologically independent 1FF2FF and Nkx2.5;1KO2KO samples (n=10) using a 
Qiagen RNeasy Plus Micro kit, quantified, and identical amounts of cDNA 
generated via reverse transcription using iScript reverse transcription supermix 
(Bio-Rad) according to manufacturer guidelines. Transcription expression was 
measured by quantitative qPCR using SYBR Green Master Mix. Relative 
expression levels were calculated using the ∆∆Ct method using Gapdh 
(Unchanged in our transcriptome analysis) as a reference transcript. All analyses 
performed in triplicate (n=3). Primer sequences are as follows: 
Primers for Early/Late Exon Quantification 





















Cryptic Event Identification & Volcano Plot 
We considered all transcripts with a fold-change FDR<0.05 and determined the 
presence of alternative transcripts from intragenic transcription start sites (cryptic 




cryptic event was called when a single transcript had a significantly decreased 
expression of the first probe and no difference between a later probe in DKO 
compared to Cntrl. We hypothesized that this transcriptional signature of distal 
normalization was consistent with intragenic transcript generation. Using this list 
of transcripts with cryptic events, we created a volcano plot of log2(Fold Change) 
vs. -log2(FDR) and performed gene ontology using PANTHER Gene List Analysis. 
 
Statistical Analysis 
Data are shown as means with error bars representing the standard deviation 
(mean(SD)). Significant differences between means were determined using an 
unpaired two-tailed Student’s t-test or χ2 test. The level of significance (α) was set 
at 0.05 for all analyses. Per GraphPad Prism standard annotation: ns, p>0.05, *, 
p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001. Analysis was performed using 
either Microsoft Excel or GraphPad Prism. Unless otherwise noted, a minimum of 






Among mammalian HDACs, paralogous Hdac1 and Hdac2 have the 
highest activity towards nucleosome substrates, enabling chromatin 
remodeling[276]. To investigate the role of Hdac1 and Hdac2 in early cardiac 
metabolism, we genetically ablated murine Hdac1/Hdac2 using Nkx2.5IRES-
Cre[427],Hdac1Flox[390], and Hdac2Flox[428] (Nkx2.5;1KO2KO) alleles. Complete loss of 
Hdac1/Hdac2 was observed in the developing heart starting at E10.5 (Figure 2.2). 
Nkx2.5;1KO2KO embryos were comparable in size at E10.5, however these 
embryos exhibited complete embryonic lethality by E11.5 (Figure 2.1A-C). We 
observed increased light transmission through the primitive heart tube (PHT) in 
E10.5 Nkx2.5;1KO2KO embryos, suggesting defective cardiogenesis (Figure 2.1C). 
Morphologic staining revealed a thinner myocardium and reduced eosinophilic 
cytoplasmic in E10.5 Nkx2.5;1KO2KO cardiomyocytes (Figure 2.1D-E), without 
major changes in proliferation, apoptosis, or cell number (data not shown). 
Transmission electron micrographs of E10.5 PHTs showed Nkx2.5;1KO2KO 
cardiomyocytes had accumulations of cytoplasmic lipid droplets, a fragmented 
contractile network, and abnormal mitochondria consistent with failure to initiate 
oxidative cardiac metabolism and subsequently arrested cardiac development 









Figure 2.1 - Disruption of Hdac1/Hdac2 within Nkx2.5IRES-Cre+ cells causes 
complete embryonic lethality at E11.5. (A) Nkx2.5IRES-Cre;1F+2F+ crossed with 
1FF2FF. The number and genotypes recovered compared to expected Mendelian 
ratios are tabulated. a, 3 embryos pale/dying. (B) Nkx2.5;1KO2KO and 1FF2FF 
embryos at E11.5 (arrows, pooled blood). (C) Nkx2.5;1Het2Het;R26R-LacZ-/+ and 
Nkx2.5;1KO2KO;R26R-LacZ-/+ E10.5 embryos. (D) Hematoxylin & eosin stained 
Nkx2.5;1Het2Het and Nkx2.5;1KO2KO E10.5 sagittal sections at AVC level (arrows, 
eosinophilic cytoplasm; bars, compact thickness). (E) Compact myocardial 
thickness in control and Nkx2.5;1KO2KO E10.5 PrVs (***, p=0.0001). (F) 
Transmission electron micrographs of Nkx2.5;1KO2KO and 1FF2FF E10.5 
cardiomyocytes (Blue, contractile fibers; Orange, cytoplasmic lipid droplets). (G) 
Transmission electron micrographs of Nkx2.5;1KO2KO and 1FF2FF E10.5 










Figure 2.2 – Complete loss of Hdac1/Hdac2 in primitive heart tube 
cardiomyocytes at E10.5. (A-B) Hdac1 (A) and Hdac2 (B) staining on 
Nkx2.5;1KO2KO and 1FF2FF E10.5 sagittal sections at AVC level with cardiac 
troponin (cTnT) and Hoechst nuclear counterstain (solid white arrows, Hdac1+ or 
Hdac2+ cardiomyocytes; hollow white arrows, Hdac1- or Hdac1- cardiomyocytes; 
gray arrows, Hdac1+/cTnT- or Hdac2+/cTnT- cells). Grayscale images are unedited. 






 Observed (Expected) 
Genotype P0 E10.5 
Hdac1F/+, Hdac2F/+ 6 (6.5) 14 (13.5) 
Hdac1F/F, Hdac2F/+ 6 (6.5) 12 (13.5) 
Hdac1F/+, Hdac2F/F 2 (6.5) 14 (13.5) 
Hdac1F/F, Hdac2F/F 11 (6.5) 12 (13.5) 
Tnnt-Cre; Hdac1F/+, Hdac2F/+ 7 (6.5) 12 (13.5) 
Tnnt-Cre; Hdac1F/F, Hdac2F/+ 6 (6.5) 11 (13.5) 
Tnnt-Cre; Hdac1F/+, Hdac2F/F 14 (6.5) 23 (13.5) 
Tnnt-Cre; Hdac1F/F, Hdac2F/F 0 (6.5) 10 (13.5) 
Total (p value): 52 (p=0.003) 108 (p=0.28) 
 
Table 2.2 – Genotypes of samples lacking Hdac1/Hdac2 in cardiomyocytes, 
collected at various developmental stages. Tnnt-Cre; Hdac1F/+; Hdac2F/+ mice 
were crossed with Hdac1F/F; Hdac2F/F mice and samples were collected at the 





Nkx2.5IRES-Cre marks a multipotent progenitor population which gives rise to 
several cardiac cell types including cardiomyocytes, smooth muscle and 
endocardium[51, 429]. We genetically ablated Hdac1 and Hdac2 in each of these cell 
types to investigate where Hdac1/Hdac2 may be functioning. We did not observe 
similar phenotypes in either smooth muscle or endocardium with loss of 
Hdac1/Hdac2 (Appendix A-B). However, we found that deletion of Hdac1 and 
Hdac2 specifically within cardiomyocytes with Tnnt2-Cre[430] (Tnnt2;1KO2KO) 
caused embryonic lethality around E10.5 (Table 2.2), mirroring Nkx2.5;1KO2KO 
samples. Overall, these data suggest Hdac1 and Hdac2 function specifically within 
cardiomyocytes to sustain mammalian cardiogenesis at E10.5. 
To define transcriptional changes, we performed Affymetrix Clariom D Pico 
assays on E10.5 Nkx2.5;1KO2KO PHTs. Among 8,127 differentially regulated 
transcripts with NCBI identifiers, 52% were depressed in Nkx2.5;1KO2KO, while 
48% were increased (Figure 2.3A-B). PANTHER analysis showed enrichment in 
mitochondrial metabolism categories, such as TCA cycle, ATP formation, cristae 
formation, and complex I biogenesis without corollary upstream changes (Figure 
2.3C, Figure 2.4)[431-433]. Despite relatively equal numbers of up/down-regulated 
transcripts, enriched categories contained almost exclusively down-regulated 
genes, suggesting Hdac1/Hdac2 facilitate metabolic gene expression (Figure 
2.3C). We found corresponding reductions in mitochondrial DNA content relative 
to nuclear DNA in E10.5 Nkx2.5;1KO2KO PHTs (Figure 2.3D)[434]. Similarly, reduced 




E10.5 Nkx2.5;1KO2KO hearts confirms requirement of Hdac1 and Hdac2 for 
mitochondrial maturation (Figure 2.3E).  
There is a strong interrelationship between cardiac bioenergetics and 
structural development. Transition from early anaerobic fetal metabolism to 
OXPHOS, facilitated by mitochondrial permeability transition pore (mPTP) closure 
between E9.5-E11.5, is necessary and sufficient to drive cardiomyocyte 
differentiation[76]. Recent studies demonstrated E10.5 is a metabolic checkpoint 
with disruptions of cardiac bioenergetics resulting in early embryonic lethality. 
Consequently, we propose loss of Hdac1/Hdac2 disrupts the anaerobic to 









Figure 2.3 – Hearts lacking Hdac1 and Hdac2 exhibit dysregulation of 
metabolic and cardiac gene programs. (A) Analysis of differentially regulated 
transcripts at various levels. (B) Heatmap of identified, differentially regulated 
transcripts grouped by Spearman clustering. (C) Top enriched PANTHER 
Reactome terms (gold with parent categories (green). Doughnuts (right) show 
distribution of transcript changes. (D) Mitochondrial DNA (mtDNA) quantification 
relative to nuclear DNA (nDNA) in Nkx2.5;1KO2KO and 1FF2FF E10.5 PHTs (***, 
p=0.0005). (E) Atp5a, Slc25a24, and Got2 staining on Nkx2.5;1KO2KO and 1FF2FF 
E10.5 sagittal sections at AVC level with Hoechst nuclear counterstain. Grayscale 









Figure 2.4 - Loss of Hdac1/Hdac2 causes downregulation of metabolic and 
cardiac gene programs without concordant upstream changes. (A) Heatmap 
of Mitochondrial Biogenesis Reactome gene set (R-MMU-1592230). (B) Heatmap 
of Mitophagy Reactome gene set (R-MMU-5205647). (C) Heatmap of Tricarboxylic 
Acid Cycle (TCA Cycle) WikiPathways gene set (WP434). (D) Heatmap of Electron 
Transport Chain WikiPathways gene set (WP295) separated by individual chain 
components/complexes. Black text, significantly changed (FDR<0.05); gray text, 





We next determined how Hdac1/Hdac2 cooperate to facilitate metabolic 
transcriptional programs during cardiogenesis. Examination of exon-level 
expression data hearts revealed a transcriptional signature of lowered initiation at 
canonical transcription start sites (TSSCs) but increased initiation from 
downstream, alternative transcription start sites (TSSAs) specifically in 
downregulated metabolic transcripts (Figure 2.5A-G). Examination of raw exon-
level expression values suggest that results are independent of relative exon 
abundance or transcript recovery (Figure 2.6A-B). Highlighting two critical 
transcripts, citrate synthase (CS) and NADH:Ubiquinone Oxioreductase Subunit 
B9 (Ndufb9), we looked for evidence of non-canonical transcripts using 5’ Rapid 
Amplification of cDNA Ends (5’RACE). We identified strong control bands 
corresponding to canonical transcripts for both CS and Ndufb9 (Figure 2.5H-I). No 
canonical transcript was found for CS following Hdac1/Hdac2 ablation, instead a 
truncated transcript originating from a distal TSSA was identified (Figure 2.5H). 
Two alternative Ndufb9 transcripts were identified, originating from two distinct 
TSSAs. We observed decreased intensity of the canonical and 2nd alternative 
Ndufb9 transcripts in E10.5 Nkx2.5;1KO2KO hearts (Figure 2.5I). To confirm our 
findings, we quantified abundance of early exon junctions relative to late exon 
junctions, finding a significantly reduced ratio of early to late exon junction 
expression in Nkx2.5;1KO2KOs consistent with reduced canonical and increased 
alternative transcription (Figure 2.6C). Together, these results suggest 




facilitate the anaerobic to OXPHOS switch during early cardiac development[435, 
436]. 
Transcription-induced histone modifications at an alternative transcription 
start site can antagonize the permissive environment of proximal promoter and 
enhancer elements, attenuating gene expression from canonical transcription start 
site[410, 435]. Supporting this model, several covalent histone modifications have 
been associated with cryptic transcription including H3K14ac, H3K23ac, H4K16ac, 
and H3K36me3[437]. Nkx2.5;1KO2KO PHT nuclei exhibited an increased number of 
H3K23ac and H4K16ac foci at E10.5 (Figure 2.7A-B). Similarly, we observed 
enrichment of H3K36me3, H3K23ac, H3K14ac, and H4K16ac at the TSSAs of CS 
and Ndufb9, consistent with cryptic initiation of transcription (Figure 2.7C-F). 
Hdac1 and Hdac2 occupancy at the TSSA of CS, TSSA1 of Ndufb9, and TSSA2 of 
Ndufb9 in E10.5 PHTs (Figure 2.7G-I) suggest Hdac1/Hdac2 cooperatively and 
directly suppress activating histone marks throughout actively transcribed gene 










Figure 2.5 – Hdac1 and Hdac2 suppress cryptic transcription during 
cardiogenesis. (A) Distribution of differentially regulated transcripts (black), 
differentially regulated transcripts with a cryptic signature (red), and unchanged 
transcripts (grey) in Nkx2.5;1KO2KO compared to 1FF2FF E10.5 PHTs. (B-C) 
Normalized exon-level expression values for citrate synthase (CS, B) and Ndufb9 
(C) in Nkx2.5;1KO2KO and 1FF2FF E10.5 PHTs. (D-G) PANTHER (D-E) and GSEA 
(F-G) analysis of differentially regulated, identified cryptic transcripts. (H-I) 5’RACE 
for CS (F) and Ndufb9 (E). Left – 5’RACE products (Black – canonical; Blue/Green 
– alternative). Right – Alignment of sequenced products. TSSC, canonical TSS; 






Figure 2.6 - Loss of Hdac1/Hdac2 increases exonic transcript generation. (A-
B) Raw exon-level expression values (log2) for citrate synthase (CS, A) and Ndufb9 
(B) in Nkx2.5;1KO2KO and 1FF2FF E10.5 PHTs. (C) RT-qPCR showing the relative 
abundance of CS or Ndufb9 transcripts spanning an early exon junction (CS – 
Exon 1-2; Ndufb9 – Exon 1-2) compared to late exon junction (CS – Exon 6-7; 









Figure 2.7 - Hdac1 and Hdac2 cooperate to suppress cryptic transcription 
through deacetylation of key histone residues at alternative transcription 
start sites during mammalian cardiogenesis. (A-B) H3K23ac (A) and H4K16 
(B) staining on Nkx2.5;1KO2KO and 1FF2FF E10.5 sagittal sections at AVC level with 
cardiac troponin (cTnT) and Hoechst counterstains. Grayscale images are 
unedited. (C-F) H3K36me3 (C; *CS-C, p=0.0135; ***CS-A, p=0.0006; nsNdufb9-C, 
p=0.662; ***Ndufb9-A1, p<0.0001; *Ndufb9-A2, p=0.0328), H3K23ac (D; *CS-C, p=0.0129; 
*CS-A, p=0.0361; nsNdufb9-C, p=0.063; **Ndufb9-A1, p=0.0023; *Ndufb9-A2, p=0.0448), 
H3K14ac (E; *CS-C, p=0.0327; *CS-A, p=0.0161; nsNdufb9-C, p=0.588; *Ndufb9-A1, 
p=0.0168; nsNdufb9-A2, p=0.353), H4K16ac (F; **CS-C, p=0.0095; **CS-A, p=0.0013; 
nsNdufb9-C, p=0.788; **Ndufb9-A1, p=0.0059; *Ndufb9-A2, p=0.019) ChIP-qPCR showing 
relative enrichment over TSSC/TSSAs for CS and Ndufb9 in Nkx2.5;1KO2KO and 
1FF2FF E10.5 PHTs. (G-I) ChIP-qPCR showing relative enrichment (TSSA vs. 
TSSC) of Hdac1 (dark gray) and Hdac2 (light gray) at CS TSSA (G; **Hdac1, 
p=0.0014; *Hdac2, p=0.0156) ) and Ndufb9 TSSA1 (H; *Hdac1, p=0.021; **Hdac2, 
p=0.0032), TSSA2 (I; ***Hdac1, p=0.0005; *Hdac2, p=0.0291), normalized to IgG 
(black). (J) Schematic showing how Hdac1/Hdac2 control cardiomyocyte 
development at a critical metabolic checkpoint. TSSC, canonical TSS; TSSA#, 
alternative TSS; AVC, atrioventricular canal; PrV, primitive ventricle; CHD, 







To our knowledge, this report is the first link between HDACs and cryptic 
transcription during vertebrate development and the first to link cryptic transcription 
and mitochondrial function. Cryptic transcription is observed in lower organisms 
and mammalian cell lines, yet no reports describe cryptic transcription in a 
vertebrate system[435, 437-443]. In yeast, cryptic transcription is regulated by Set2 and 
Rpd3s[409, 411, 415]. Set2, an H3K36 methyltransferase, is recruited to active loci by 
RNA Polymerase II, causing accumulation of H3K36 trimethylation. H3K36me3 
recruits Rpd3s (homologous to the Sin3 complex) through Eaf3’s chromodomain 
to deacetylate residues including H3K23, H3K14, and H4K16[415, 435, 437, 444, 445]. 
This axis restores basal chromatin conformations following transcription, 
preventing cryptic initiation of transcription. HDAC or DNA methyl transferase 
inhibition increases cryptic transcription across the genome suggesting much 
much like inappropriately condensed chromatin can disrupt initiation, cryptic 
transcription results from inappropriately open chromatin[410, 437]. Open 
conformations expose non-canonical promoter and enhancer regions to act as 
initiation sites, driving the synthesis of non-coding mRNA transcripts and disrupting 
canonical transcription. Cumulatively, these results suggest chromatin 
homeostasis is crucial for ordered transcription. Here we demonstrate mammalian 
Rpd3 homologs, Hdac1/Hdac2, redundantly suppress cryptic initiation of 




developing murine hearts promotes cryptic transcription at metabolic loci, including 
CS and Ndufb9, during a critical period of bioenergetic maturation. Mechanistically, 
we identified accumulation of H3K36 trimethylation and H3K23/H3K14/H4K16 
acetylation consistent with inappropriately open chromatin at the TSSAs of CS and 
Ndufb9. This suggests Hdac1/Hdac2, much like Rpd3, suppress cryptic 
transcription by restoring basal chromatin accessibility following transcription 
(Figure 2.7J).  
Despite being termed “co-repressors” and a repressive mechanism of 
action, Hdac1/Hdac2 are enriched in gene bodies of actively transcribed genes[407]. 
Additionally, transcriptome analysis following Hdac1/Hdac2 inhibition/inactivation 
reveals a mix differential gene expression consistent with HDACs having both 
permissive and repressive roles. We propose a mechanism that reconciles the 
repressive enzymatic activity of Hdac1/Hdac2 with their experimentally-defined 
roles as transcriptional activators. Our study suggests Hdac1/Hdac2 restore basal 
chromatin conformation of active loci by pruning activating histone marks 
deposited during transcription. We show that Hdac1/Hdac2 cooperatively regulate 
genome-wide levels of H3K23 and H4K16 acetylation, two marks associated with 
cryptic transcription, with loss of Hdac1/Hdac2 increasing cryptic transcription. 
These data, and previous literature reports, establish Hdac1/Hdac2 with duals 





Our study highlights the integration of epigenetics, transcriptional fidelity, 
and metabolism during murine cardiogenesis. Early in development, the PHT 
sustains contraction through anaerobic metabolism[417, 433]. Between E9.5-E11.5 
the mPTP closes, establishing an electrochemical gradient for oxidative energy 
production[71, 76]. Failure causes lethality, positioning E10.5 as a checkpoint of 
cardiac bioenergetic maturation[80-82, 426, 433]. Our study demonstrates 
Hdac1/Hdac2 are required to pass this bioenergetic checkpoint, with loss 
precipitating embryonic lethality from failure of oxidative metabolism. Abnormally 
thinned myocardium, down regulated metabolic genes, and lethality between 
E10.5 and E11.5 in Nkx2.5;1KO2KO are consistent with failure to pass this 
checkpoint. Additionally, cytoplasmic accumulations of lipid droplets and abnormal 
mitochondrial morphology are consistent with a failed transition. Mechanistically, 
Hdac1/Hdac2 maintain transcriptional fidelity of gene programs required for 
mitochondrial biogenesis, including all complexes of the electron transport chain. 
Overall, this study establishes Hdac1/Hdac2 as regulators of cardiac bioenergetic 
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CHAPTER III – Dose-dependent roles for Hdac1 and Hdac2 during outflow 
tract development 
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Abstract 
Background: Approximately 40,000 infants are born in the US each year with 
congenital heart defects. Of these, one third have pathology affecting the outflow 
tract (pulmonary artery and aorta). Despite evidence that class I histone 
deacetylases regulate mammalian outflow tract morphogenesis, the roles of 
Hdac1 and Hdac2 in this process remain undefined. 
Results: Complete loss of Hdac1/Hdac2 in the murine second heart field is 
embryonically lethal around E9.5. A single allele of either Hdac1 or Hdac2 rescues 
embryonic lethality. Interestingly, embryos expressing a single allele of either 
Hdac1 or Hdac2 in the second heart field die perinatally from cyanosis, persistent 
truncus arteriosus, interrupted aortic arch, and ventricular septal defect while 




Embryos expressing a single allele of Hdac1 or Hdac2 in the second heart field 
have outflow tract elongation defects at E9.5. Mechanistically, transcriptome 
analysis identifies that Hdac1 and Hdac2 coordinate expression of diverse sets of 
genes, including extracellular matrix genes. These results suggest that posterior 
second heart field cells are unable to join the primitive heart tube at E9.5 owing to 
migration and signaling defects.  
Conclusions: Overall, our results show that Hdac1 and Hdac2 redundantly regulate 
second heart field progenitor number and distribution. Additionally, within the 
posterior second heart field Hdac1/Hdac2 facilitate outflow tract elongation and 




 Each year approximately 40,000 infants are born in the United States with 
congenital heart defects, making it the most common congenital anomaly and a 
leading cause of death in the first five years of life[3, 4]. Although congenital heart 
disease affects all parts of the heart, almost one third of patients have defects in 
the outflow tract (pulmonary artery and aorta)[52]. Defects in outflow tract 
development are often severe, requiring clinical intervention within the first year of 
life[3, 7]. Commonly, outflow tract dysfunction presents as neonatal cyanosis owing 




Despite their high prevalence, the developmental origins of congenital outflow tract 
defects remain elusive. 
In mammals, the heart is the first embryonic organ to form during 
development and its vital pumping action sustains embryogenesis[16]. Initially, 
E8.25 in mice, the first heart field forms a linear, beating, heart tube at the anterior 
midline of the embryo[48, 49]. The embryonic outflow tract is a single vessel, the 
truncus arteriosus, that carries blood away from the arterial pole of the primitive 
heart tube[52]. As development progresses, second heart field progenitor cells 
residing in the dorsal pericardial wall join the primitive heart tube enabling 
elongation, looping, rotation[53], and outflow tract septation. Interestingly, studies 
have repeatedly shown patterning defects at the initial stage of outflow tract 
formation result in outflow tract abnormalities at birth[53-56, 59, 143, 147, 148, 193]. 
The anterior portion of the second heart field primarily contains myocardial 
cells at the arterial pole of the primitive heart tube while the posterior portion is a 
pool of highly proliferative undifferentiated cells[59]. The posterior second heart 
field, guided by the surrounding neural crest and primitive heart tube, provides a 
steady stream of cells to both the arterial and venous cardiac poles, enabling 
elongation, looping, rotation, and septation[59]. Between E9.5-E10.5, the second 
heart field and neural crest populate formerly acellular intraluminal swellings within 
the truncus arteriosus termed endocardial cushions[62-64]. These endocardial 




aorticopulmonary septum which migrates proximally, dividing the truncus 
arteriosus into the aorta and pulmonary artery[56]. 
Failure to divide the outflow tract causes persistent truncus arteriosus and 
neonatal cyanosis due to the mixing of oxygenated and deoxygenated blood as 
they leave the heart[53]. Clonally, the proximal portions of the outflow tract, primarily 
the sub-pulmonary portions of the aorta and pulmonary artery, are derived from 
the second heart field while the distal outflow tract arises from cardiac neural crest 
cells[59, 93, 141, 142]. Interestingly, proximal outflow tract defects, such as persistent 
truncus arteriosus, often occur with distal defects, as interrupted aortic arch[126, 155, 
159, 160]. Interruption of the aortic arch means that communication between the 
proximal and distal aortic arch is absent; Instead, blood flows through the ductus 
arteriosus to the systemic circulation. The combination of interrupted aortic arch 
and persistent truncus arteriosus is clinically classified as type A4 persistent 
truncus arteriosus[53]. Interestingly, studies of murine cardiogenesis recognized 
that persistent truncus arteriosus arises from disturbances in either anterior second 
heart field, posterior second heart field, or cardiac neural crest progenitors[92], 
however many of the factors regulating this process remain undefined. 
 Persistent truncus arteriosus has been observed in patients with copy 
number variation at specific genomic regions, including 22q11.2, 1p35, and 6q21-
22, suggesting they play a role in the pathogenesis of outflow tract anomalies[159, 
160, 227, 228, 345]. Initial studies found that TBX1 disruption, which resides within the 




field is responsible for some cases of persistent truncus arteriosus seen in 
22q11.2The causative genes in 1p35 and 6q21-22 remain undefined. 
There is a growing consensus that epigenetic regulation of chromatin plays 
a critical role in development and disease. A recent study identified that mutations 
in histone modifying genes are enriched in populations that outflow tract defects 
while evidence from our lab and others demonstrated that class I HDACs modulate 
many developmental and cellular processes including cardiac hypertrophic 
responsiveness, cardiomyocyte proliferation, cardiac progenitor cell differentiation, 
crest proliferation, cardiomyocyte metabolic maturation, and endothelial-
mesenchymal transition during cardiogenesis[223, 357-359, 372, 373, 382, 390, 446]. 
Additionally, our lab recently identified that Hdac3, a class I HDAC, plays a major 
role in mammalian outflow tract development[372]. The typically altered regions in 
the 1p35 and 6q21-22 syndromes include HDAC1 and HDAC2 respectively, 
suggesting they may regulate mammalian outflow tract morphogenesis[227, 228, 345]. 
HDAC1 and HDAC2 are highly homologous, broadly expressed class I histone 
deacetylases and core components of the Sin3, NuRD, and Co-REST regulatory 
complexes[275, 276, 342]. Despite their developmental importance and residence in 
the typically altered regions of the 1p35 and 6q21-22 syndromes, the roles of 
HDAC1 and HDAC2 in outflow tract development remain unknown. Here we 
demonstrate that Hdac1 and Hdac2 regulate outflow tract elongation, septation, 






Materials and Methods 
Mice 
Isl1-Cre[447], Mef2C-Cre[150], R26R-LacZ[448], R26R-mG/mT[449], Hdac1Flox[390], and 
Hdac2Flox[428] mice used in this study have been previously described. All animal 
protocols were approved by the University of Massachusetts Medical School 
Institutional Animal Care and use Committee (IACUC). Embryonic samples were 
generated via timed mating. Following the identification of a vaginal plug, pregnant 
females were isolated, sacrificed, and embryos dissected at the appropriate 
embryonic timepoint. Mice were then separated into groups according to their 
genotype and developmental stage for further analysis. 
 
Histology 
Tissue samples were collected, fixed in 4% paraformaldehyde in 1X PBS at 4ºC 
overnight, dehydrated through an ethanol gradient, embedded in paraffin, and 
section at 8µm thickness on a Leica fully motorized rotary microtome. 
 
Antibodies and Reagents 
The following antibodies were used in this study: Hdac1 (Abcam), Hdac2 (Thermo-
Fisher). Eosin Y and Harris modified hematoxylin were obtained from Fisher while 
X-gal was purchased from 5-Prime. Vectashield permanent mounting medium, 
Vectashield Elite ABC reagent kit, and DAB peroxidase substrate kit were 






Images of dissected embryos were captures on a Leica Mz10 F fluorescence 
stereomicroscopy via a 0.7X C-mount, Achromat 1.0 x 90 mm objective, SOLA 
light engine (Lumencore), DS-Fi1 color camera (Nikon) through NIS-Elements 
Basic Research Software (Nikon). Images of stained sections were captures using 
a Nikon Eclipse 80i microscope via CFI Plan Fluro 4X/10X/20X/40X objective 
lenses, SOLA light engine, DS-Fi1 color camera, and NIS-Elements Basic 
Research Software. All analysis was performed on at least 3 biologically 
independent samples (n=3). 
 
Hematoxylin and Eosin Staining 
Staining was performed via deparaffinizing sections in xylenes, rehydrating 
through an ethanol gradient, a 30sec stain with 30% Harris modified hematoxylin 
(in diH2O) followed by a 30sec counterstain with eosin Y. Stained slides were 
rinsed and then dehydrated through an ethanol gradient, cleared with xylenes, and 
mounted using Vectashield Permanent Mounting Medium. All analysis was 
performed on at least 3 biologically independent samples (n=3). 
 
LacZ (β-gal) Staining 
Samples for LacZ (β-gal) staining were quickly dissected in cold PBS and fixed in 
2% paraformaldehyde for 30min at 4ºC. Samples were then washed in PBS at 
room temperature and stained overnight in staining solution (5mM potassium 




0.04% Nonidet P40, 0.1% X-gal, in 1X PBS) in the dark at 37ºC or until staining 
developed. Samples were then washed in 1X PBS and fixed overnight in 4% 
paraformaldehyde in PBS at 4ºC. All analysis was performed on at least 3 
biologically independent samples (n=3). 
 
Immunohistochemistry 
Selected sections were deparaffinized in xylenes, pretreated using the Aptum 
Antigen Retriever 2100 and Aptum R-Buffer A or Sodium Citrate Buffer (pH 6.0). 
Immunohistochemistry was conducted with the Vectastain Elite ABC kit and DAB 
Peroxidase Substrate kit following manufacturer guidelines. Sections were 
incubated with primary antibody (Hdac1 1:100; Hdac2 1:100) overnight at 4ºC. If 
performed, counterstaining consisted of 30 sec incubation with 30% Harris 
modified hematoxylin (in diH2O) after 3,3’-diaminobenzidine development. All 
slides were ethanol-dehydrated, cleared with xylenes, and mounted using 
Vectashield permanent mounting medium. 
 
Morphometric Analysis 
Quantitative morphologic analysis was performed using ImageJ software to 
measure and record anatomical features of interest. Average measurements were 
calculated for each condition and are presented as mean (SD). All analysis was 
performed on at least 3 biologically independent samples (n=3). 




Posterior second heart fields were isolated from E9.5 mouse embryos via 
fluorescent microdissection using R26R-mG/mT as a reporter/guide and snap-
frozen in liquid nitrogen before being stored at -80ºC. RNA was extracted from 
pools of Isl1;1Het2Het, Isl1;1KO2Het, Isl1;1Het2KO, and Isl1;1KO2KO posterior second 
heart fields using a Qiagen RNeasy Plus Micro kit. Then Clariom D Transcriptome 
Assay (Affymetrix) was performed in triplicate (n=3) from pooled samples by the 
University of Massachusetts Genomics Core Facility. Raw data were analyzed 
using the Affymetrix Transcriptome Analysis Console with a significant cutoff of 
FDR<0.05. Data were further analyzed using DAVID Functional Annotations 
Bioinformatics Microarray Analysis and PANTHER Gene List Analysis using 
default settings. Lists of enriched ontologic categories were generated and used 
to create heatmaps and enrichment plots. Heatmaps of were generated using 
GraphPad Prism. Relative transcript expression is reported as the log-transformed 
expression value is normalized to the median across all six samples.  
 
Statistical Analysis 
Data are shown as means with error bars representing the standard deviation 
(mean(SD)). Significant differences between means were determined using an 
unpaired two-tailed Student’s t-test or χ2 test. The level of significance (α) was set 
at 0.05 for all analyses. Per GraphPad Prism standard annotation: ns, p>0.05, *, 
p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001. Analysis was performed using 







Hdac1 and Hdac2 function semi-redundantly within Isl1-Cre+ progenitor cells 
 While the genetic underpinnings of outflow tract development are 
established, the role of Hdac1 and Hdac2 in mammalian outflow maturation 
remains undefined. To investigate how Hdac1 and Hdac2 contribute to mammalian 
outflow tract morphogenesis, we genetically ablated Hdac1 and Hdac2 in murine 
second heart field progenitor cells using Isl1-Cre[447], Hdac1Flox[390], and 
Hdac2Flox[428] alleles. Isl1-Cre;Hdac1Flox/+ Hdac2Flox/+ males were crossed with 
Hdac1Flox/Flox, Hdac2Flox/Flox females and offspring were collected at various 
timepoints (Table 3.1). Mice lacking both Hdac1 and Hdac2 (Isl1;1KO2KO) were not 
recovered at birth (P0), indicating embryonic lethality. Mice with a single allele of 
Hdac1 (Isl1;1Het2KO) or Hdac2 (Isl1;1KO2Het) were recovered in Mendelian ratios 
(Table 3.1). Single allele pups were in distress or deceased when collected. The 
pups recovered alive were cyanotic, showed increased work of breathing, and 
exhibited minimal response to painful stimuli, suggesting a single allele of 
Hdac1/Hdac2 is unable to sustain mice beyond the perinatal period (Figure 3.1). 
Immunostaining for Hdac1 and Hdac2 confirmed loss of Hdac1 but not Hdac2 in 
Isl1;1KO2Het hearts and loss of Hdac2 but not Hdac1 in Isl1;1Het2KO hearts at P0, 
indicating efficient recombination of Hdac1 and Hdac2 by Isl1-Cre (Figure 3.2).  
Isl1-Cre+ descendants contribute primarily to the right ventricle, outflow 
tract, and atria so we examined the hearts of single allele mice at P0 (Figure 3.3)[15, 




engorged atria compared to 1FF2FF controls. Isl1;1Het2KO hearts were of 
comparable size to 1FF2FF hearts, however they also displayed prominent surface 
vasculature and enlarged atria. Careful dissection revealed a singular outflow tract 
vessel in Isl1;1KO2Het and Isl1;1Het2KO hearts consistent with persistent truncus 
arteriosus (Figure 3.3A). Additionally, we observed an interrupted aortic arch 
where the ascending aorta supplies the head and a persistent/dilated ductus 
arteriosus supplies the descending aorta and systemic circulation (Figure 3.3A). 
Clinically, this is defined as Van Praagh type A4 persistent truncus arteriosus[53]. 
To further investigate the abnormal cardiac anatomy observed, we dehydrated, 
embedded, and cut frontal sections of 1FF2FF, Isl1;1KO2Het, and Isl1;1Het2KO P0 
hearts. 1FF2FF hearts have clearly defined and distinct pulmonary and aortic valves 
with refined leaflets at P0. Single allele hearts had a single truncal valve with 
abnormally thickened leaflets and a common arterial outflow (Figure 3.3B). 
Additionally, we also observed a ventricular septal defect, connecting the left and 
right ventricles (Figure 3.3C). Together, these analyses confirm that a single allele 
of Hdac1 or Hdac2 is sufficient to sustain mice to birth, but in insufficient for proper 





 Observed (Expected) 
Genotype P0 E14.5 E9.5 
Hdac1F/+, Hdac2F/+ 12 (9) 15 (8) 22 (21) 
Hdac1F/F, Hdac2F/+ 8 (9) 5 (8) 24 (21) 
Hdac1F/+, Hdac2F/F 8 (9) 11 (8) 15 (21) 
Hdac1F/F, Hdac2F/F 12 (9) 9 (8) 32 (21) 
Isl1-Cre; Hdac1F/+, Hdac2F/+ 9 (9) 6 (8) 20 (21) 
Isl1-Cre; Hdac1F/F, Hdac2F/+ 10a (9) 4 (8) 20 (21) 
Isl1-Cre; Hdac1F/+, Hdac2F/F 13b (9) 7 (8) 17 (21) 
Isl1-Cre; Hdac1F/F, Hdac2F/F 0 (9) 7c (8) 18d (21) 
Total (p value): 72 (p=0.069) 64 (p=0.128) 168 (p=0.236) 
 
Table 3.1: Genotypes of samples lacking Hdac1/Hdac2 in second heart field 
progenitors, collected at various developmental stages. Isl1-Cre; Hdac1F/+; 
Hdac2F/+ mice were crossed with Hdac1F/F; Hdac2F/F mice and samples were 
collected at the designated time point. a8 pups found cyanotic and in embryonic 
distress. b2 pups recovered cyanotic and in embryonic distress. c7 embryos found 





Figure 3.1 – Mice with a single allele of Hdac1 or Hdac2 appear cyanotic and 
in distress shortly after birth. Control pups (left) appear pink and in no distress. 
Isl1;1Het2KO pups (middle) appear pale with increased work of breathing, consistent 
with cyanosis. Isl1;1KO2Het pups (right) are cyanotic and only minimally responsive 





Figure 3.2 – Isl1Cre efficiently recombines Hdac1 and Hdac2 in right 
ventricular myocardium at birth. Hdac1 immunostaining (brown, left) or Hdac2 
immunostaining (brown, right) on 1FF2FF (top), Isl1;1KO2Het (middle), and 
Isl1;1Het2KO (bottom) right ventricular myocardium. Black arrows indicate preserved 







 Observed (Expected) 
Genotype P0 E9.5 
Hdac1F/+, Hdac2F/+ 8 (8.75) 8 (8.75) 
Hdac1F/F, Hdac2F/+ 6 (8.75) 5 (8.75) 
Hdac1F/+, Hdac2F/F 11 (8.75) 12 (8.75) 
Hdac1F/F, Hdac2F/F 11 (8.75) 7 (8.75) 
Mef2c-Cre; Hdac1F/+, Hdac2F/+ 16 (8.75) 16 (8.75) 
Mef2c-Cre; Hdac1F/F, Hdac2F/+ 10 (8.75) 9 (8.75) 
Mef2c-Cre; Hdac1F/+, Hdac2F/F 8 (8.75) 8 (8.75) 
Mef2c-Cre; Hdac1F/F, Hdac2F/F 0 (8.75) 5 (8.75) 
Total (p value): 70 (p=0.169) 70 (p=0.142) 
 
Table 3.2: Genotypes of samples lacking Hdac1/Hdac2 in anterior second 
heart field progenitors, collected at various developmental stages. Mef2c-
Cre; Hdac1F/+; Hdac2F/+ mice were crossed with Hdac1F/F; Hdac2F/F mice and 





Figure 3.3 – Disruption of Hdac1 and Hdac2 in Isl1Cre+ progenitors results in 
persistent truncus arteriosus, interrupted aortic arch, and ventricular septal 
defect at birth. (A) Gross images of dissected and isolated P0 1FF2FF (left), 
Isl1;1KO2Het (right, top), and Isl1;1Het2KO (right, bottom) hearts with or without atria 
removed. (B) Hematoxylin and eosin stained frontal sections of 1FF2FF (left), 
Isl1;1KO2Het (right, top), and Isl1;1Het2KO (right, bottom) hearts at the level of the 
pulmonary valve (left, top), aortic valve (left, bottom), and truncal valve (right). (C) 
Hematoxylin and eosin stained frontal sections of 1FF2FF (left), Isl1;1KO2Het (right, 
top), and Isl1;1Het2KO (right, bottom) hearts at the level of the pulmonary valve (left, 
top), aortic valve (left, bottom), and truncal valve (right) showing a ventricular 
septal defect. RA, right atrium; (RA), right atrium removed; LA, left atrium; (LA), 
left atrium removed; RV, right ventricle; LV, left ventricle; Ao, aorta; PA, pulmonary 
artery; PTA, persistent truncus arteriosus; IAA, interrupted aortic arch; PV, 
pulmonic valve; AV, aortic valve; TV, truncal valve; VSD, ventricular septal defect; 





Hdac1 and Hdac2 function in a dose-dependent manner specifically within the 
posterior second heart field to facilitate outflow tract elongation at E9.5  
 
 The second heart field has two divisions: the anterior second heart field and 
the posterior second heart field[59, 93, 147]. The anterior division, targeted by Mef2C-
Cre, contains differentiated cardiac cells while the posterior portion, lacking a 
distinct Cre marker, is a pool of uncommitted progenitors[150]. To characterize 
whether Hdac1 and Hdac2 function specifically within the anterior second heart 
field, we crossed Mef2C-Cre;Hdac1Flox/+ Hdac2Flox/+ males with Hdac1Flox/Flox 
Hdac2Flox/Flox females and collected offspring at various developmental timepoints 
(Table 3.2). Similar to Isl1-Cre, we found that mice lacking both Hdac1 and Hdac2 
in the anterior second heart field (Mef2C;1KO2KO) died during development. 
Interestingly, we found that single allele mice (Mef2C;1KO2Het and Mef2C;1Het2KO) 
were recovered at birth in expected Mendelian ratios without any survival or 
structural defects. In fact, mice with a single allele of Hdac1 or Hdac2 in the anterior 
second heart field live free from any apparent defects for upwards of 30 weeks 
(data not shown). These results suggest that Hdac1 and Hdac2 function 
redundantly within both segments of the second heart field but dose-sensitive 
functions of Hdac1 and Hdac2 are restricted to the posterior second heart field.  
Mammalian outflow tract development is an intricate process involving 
elongation, septation, rotation, and remodeling of the truncus arteriosus into the 




the addition of second heart field progenitors to the primitive heart tube, facilitating 
formation and elongation of an immature outflow tract[51, 56]. Failure of proper 
development at this stage disrupts downstream events, including septation[52]. 
Disruption of Hdac1/Hdac2 in second heart field progenitor cells disrupts outflow 
tract morphology at birth, indicating they modulate embryonic outflow tract 
development. Consequently, we collected embryos at E9.5 and examined outflow 
tract morphology (Figure 3.4) with a R26R-LacZ[448] allele to track the number and 
distribution of Cre+ cells. The overall morphology of Isl1;1Het2Het and Mef2C;1Het2Het 
embryos is comparable at E9.5 (Figure 3.4A). In Mef2C-Cre samples, we noted 
LacZ staining is restricted to the primitive right ventricle, immature outflow tract, 
with minimal staining in the pharyngeal mesoderm and dorsal pericardial wall while 
in Isl1-Cre samples, LacZ staining was observed within the primitive right ventricle, 
immature outflow tract, with broad in the pharyngeal mesoderm and dorsal 
pericardial wall. We also noted that Isl1-Cre+ cells extend cranially into the first and 
second pharyngeal arches and caudally with isolated staining in the distal tail. 
Overall morphology and LacZ staining of Isl1;1KO2Het and Isl1;1Het2KO 
embryos are similar to Isl1;1Het2Het controls. Isl1;1KO2KO embryos at E9.5 exhibit 
reduced intensity and distribution of LacZ staining consistent with depletion of Isl1-
Cre+ progenitors at E9.5. Mef2C;1KO2Het and Mef2C;1Het2KO embryos appear 
similar to Isl1;1Het2Het and Mef2C;1Het2Het controls, while Mef2C;1KO2KO embryos 




Close examination of the primitive heart tube suggested Isl1;1KO2Het, 
Isl1;1Het2KO, and Isl1;1KO2KO embryos have a shortened outflow tract and primitive 
right ventricle (Figure 3.4A). Additionally, Isl1;1KO2KO hearts appear abnormally 
rotated. Consequently, we performed quantitative morphometric analysis (Figure 
3.4B-D). Outflow tract length, from the body wall to the outer right ventricular wall, 
was significantly decreased in Isl1;1KO2Het, Isl1;1Het2KO, and Isl1;1KO2KO but outflow 
tract length was unchanged with disruption of Hdac1 and Hdac2 by Mef2C-Cre 
(Figure 3.4B). Additionally, primitive right ventricular length was significantly 
shortened in Isl1;1KO2Het, Isl1;1Het2KO, and Isl1;1KO2KO compared to controls but 
that right ventricular length was unchanged in all Mef2C-Cre samples (Figure 
3.4C). Finally, there is a significant increase in the outflow tract-right ventricle angle 
in Isl1;1KO2KO E9.5 embryos compared to Isl1;1Het2Het embryos (Figure 3.4D). We 
did not identify any significant changes in any other Isl1-Cre or Mef2C-Cre 
genotypes. Together this suggests Hdac1 and Hdac2 redundantly maintain 
second heart field progenitors at E9.5. Additionally, these data indicate that a 
single allele of Hdac1 or Hdac2 within either Isl1-Cre or Mef2C-Cre progenitors is 
able to rescue the depletion of progenitor cells visualized by decreased lacZ 
staining. Finally, a single allele of Hdac1 or Hdac2 in Isl1-Cre progenitor cells is 
unable to facilitate proper outflow tract elongation, resulting in a significantly 










Figure 3.4 – Hdac1 and Hdac2 function in a dose-dependent manner 
specifically within the posterior segment of the second heart field to facilitate 
outflow tract elongation at E9.5. (A) Left lateral views of Isl1;1Het2Het, Isl1;1KO2Het, 
Isl1;1Het2KO, Isl1;1KO2KO, Mef2C;1Het2Het, Mef2C;1KO2Het, Mef2C;1Het2KO; and 
Mef2C;1KO2KO embryos at E9.5. (B-D) Quantification of outflow tract length (B; 
**Isl1-1KO2Het, p=0.0037; **Isl1-1Het2KO, p=0.0017; *Isl1-1KO2KO, p=0.0132; nsMef2C-1KO2Het, 
p=0.967; nsMef2C-1Het2KO, p=0.747; nsMef2C-1KO2KO, p=0.439), primitive right 
ventricular length (C; **Isl1-1KO2Het, p=0.0071; *Isl1-1Het2KO, p=0.0104; *Isl1-1KO2KO, 
p=0.0346; nsMef2C-1KO2Het, p=0.963; nsMef2C-1Het2KO, p=0.997; nsMef2C-1KO2KO, 
p=0.998), and outflow tract-right ventricle angle (D; nsIsl1-1KO2Het, p=0.328; nsIsl1-
1Het2KO, p=0.155; *Isl1-1KO2KO, p=0.0174; nsMef2C-1KO2Het, p=0.873; nsMef2C-1Het2KO, 
p=0.929; nsMef2C-1KO2KO, p=0.174) at E9.5 in Isl1;1Het2Het, Isl1;1KO2Het, Isl1;1Het2KO, 
Isl1;1KO2KO, Mef2C;1Het2Het, Mef2C;1KO2Het, Mef2C;1Het2KO; and Mef2C;1KO2KO 





Transcriptome analysis of Isl1;1KO2Het and Isl1;1Het2KO hearts reveals 
dysregulation of discrete sets of genes, including extracellular matrix genes 
 As dose-dependent functions of Hdac1 and Hdac2 are restricted to the 
posterior segment of the second heart field, we performed a fluorescent guided 
microdissection to specifically isolate this population (Figure 3.5A)[449]. We 
crossed Isl1;1Het2Het males with 1FF2FF;R26RmG/mT females, collected E9.5 
embryos, and dissected GFP+ tissue in the pharyngeal mesoderm inferior to the 
pharyngeal arches, superior to the primitive gut, and ventral to the neural tube 
(Figure 3.5A). Consistent with LacZ staining, we observed a decrease in overall 
intensity and distribution of GFP expression in Isl1;1KO2KO samples. Using the 
isolated posterior second heart fields, we performed an Affymetrix Clariom D 
transcriptome assay to define the transcriptional changes following disruption of 
Hdac1 and Hdac2. Comparing Isl1;1KO2KO to control, we identified 1706 
differentially regulated, transcripts with NCBI identifiers (data not shown). Of these, 
941 were downregulated (55.16%) while 765 were upregulated (44.84%). 
Ontologically, downregulated genes enriched in cardiac development and 
cardiomyocyte proliferation categories while upregulated genes clustered as 
contractile genes. From these changes, we hypothesized that ablation of both 
Hdac1 and Hdac2 results in premature differentiation of Isl1-Cre progenitor cells, 
reducing proliferation, and depleting second heart field progenitors at E9.5. While 




to the dose-dependent roles of Hdac1 and Hdac2 specifically within the posterior 
second heart field. 
 Using a significance cutoff of FDR<0.05, there are 175 differentially 
regulated transcripts with NCBI identifiers in the Isl1;1KO2Het E9.5 posterior second 
heart field compared to controls (Figure 3.5B). Additionally, there are 471 
differentially regulated, identified transcripts in the Isl1;1Het2KO E9.5 posterior 
second heart field compared to controls (Figure 3.5B). A greater number of 
dysregulated transcripts with a single allele of Hdac1 compared to Hdac2 is 
interesting given the general trend observed during embryogenesis that Hdac1 
plays a more critical role than Hdac2. Of these differentially regulated transcripts 
in the single allele posterior second heart fields, 105 transcripts were common 
between Isl1;1KO2Het and Isl1;1Het2KO. Out of the 105 common transcripts, 67 were 
downregulated in both cases, 30 were upregulated in both cases, and 8 were not 
consistently regulated between the two experimental conditions (Figure 3.5B). A 
heatmap showing the commonly dysregulated transcripts in both conditions is 
presented, showing general concordance between conditions (Figure 3.5C). We 
utilized these lists of differentially regulated, identified transcripts for PANTHER 
gene ontology (Figure 3.5 D-G). Using the list of all commonly dysregulated, 
identified transcripts, PANTHER Cellular Component enrichment analysis found 
significant enrichment in primarily transcripts coding for proteins with extracellular 
functions (Figure 3.5D). Reactome analysis using just commonly downregulated 




molecular function showed similar results for all common differentially regulated 
transcripts (Figure 3.5F) and commonly downregulated transcripts (Figure 3.GH). 
Overall these results suggest that Hdac1 and Hdac2 facilitate expression of key 
extracellular signaling molecules and structural proteins within the posterior 









Figure 3.5 – Transcriptome analysis of micro-dissected E9.5 posterior 
second heart field tissue in Isl1;1KO2Het and Isl1;1Het2KO. (A) Fluorescent-
guided microdissection of posterior second heart field containing domain in E9.5 
Isl1;1Het2Het, Isl1;1KO2Het, Isl1;1Het2KO, and Isl1;1KO2KO embryos. Green indicates 
Isl1-Cre expressing cells. (B) Commonly dysregulated, identified transcripts 
between Isl1;1KO2Het and Isl1;1Het2KO transcriptome analysis. (C) Heatmap 
showing distribution of commonly dysregulated, identified transcripts with matched 
fold-change magnitudes in Isl1;1KO2Het and Isl1;1Het2KO at E9.5. (D-G) PANTHER 
gene ontology enrichment analysis by cellular component (D), reactome (E, 
downregulated common identified transcripts), and molecular function (F, all 
common identified transcripts; G, downregulated common identified transcripts) 









Figure 3.6 – Altered development resulting from disruption of Hdac1 and 
Hdac2 in the posterior second heart field. (A) Between E8.5 and E9.5, posterior 
second heart field (pSHF) cells join the poles of the primitive heart tube, enabling 
elongation. (B) Addition of posterior second heart field progenitor cells is defective 
in Isl1;1KO2Het and Isl1;1Het2KO embryos, resulting in a shortened outflow tract at 
E9.5. (C) Resultant type A4 persistent truncus arteriosus in Isl1;1KO2Het and 
Isl1;1Het2KO pups at birth. aSHF, anterior second heart field; pSHF, posterior 
second heart field; CNC, cardiac neural crest cells; OFT, outflow tract; RV, right 
ventricle; LV, left ventricle; FHF, first heart field; Ao, aorta; PA, pulmonary artery; 








 Outflow tract development is a complex process requiring multiple 
progenitor populations[52]. Consequently, disruption of outflow tract morphogenesis 
stems from varied points and causes varied of symptoms, ranging from clinically 
silent to life-threatening[4, 7, 52]. Recent evidence characterized the posterior second 
heart field as especially critical to outflow tract development[59, 152]. While much of 
the dynamics of outflow tract development is understood, the role of epigenetics 
and histone modifying enzymes in this process is not well explored. Our lab and 
others have shown that class I histone deacetylases, the primary nuclear 
deacetylases, control cardiogenesis and outflow tract development[275, 358, 372, 382]. 
Specifically, Hdac3 was found to silence TGF-β1 with ablation of Hdac3 leading to 
inappropriate epithelial-to-mesenchymal transition and a spectrum of outflow tract 
defects[372]. There are no direct links between Hdac1/Hdac2 and mammalian 
outflow tract morphogenesis. However, they reside within the typically altered 
region of a pair of rare chromosomal syndromes with outflow tract anomalies, 
suggesting a yet undiscovered role in outflow tract development[227, 228, 345]. 
 Mice with genetic ablation of Hdac1 and Hdac2 in both the second heart 
field (Isl1-Cre) and anterior second heart field (Mef2C-Cre) display complete 
embryonic lethality (Table 3.1-3.2) and depletion of second heart field progenitors 




Hdac2 do not display progenitor depletion, instead surviving to birth. This suggests 
Hdac1 and Hdac2 redundantly maintain second heart field progenitors at E9.5. 
Depletion of progenitors at E9.5 suggests a failure to balance proliferation 
and apoptosis. Transcriptome analysis of Isl1;1KO2KO E9.5 posterior second heart 
fields reveals gene changes consistent with reduced proliferation, yet increased 
cardiac differentiation (Figure 3.5). Thus, we propose Hdac1 and Hdac2 
redundantly suppress differentiation of second heart field progenitors, promoting a 
proliferative stem-like state. Hdac1 and Hdac2 have been repeatedly shown to 
control proliferation and differentiations in vivo and in vitro[450]. 
Overexpression/activation of Hdac1/Hdac2 in cancer increases proliferation, while 
loss of Hdac1/Hdac2 during development decreases proliferation[276]. Combining 
these results with the data presented here, it appears that Hdac1 and Hdac2 
redundantly second heart field progenitor proliferation and differentiation. While 
future experiments are necessary to elucidate the cellular and molecular 
mechanisms by which Hdac1 and Hdac2 redundantly regulate the balance 
between proliferation and differentiation in the second heart field, this study 
establishes a critical, redundant role for Hdac1 and Hdac2 within second heart field 
progenitor cells. 
 While a single allele of Hdac1 or Hdac2 in the second heart field is sufficient 
to sustain embryos to birth, they quickly succumb to cardiac defects in the neonatal 
period (Figure 3.1, 3.3). Interestingly, this appears restricted to the posterior 




field rescues defects while a single allele of Hdac1/Hdac2 in the second heart field 
does not (Table 3.2). 
The posterior second heart field resides within the pharyngeal mesoderm 
and dorsal pericardial wall, in continuity with the arterial and venous poles of the 
developing primitive heart tube[147, 152, 167, 451, 452]. Cells destined to join the 
developing outflow tract proliferate within this region before migrating to join the 
heart tube at the arterial and venous poles. It has been repeatedly shown that 
disruption of posterior second heart field migration disrupts outflow tract elongation 
and causes a range of cardiac defects, including persistent truncus arteriosus. 
Tbx1, considered a causative gene in DiGeorge syndrome, promotes progenitor 
migration and outflow tract elongation specifically within the posterior second heart 
field[59, 152, 159-161]. Posterior second heart field migration is coordinated by local 
extracellular signals and the cardiac neural crest. This segment of the second heart 
field is sensitive to a variety of extracellular signaling pathways including the 
retinoic acid pathway, Hedgehog signaling, and BMP signaling[107, 453, 454]. 
Transcriptome analysis of single allele posterior second heart fields suggests that 
both the local extracellular environment and responsiveness to these signaling 
pathways are sensitive to the dose of Hdac1 and Hdac2 (Figure 3.5). For example, 
transcript changes suggest decreases in BMP, Wnt, FGF, and Hedgehog 
signaling. As all changes are mild, it is unlikely that any one alone causes 
persistent truncus arteriosus, the cumulative effect of these disruptions alters 




Understanding how genetic dosage of Hdac1/Hdac2 affects the posterior second 
heart field is critical to understanding how chromatin modifying enzymes influence 
outflow tract development. 
 Hdac1 and Hdac2 have a range of redundant, independent, and dose-
dependent roles[275, 276, 342]. Redundancy between Hdac1 and Hdac2 is 
unsurprising given their similarity, compensatory induction following paralog 
ablation, and common residence in NuRD, Sin3, and CoREST complexes[276]. The 
phenotype observed following ablation of Hdac1 and Hdac2 in cardiomyocytes, 
neurons, oligodendrocytes, adipocytes, and skeletal muscle is rescued by a single 
allele of either Hdac1 or Hdac2. There are several reports detailing incomplete 
rescue following reintroduction of a single allele of Hdac1 or Hdac2.In T-cells and 
in epidermal cells, a single allele of Hdac1 was able to rescue the double knockout 
phenotype while Hdac2 did not ameliorate the defect[375, 385]. Similarly, there are 
cases where a single allele of Hdac2 rescued while Hdac1 did not. In the murine 
brain, a single allele of Hdac2 rescued the double knockout phenotype while 
reintroduction of a single Hdac1 allele was unable to rescue[404]. Here we describe 
a case where a single copy of either Hdac1 or Hdac2 was sufficient to rescue the 
embryonic lethality observed in double knockout embryos, yet was unable to 
sustain embryos beyond the neonatal period. Unlike other contexts, it appears that 
both Hdac1 and Hdac2 have equal weight within the posterior second heart field. 




expression following paralog loss, suggesting that compensatory upregulation of 
Hdac1/Hdac2 is critical for redundancy in some contexts. 
Single allele pups are born in varying degrees of distress and succumb 
quickly to a mix of persistent truncus arteriosus, interrupted aortic arch, and 
ventricular septal defect. We found that a larger number of genes were 
dysregulated in Isl1;1Het2KO E9.5 posterior second heart fields (471) compared to 
Isl1;1KO2Het (175). This evidence challenges the established paradigm that Hdac1 
is more important during embryogenesis than Hdac2[357, 381, 382, 384, 455]. 
Despite their defined roles as transcriptional repressors, Hdac1 and Hdac2 
have been repeatedly found to function in roles that suggest that they can activate 
transcription[276]. For instance, Hdac1 and Hdac2 are almost preferentially found to 
be associated with transcriptionally active loci and ablation of both Hdac1 and 
Hdac2 invariably leads to a mix of transcript up- and down-regulation[407]. Of the 
105 commonly regulated, identified genes, we found that almost 2/3rds of them 
are decreased, suggesting Hdac1/Hdac2 mediate their expression in a dose-
sensitive manner. Exactly how Hdac1 and Hdac2 cooperate to promote 
extracellular cellular matrix homeostasis and outflow tract elongation within the 
posterior second heart field at E9.5 is a critical area for future investigation. Overall, 
this study defines both redundant and dose-sensitive roles for Hdac1 and Hdac2 
within the segments of the second heart field during mammalian cardiogenesis 
(Figure 3.6). Further investigation is necessary to specifically define how 
Hdac1/Hdac2 regulate these critical progenitor cell populations and contribute to 




CHAPTER IV – Histone Deacetylase 1 and 2 are essential for murine neural 
crest proliferation, pharyngeal arch development, and craniofacial 
morphogenesis 
 
Chapter IV is adapted from a published manuscript to include supplemental data 
and is included with permission: 
 
Milstone ZJ, Lawson G, Trivedi CM. (2017). Histone deacetylase 1 and 2 are 
essential for murine neural crest proliferation, pharyngeal arch development, and 
craniofacial morphogenesis. Developmental Dynamics, 246(12), 1015-1026. 
 
Author contributions: 
I provided all data shown in Figure 4.1, Figure 4.2 A-Z, Table 4.1, Figure 4.3, and 
Figure 4.4. Additionally, I conducted the mouse breeding and sample preparation 
relevant to Figure 4.2AA-AI. Grace Lawson performed the morphologic staining 




Background: Craniofacial anomalies involve defective pharyngeal arch 
development and neural crest function. Copy number variation at 1p35, containing 




patients with craniofacial defects, suggesting an important role in guiding neural 
crest development. However, the roles of Hdac1 and Hdac2 within neural crest 
cells remain unknown. 
Results: The neural crest and its derivatives express both Hdac1 and Hdac2 during 
early murine development. Ablation of Hdac1 and Hdac2 within murine neural crest 
progenitor cells cause severe hemorrhage, atrophic pharyngeal arches, defective 
head morphogenesis, and complete embryonic lethality. Embryos lacking Hdac1 
and Hdac2 in the neural crest exhibit decreased proliferation and increased 
apoptosis in both the neural tube and the first pharyngeal arch. Mechanistically, 
loss of Hdac1 and Hdac2 upregulates cyclin-dependent kinase inhibitors Cdkn1a, 
Cdkn1b, Cdkn1c, Cdkn2b, Cdkn2c, and Tp53 within the first pharyngeal arch.  
Conclusions: Our results show that Hdac1 and Hdac2 function redundantly within 
the neural crest to regulate proliferation and the development of the pharyngeal 




The neural crest (NC) is a migratory cell population unique to vertebrates, 
which delaminates from the dorsal neural tube early in development[173-176]. The 
NC migrates along the length of the developing embryo, colonizes a wide array of 
critical structures, and contributes to the development of almost every tissue and 




epithelial-to-mesenchymal transition in order to form mesenchymal structures[57]. 
In mammals, the NC is divided into several regional subpopulations including the 
cranial-NC, cardiac-NC, and trunk-NC[177, 178]. Trunk NCCs form the majority of the 
peripheral nervous system, skin melanocytes, and endocrine cells[179, 181]. Cranial 
NCCs migrate from the fore-, mid-, and hindbrain to colonize anterior portions of 
developing embryos including the frontal prominence and cranial pharyngeal 
arches (PhAs) early in development[182, 183]. These cells will go on to form the 
craniofacial skeleton, smooth muscle of the head and neck, and certain specialized 
organs/structures[183]. Similarly, the cardiac NC travels from the dorsal portion of 
the embryo to populate the caudal PhAs and pharyngeal mesoderm[184]. Under 
guidance from cardiac progenitors, cardiac NCCs populate the developing outflow 
tract (aorta and pulmonary artery) in mammalian embryos enabling rotation and 
septation[47, 58]. 
The PhAs are bilaterally paired structures numbered from 1 to 6, which 
contain a nerve, artery and mesenchymal component[14]. The first PhA, often 
termed the mandibular or maxillary arch, gives rise to the numerous structures 
including maxillary artery, trigeminal nerve, muscles of mastication, and a mix of 
skeletal components including the mandible and maxilla[38]. The second, third, 
fourth, and sixth arch give rise to other nerves, muscles, and bones in the 





Mirroring the complex roles and derivatives of the NC, numerous congenital 
anomalies and syndromes have been mapped to defects in NCC function[457-460]. 
Cranial NC abnormalities have been identified in patients with thymic aplasia[461], 
palate defects[462], and craniofacial malformations[459]. Trunk NC defects have been 
implicated in pigment abnormalities and abnormal enteric innervation[463]. 
Additionally, cardiac NC defects are found in patients with outflow tract septation 
defects[125], aortic arch anomalies[126], and cardiac conduction defects[464]. These 
defects often present together and are grouped clinically into syndromes such as 
DiGeorge Syndrome (22q11.2)[159], Treacher-Collins Syndrome[207], or CHARGE 
Syndrome[199]. Despite evolving understanding of the NC in mammalian 
development, epigenetic factors regulating its behavior remain largely unknown. 
Studies of patients with craniofacial abnormalities of unknown origin 
identified ranges of chromosomal regions and histone-modifying genes that may 
be involved[465]. For instance, copy number variations at 1p35, a region including 
the class I histone deacetylase (HDAC) HDAC1, and 6q21-22, containing HDAC2 
were found in patients with craniofacial abnormalities, suggesting that dose-
dependent disruptions in epigenome homeostasis may influence NC behavior[227, 
228]. HDACs, classified into five subfamilies based on their phylogenetic analysis 
and sequence homology, are a major family of histone modifying enzymes with 
roles in numerous biologic processes, including craniofacial development. A long-
held assumption about HDACs is that they are ubiquitously expressed. However, 




specific manner during development. For instance, Hdac7 is endothelial specific 
and loss results in vascular defects[318]. Hdac8, specifically expressed in fore and 
midbrain regions at E10 and E11.5, is critical for skull development[363, 466]. 
Similarly, murine embryos show restricted, distinct, and non-overlapping Hdac1 
and Hdac2 mRNA expression areas at E11.5 and E13[466]. However, endogenous 
Hdac1 expression pattern during early murine development remains unknown. 
Hdac1 and Hdac2 are closely related, ~80% homologous, enzymatically active 
class I histone deacetylases[283, 467]. Global ablation of Hdac1 is embryonically 
lethal early in development due to proliferation arrest caused by upregulation of 
P21 (Cdkn1a)[381]. Hdac2-null mice show cardiac defects and variable levels of 
lethality at birth depending upon genetic background[25, 357, 382, 384, 404]. Hdac1 and 
Hdac2 function together in repressive complexes including Sin3a, NuRD, and Co-
REST[292, 296, 468, 469]. Consequently, Hdac1 and Hdac2 are considered to have 
overlapping, redundant functions. Indeed, Hdac1 and Hdac2 redundantly regulate 
various cellular and developmental processes, including cardiac morphogenesis, 
adipogenesis, brain development, intestinal homeostasis, proliferation, and stem-
cell self-renewal[374, 382, 388, 394, 470, 471]. In some cases, a single allele of Hdac1 or 
Hdac2 is enough to rescue the double knockout phenotype[375, 385, 404]. While the 
developmental roles of Hdac1 and Hdac2 are emerging, their function in NC 
progenitor cells remains unknown. 
Using a novel conditional Hdac1Flox allele, a previously characterized 




and Hdac2 in NC progenitor cells. Loss of both Hdac1 and Hdac2 (Wnt1;1KO2KO) 
resulted in embryonic lethality around E11.5 secondary to vascular defects and 
atrophic PhAs. Furthermore, Wnt1;1KO2KO embryos show reduced proliferation of 
NC progenitor cells within the neural tube and first PhA. Mechanistically, ablation 
of Hdac1 and Hdac2 causes upregulation of cyclin-dependent kinase inhibitors 
Cdkn2b, Cdkn2c, Cdkn1b, Cdkn1c, Cdkn1a, and Tp53 within first PhA at E9.5. 
Interestingly, we observed that a single copy of Hdac1 in an Hdac2 knockout 
background (Wnt1;1Het2KO) or a single copy of Hdac2 in an Hdac1 knockout 
background (Wnt1;1KO2Het) was sufficient to rescue the craniofacial phenotype, 
first PhA phenotype, and embryonic lethality. These results reveal redundant and 
essential roles for Hdac1 and Hdac2 in the developing neural crest and its 
derivatives. 
 
Materials and Methods 
Mice 
Wnt1-Cre2 (Jackson Laboratory, 022137)[472], Mesp1-Cre[83], R26R-LacZ[448], and 
Hdac2Flox[428] mice have been previously described. Frozen embryos of 
Hdac1tm1a(EUCOMM)Wtsi (strain EM:04097) were obtained from the European Mouse 
Mutant Archive (EMMA). The University of Massachusetts Medical School 
Transgenic Animal Facility regenerated cryopreserved embryos. The knockout-
first allele, Hdac1tm1a(EUCOMM)Wtsi, mice were bred with wild type mice and are 




ACTB-FLPe (Jackson Laboratory, 003800) to generate Hdac1Flox mice. Hdac1Flox 
mice were bred with Hdac2Flox, R26R-LacZ, and Wnt1-Cre2 mice to generate mice 
for analysis. All animal protocols were approved by the University of 




Collected tissues were fixed in 2-4% paraformaldehyde in PBS at 4ºC overnight, 
ethanol dehydrated, embedded in paraffin, and section at 8µm thickness via 
microtome. 
 
Antibodies and Reagents 
The following antibodies were utilized in this study: Hdac1C (Abcam), Hdac1N 
(Sigma), Hdac2 (Invitrogen), α-tubulin (Sigma), PHH3 (Cell Signaling), SMA 
(Abcam), CC3 (Cell Signaling). Eosin Y and Harris modified hematoxylin were 
purchased from Fisher while X-gal was purchased from 5 Prime. Vectashield 
mounting medium, Vectastain Elite ABC reagent kit, and DAB Peroxidase 
Substrate kit were purchased from Vector Labs 
 
Hematoxylin and Eosin Staining 
Staining was performed through deparaffinizing sections in xylenes, rehydrating 




diH2O), followed by 30sec counterstain with eosin Y. Slides were then rinsed and 
dehydrated through an ethanol gradient, cleared with xylenes, and mounted using 
Vectashield permanent mounting medium. 
 
LacZ Staining 
Tissue samples were dissected in cold PBS and quickly fixed in 2% 
paraformaldehyde in PBS for 30min at 4ºC. They were then washed in PBS at 
room temperature and stained over night in LacZ staining solution (5mM potassium 
ferricyanide, 5mM potassium ferrocyanide, 2mM MgCl2, 0.01% deoxycholic acid, 
0.04% Nonidet P 40, 0.1% X-Gal, in 1X PBS) in the dark at 37ºC until blue (LacZ) 
staining developed. Following this, samples were washed in 1X PBS and fixed 
overnight in 4% paraformaldehyde in PBS at 4ºC. 
 
Immunohistochemistry 
Selected sections were deparaffinized in xylenes, pretreated using the Aptum 
Antigen Retriever 2100 and Aptum R-Buffer A or Sodium Citrate Buffer (pH 6.0). 
Immunohistochemistry was conducted with the Vectastain Elite ABC kit and DAB 
Peroxidase Substrate kit following manufacturer guidelines. Sections were 
incubated with primary antibody (Hdac1 1:100; Hdac2 1:100; PHH3 1:100, SMA 
1:100, CC3 1:100, P21 1:100) overnight at 4ºC. If performed, counterstaining 
consisted of 30 sec incubation with 30% Harris modified hematoxylin (in diH2O) 








Tissue lysates were prepared in lysis buffer (20mM Tris-HCl pH 7.5, 15mM NaCl, 
1mM Na2EDTA, 1mM EGTA, 1% Triton X-100, 1µg/mL leupeptin, 2.5mM sodium 
pyrophosphate, 1mM Na3VO4, and 1mM beta-glycerolphosphate; 1mM 
phenylmethylsulfonyl fluoride was added before use). Protein samples were 
resolved on a 4-12% SDS-Page acrylamide gel before transfer to a PVDF 
membrane. Primary antibodies against Hdac1C (1:1000), Hdac1N (1:1000), and 
Hdac2 (1:1000) were used. Primary antibodies were visualized with HRP-
conjugated secondary antibodies. Blots were probed with α-tubulin (1:1000 or 
1:2500) for loading control. 
 
Morphometric Analysis 
Quantitative morphologic analysis was performed using ImageJ software to 
measure and record anatomical features of interest. These measurements were 
normalized to the primitive heart tube length to control for any variability in embryo 
size and are presented as mean (SD). 
 




Total RNA was extracted from microdissected first pharyngeal arches using the 
Qiagen Plus Micro RNeasy Kit according to the manufacturer guidelines. cDNA 
was reverse transcribed using iScript Reverse Transcription Supermix (BioRad) 
according to the manufacturer guidelines. Transcript expression was measured by 
qRT-PCR using SYBR Green PCR Master Mix (ThermoFisher). Signals were 
normalized to Gapdh controls and represented as relative expression ratios of 
experimental samples relative to Wnt1;1Het2Het controls using the ∆∆Ct method. 
Primer sequences available upon request. 
 
Statistical Analysis 
Statistical significance between groups was determined using an unpaired two-








Figure 4.1 - The neural crest and its derivatives express both Hdac1 and 
Hdac2 during early murine development. (A) Hdac1LacZ knock-in allele targeting 
map and generation scheme. (B-G) Whole-mount X-gal staining for β-
galactosidase (blue, LacZ) of Hdac1LacZ/+ and Hdac1+/+ embryos at various 
developmental stages. B, ventral view of Hdac1+/+ at E7.75. C, ventral view of 
Hdac1LacZ/+ at E7.75. D, right lateral view of Hdac1+/+ at E8.75. E, right lateral view 
of Hdac1LacZ/+ at E8.75. F, right lateral view of Hdac1+/+ at E9.5. G, right lateral 
view of Hdac1LacZ/+ at E9.5. (H-M) C-terminal Hdac1 immunostaining (brown) on 
whole-mount X-Gal stained (LacZ, blue) E9.5 Hdac1LacZ/+ sagittal sections 
including the outflow tract (OFT, H), primitive ventricle (PrV, I), atrioventricular 
canal (AVC, J), midbrain and telencephalic vesicle (MB & TV, K), otic pit (OtP, L), 
and caudal somites (So, M). (N-S) Hdac2 immunostaining (brown) on whole-mount 
X-gal stained (LacZ, blue) E9.5 Hdac1LacZ/+ sagittal sections including the OFT (N), 
PrV (O), AVC (P), MB and TV (Q), OtP (R), and So (S). Arrows indicate 





 Observed (Expected) 
Genotype P21 P0 E11.5 E10.5 E9.5 
Hdac1F/+, Hdac2F/+ 4 (5) 13 (8) 3 (4.625) 7 (5.875) 8 (8.75) 
Hdac1F/+, Hdac2F/F 7 (5) 7 (8) 3 (4.625) 7 (5.875) 8 (8.75) 
Hdac1F/F, Hdac2F/+ 10 (5) 15 (8) 1 (4.625) 3 (5.875) 5 (8.75) 
Hdac1F/F, Hdac2F/F 8 (5) 10 (8) 13 (4.625) 5 (5.875) 14 (8.75) 
Wnt1-Cre2; Hdac1F/+, 
Hdac2F/+ 
11 (5) 9 (8) 6 (4.625) 4 (5.875) 10 (8.75) 
Wnt1-Cre2; Hdac1F/+, 
Hdac2F/F 
0 (5) 6a,b (8) 4 (4.625) 7 (5.875) 13 (8.75) 
Wnt1-Cre2; Hdac1F/F, 
Hdac2F/+ 
0 (5) 4c,d (8) 2 (4.625) 5 (5.875) 5 (8.75) 
Wnt1-Cre2; Hdac1F/F, 
Hdac2F/F 
0 (5) 0 (8) 5e (4.625) 9 (5.875) 7 (8.75) 











Table 4.1: Genotypes of samples lacking Hdac1/Hdac2 in neural crest 
progenitors, collected at various developmental stages. Wnt1-Cre2; Hdac1F/+; 
Hdac2F/+ mice were crossed with Hdac1F/F; Hdac2F/F mice and samples were 
collected at the designated time point. a2 pups found cyanotic with distended 
abdomen/pulmonary distress. b3 pups recovered dead. c2 pups recovered dead. 







The neural crest and its derivatives express both Hdac1 and Hdac2 during early 
murine development: 
 Hdac1 alleles were generated using a Knockout-first strategy[473] (Figures 
4.1-4.2). This strategy generates an Hdac1 knock-in reporter allele (Tm1a, 
Hdac1LacZ, Figure 4.1A), Hdac1 reporter knockout allele (Tm1b, not shown), and 
Hdac1 conditional-ready allele (Tm1c, Hdac1Flox, Figure 4.2A) following exposure 
to site-specific recombinases Cre and Flp in different orders. In this study, the 
Tm1a knockout-first allele is utilized as a knock-in reporter allele, but in many 
cases exposure to Cre-recombinase (without exposure to Flp-recombinase) is 
necessary to generate a robust reporter allele[473]. The flexibility of this allele is an 
advantage when compared to other published Hdac1 alleles; the reporter function 
enables tracking the spatiotemporal dynamics of in vivo Hdac1 during 
development (Figure 4.1A), while the conditional deletion of exon 3 completely 
abolishes Hdac1 expression in a tissue-specific manner (Figure 4.2). 
The insertion of a LacZ cassette between exons 2 and 3 (Figure 4.1A) 
results in the expression of β-galactosidase under the control of native Hdac1 
promoter and enhancer elements which, in turn, causes blue staining following 
incubation with X-gal (Figure 4.1C, E, G) compared to controls (Figure 4.1B, D, 
F). X-Gal staining of Hdac1LacZ/+ and Hdac1+/+ embryos at E7.75 (Figure 4.1B-C), 




(blue) in Hdac1LacZ/+ embryos compared to Hdac1+/+ controls. To further investigate 
the specificity of the Hdac1LacZ knock-in allele and the overlapping spatiotemporal 
expression pattern of Hdac1 and Hdac2 during development, we sectioned E9.5 
Hdac1LacZ/+ embryos and performed immunostaining using a C-terminal Hdac1 
antibody (Hdac1) (Figure 4.1H-M) and Hdac2 antibody (Figure 4.1N-S). Hdac1 
staining (brown) and Hdac1LacZ staining (blue) overlapped in all examined 
developmental structures including the outflow tract (OFT, Figure 4.1H), primitive 
ventricle (PRV, Figure 4.1I), atrioventricular canal (AVC, Figure 4.1J), midbrain & 
telencephalic vesicle (MB & TV, Figure 4.1K), otic pit (OtP, Figure 4.1L), and 
caudal somites (So, Figure 4.1M). Similarly, immunostaining for Hdac2 (brown) 
and Hdac1LacZ staining (blue) overlapped in all examined developmental structures 
including the outflow tract (Figure 4.1N), primitive ventricle (Figure 4.1O), 
atrioventricular canal (Figure 4.1P), midbrain & telencephalic vesicle (Figure 









Figure 4.2 – Hdac1 and Hdac2 function redundantly within the neural crest 
progenitor cells. (A) Hdac1Flox conditional allele targeting vector map and 
generation scheme. (B) Predicted aligned amino acid sequence for Hdac1WT and 
recombined Hdac1Flox (Hdac1KO) alleles consensus-determining sequences 
(CDS). (Blue, WT; Green, unchanged; Purple, frameshift mutation; Red, stop 
codon) (C-F) Western blot analysis of control (Mesp1;1Het, Hdac2+/+) and knockout 
(Mesp1;1KO, Mesp1;2KO) P0 heart lysate for Hdac1C (C), Hdac1N (E), and Hdac2 
(F). Hdac1C was quantified and normalized to total input α-Tubulin and is 
presented as mean (SD) (**, p=0.007) (G-J) Hdac1C and Hdac1N immunostaining 
of Mesp1;1KO and Mesp1;1Het frontal heart sections at P0 (Black – present; White 
– absent). (K-N) Hdac1C (K,M) and Hdac2 (L,N) immunostaining of 
Wnt1;1Het2Het;R26R-LacZ-/+ and Wnt1;1KO2KO;R26R-LacZ-/+ neural tubes (NT) at 
E9.5 (Black, present; White, absent). (O-Q) Left lateral (main) and right lateral 
(inset) images of Hdac1F/F;Hdac2F/F (O), Wnt1;1Het2KO (P), and Wnt1;1KO2Het (Q) 
pups at birth (White, milk spot; Black, absent milk spot; Red, distended abdomen; 
Orange, neonatal distress). (R-T) Dissected/fixed P0 Hdac1F/F;Hdac2F/F (R), 
Wnt1;1Het2KO (S), and Wnt1;1KO2Het (T) palates (PAL). (U-Z) Dissected/fixed P0 
Hdac1F/F;Hdac2F/F (U-V), Wnt1;1Het2KO (W-X), and Wnt1;1KO2Het (Y-Z) thymus (TY; 
U,W,Y) and outflow tract (OFT; V,X,Z). (AA-AF) Hematoxylin and Eosin P0 frontal 
sections of Hdac1F/F;Hdac2F/F (AA-AB), Wnt1;1Het2KO (AC-AD), and Wnt1;1KO2Het 
(AE-AF) aortic valves (AA,AC,AE) and pulmonic valves (AB,AD,AF). (AG-AI) 
Hematoxylin and Eosin staining of Hdac1F/F;Hdac2F/F (AG), Wnt1;1Het2KO (AH), 
and Wnt1;1KO2Het (AI) P0 hearts shows peri-arterial morphology in the 
aorta/pulmonary artery. Nuclear hematoxylin counterstain is present. Scale bars 
100µM. AO, aorta; PA, pulmonary artery; PAL, palate; TY, thymus; BA, 
brachiocephalic artery; LCC, left common carotid artery; LS, left subclavian artery; 
RA, right atria; LA, left atria; RV, right ventricle; LV, left ventricle; PV, pulmonic 





Hdac1 and Hdac2 function redundantly within the neural crest progenitor cells 
 While the genetic underpinnings of NC derived congenital defects are 
emerging, the role of Hdac1 and Hdac2 in this process is unknown. To investigate 
roles of Hdac1 and Hdac2 during craniofacial and cardiac outflow tract (OFT) 
development, we first validated the conditional Hdac1 and Hdac2 alleles used in 
this study (Figure 4.2A-J) before ablating Hdac1 and Hdac2 in the NC progenitor 
cells using Wnt1-Cre2[472] (Figure 4.2K-AI). Hdac1 conditional allele (Tm1c, 
Hdac1Flox) was generated from the Tm1a (Hdac1LacZ) allele by exposure to Flp-
recombinase, with LoxP sites flanking exon 3 (Figure 4.2A). Exposure of Hdac1Flox 
to Cre-recombinase results in excision of exon 3, introducing a frameshift mutation 
and premature stop codon early in the Hdac1 deacetylase domain (Hdac1KO) 
(Figure 4.2B). To verify conditional allele performance, we used Mesp1-Cre[83], a 
marker of the cardiogenic mesoderm that contributes to the majority of the 
developing mammalian heart, to delete Hdac1 or Hdac2 (Figure 4.2C-J). To query 
whether excision of exon 3 may generate semi-functional Hdac1 protein 
fragments, we performed Hdac1 immunostaining and Western blot with C-terminal 
(Hdac1C) and N-terminal (Hdac1N) antibodies (Figure 4.1C-E, G-J). Western blot 
analysis of Mesp1-Cre;Hdac1F/+ (Mesp1;1Het) and Mesp1-Cre;Hdac1F/F 
(Mesp1;1KO) P0 heart lysate shows reduction in Hdac1 protein levels assessed 
with both Hdac1N and Hdac1C antibodies (Figure 4.2C-E). Additionally, Mesp1-
Cre efficiently mediated ablation of the already-established Hdac2 allele[428] utilized 




arrows) in the left ventricle (within the Mesp1-Cre domain) by P0 following excision 
of exon 3 by Cre-recombinase using both Hdac1C and Hdac1N antibodies when 
compared to controls (Figure 4.2G-J). Next, we queried the efficacy of ablation by 
Wnt1-Cre2. To help understand the spatiotemporal dynamics of Wnt1-Cre2 
expressing neural crest progenitor cells and their derivatives, a R26R-LacZ 
allele[448] was included and X-gal staining was performed. The result of this staining 
is to mark any Wnt1-Cre2 expressing cells (and their descendants) as blue. 
Immunostaining analysis reveals loss of Hdac1 (Figure 4.2M) and Hdac2 (Figure 
4.2N) in Wnt1;1KO2KO;R26R-LacZ-/+ neural tube compared to Wnt1;1Het2Het;R26R-
LacZ-/+ neural tube (Figure 4.2K, L) at E9.5. Wnt1-Cre2; Hdac1F/F, Hdac2F/F mice 
(Wnt1;1KO2KO) displayed complete embryonic lethality while single-allele mice 
(Wnt1-Cre2; Hdac1F/F, Hdac2F/+, Wnt1;1KO2Het & Wnt1-Cre2; Hdac1F/+, Hdac2F/F, 
Wnt1;1Het2KO) were recovered in expected ratios at birth but were found to die by 
P21 (Table 4.1). The single-allele mice recovered at birth were found with varying 
perinatal defects ranging from cyanosis, distended abdomen, and neonatal 
lethality (Table 4.1, Figure 4.2O-Q). Wnt1;1KO2Het and Wnt1;1Het2KO mice were 
recovered without an observable milk spot compared to controls, indicating inability 
to feed (Figure 4.2O-Q). Additionally, some Wnt1;1Het2KO mice were recovered 
with a readily observable distended abdomen (Figure 4.2P) and dissection 
revealed trapped air in a distended stomach. Often, an absent milk spot indicates 
a craniofacial and/or palate defect; however, no craniofacial or palate defect was 




thymus, the cardiac outflow tract vessels (aorta and pulmonary artery) and valves 
(aortic valve and pulmonary valve). Wnt1;1KO2Het and Wnt1;1Het2KO mice show 
normal thymic structure (Figure 4.2U, W, Y), outflow tract course and caliber 
(Figure 4.2V, X, Z), and valve morphology (Figure 4.2AA-AF). NC progenitor cells 
also make major contributions to arterial smooth muscle in the head, neck, and 
heart[57, 177]. Peri-arterial outflow tract morphology in Wnt1;1KO2Het and 










Figure 4.3 – Wnt1;1KO2KO embryos die around E11.5 due to defects in 
craniofacial vasculature. (A-D) Wnt1;1KO2KO (C-D) and Hdac1F/F;Hdac2F/F (A-B) 
embryos at E11.5 (Orange – cranial blood; Blue – gut blood). (E-H) LacZ-stained 
Wnt1;1KO2KO;R26R-LacZ-/+ (G-H) and Wnt1;1Het2Het;R26R-LacZ-/+ (E-F) embryos 
at E10.5 (Red –nuchal angle; Blue, first pharyngeal arch; Orange, differential LacZ 
staining). (I-L) LacZ-stained Wnt1;1KO2KO;R26R-LacZ-/+ (K-L) and 
Wnt1;1Het2Het;R26R-LacZ-/+ (I-J) embryos at E9.5 (Red, posterior nuchal angle; 
Black, frontal swelling; Blue, first pharyngeal arch; Orange, differential LacZ 
staining). (M-O) First pharyngeal arch area (normalized to PHT length; M) and 
cranial length (normalized to PHT length; N) at E9.5 in Wnt1;1Het2Het;R26R-LacZ-
/+ and Wnt1;1KO2KO;R26R-LacZ-/+. Presented as mean (SD) (***, p=0.0001; **, 
p=0.0076)(Schematic diagram, O). (P-S) Eosin and LacZ stained E9.5 Frontal 
sections of Wnt1;1Het2Het;R26R-LacZ-/+ (P,R) and Wnt1;1KO2KO;R26R-LacZ-/+ (Q,S) 
craniofacial morphology at two levels. (T-W) Eosin/LacZ stained (T-U) or α-smooth 
muscle actin (V-W, SMA) immunofluorescence of Wnt1;1Het2Het;R26R-LacZ-/+ 
(T,V) and Wnt1;1KO2KO;R26R-LacZ-/+ (U,W) E9.5 posterior pharyngeal arch 
arteries (2/3/4/6, Second/Third/Fourth/Sixth arch arteries; White arrows, SMA). 
Scale bars 100µM. PhA, pharyngeal arch; PHT, primitive heart tube; NT, neural 




 Wnt1;1KO2KO embryos were recovered in expected Mendelian ratios at 
E9.5, E10.5, and E11.5 (Table 4.1). However, Wnt1;1KO2KO pups were not 
recovered at P0, indicating that they suffer complete embryonic lethality (Table 
4.1). The Wnt1;1KO2KO embryos recovered at E11.5 appeared grossly hemorrhagic 
with blood pooling in the cranial vesicles (orange) and primitive gut (blue), 
indicating recent fetal demise compared to Hdac1F/F, Hdac2F/F controls (Figure 
4.3A-D) and suggesting defects in PhA-derived artery development. 
Wnt1;1KO2KO;R26R-LacZ-/+ embryos appeared smaller, with reduced LacZ staining 
intensity (orange) (Figure 4.3G, H, K, L) compared to Wnt1-
Cre2;Hdac1F/+,Hdac2F/+;R26R-LacZ-/+ (Wnt1;1Het;2Het;R26R-LacZ-/+) controls at 
E10.5 (Figure 4.3E, F, I, J). Differential LacZ staining appears to be restricted to 
the developing head and PhAs, with LacZ staining intensity and distribution being 
similar in the developing torso and tail between Wnt1;1KO2KO;R26R-LacZ-/+ 
embryos (Figure 4.3G, H, K, L) and Wnt1;1Het2Het;R26R-LacZ-/+ controls (Figure 
4.3E, F, I, J). Additionally, Wnt1;1KO2KO;R26R-LacZ-/+ embryos presented with 
abnormal craniofacial anatomy, an attenuated posterior nuchal angle (red), 
reduced frontal swelling (black), and focally decreased LacZ staining intensity 
(orange) (Figure 4.3G, H, K, L) when compared to Wnt1;1Het2Het;R26R-LacZ-/+ 
controls (Figure 4.3E, F, I, J). Wnt1;1KO2KO;R26R-LacZ-/+ first (green) and second 
(purple) PhAs appeared atrophic when compared with controls seen by a decrease 
in size, definition, and LacZ staining intensity (blue, inset) (Figure 4.3G, H, K, L). 




was seen in Wnt1;1KO2KO;R26R-LacZ-/+ embryos (Figure 4.3G, H, K, L) compared 
to controls (Figure 4.3E, F, I, J). Quantification of the first PhA area (normalized 
to primitive heart tube length) and cranial length (normalized to primitive heart tube 
length) at E9.5 showed significant reduction (***, p=0.0001 & **, p=0.0076) in the 
normalized area and normalized length in Wnt1;1KO2KO;R26R-LacZ-/+ embryos 
compared to Wnt1;1Het2Het;R26R-LacZ-/+ controls (Figure 4.3M-O). Additionally, 
frontal sections of E9.5 Wnt1;1KO2KO;R26R-LacZ-/+ and Wnt1;1Het2Het;R26R-LacZ-
/+ embryos revealed abnormal telencephalic vesicle (TV) morphology in 
experimental embryos (Figure 4.3Q, S) compared to controls (Figure 4.3P, R), 
confirming the gross observations of craniofacial defects.  
 Eosin-stained frontal sections of the PhAs and PhA arteries (PhAAs) 
revealed that the sixth PhA and PhAA are missing in Wnt1;1KO2KO;R26R-LacZ-/+ 
embryos (Figure 4.3U, W) compared to controls (Figure 4.3T, V). The second 
PhA was visualized in a different section of Wnt1;1KO2KO;R26R-LacZ-/+ embryos 
(not shown). All other arches were found to be present, albeit smaller in double 
knockouts (Figure 4.3U, W) than controls (Figure 4.3T, V). Peri-arterial α-smooth 
muscle staining appears similar in both Wnt1;1KO2KO;R26R-LacZ-/+ and 











Figure 4.4 – Hdac1 and Hdac2 regulate proliferation in the neural tube and 
first pharyngeal arch by repressing cyclin-dependent kinase inhibitors. (A-
B) Phospho-histone H3 (PHH3) immunostaining within the first pharyngeal arch in 
Wnt1;1Het2Het;R26R-LacZ-/+ (Ai, Ai’) and Wnt1;1KO2KO;R26R-LacZ-/+ (B, B’) at E9.5 
(Black, PHH3+). (C) Quantification of PHH3 positive nuclei per 100 nuclei 
(proliferative index; presented as mean (SD); *, p=0.022). (D-E) PHH3 
immunostaining within the neural tube (NT) in Wnt1;1Het2Het;R26R-LacZ-/+ (D, D’) 
and Wnt1;1KO2KO;R26R-LacZ-/+ (E, E’) embryos at E9.5 (Black, PHH3+). (F) 
Quantification of PHH3 positive nuclei per 100 nuclei (proliferative index; 
presented as mean(SD); *, p=0.043). (G-H) Cleaved caspase 3 (CC3) 
immunostaining within the first pharyngeal arch in Wnt1;1Het2Het;R26R-LacZ-/+ (G, 
G’) and Wnt1;1KO2KO;R26R-LacZ-/+ (H, H’) at E9.5 (Black, CC3+). (I) Quantification 
of CC3 positive nuclei per 100 nuclei (apoptotic index; presented as mean (SD); 
**, p=0.0038). (J-K) CC3 immunostaining within the NT in Wnt1;1Het2Het;R26R-
LacZ-/+ (J, J’) and Wnt1;1KO2KO;R26R-LacZ-/+ (K, K’) at E9.5 (Black, CC3+). (L) 
Quantification of CC3 positive nuclei per 100 nuclei (apoptotic index; presented as 
mean (SD); *, p=0.028). (M-R) Relative mRNA levels of in E9.5 Wnt1;1Het2Het and 
Wnt1;1KO2KO microdissected first pharyngeal arches of Cdkn2b (M, *, p=0.042), 
Cdkn2c (N, *, p=0.032), Cdkn1a (O, ***, p=0.0008), Cdkn1b (P, *, p=0.035), Tp53 





Hdac1 and Hdac2 regulate proliferation in the neural tube and first pharyngeal arch 
by repressing cyclin-dependent kinase inhibitors 
To investigate the cellular and molecular basis of defective neural crest and 
PhA development in Wnt1;1KO2KO embryos at E9.5, we performed phospho-
histone H3 (PHH3, a marker of cellular proliferation) immunostaining on the first 
pharyngeal arch and the neural tube lacking both Hdac1 and Hdac2 (Figure 4.4A-
B, D-E). Wnt1;1KO2KO;R26R-LacZ-/+ embryos exhibited reduced number of PHH3+ 
nuclei within the first PhA (Figure 4.4B, B’, C) and the neural tube (Figure 4.4E, 
E’, F) compared to controls (Figure 4.4A, A’, C, D, D’, F). Quantification of the 
number of PHH3-positive nuclei per one hundred total nuclei (proliferative index) 
is significantly reduced in both the first PhA (*, p=0.022; Figure 4.4C) and the 
neural tube (*, p=0.043; Figure 4.4F) of Wnt1;1KO2KO;R26R-LacZ-/+ embryos at 
E9.5. 
Furthermore, Wnt1;1KO2KO;R26R-LacZ-/+ embryos show increased number 
of cleaved caspase 3 (CC3, a marker of apoptosis)-positive nuclei within the first 
PhA (Figure 4.4H, H’, I) and the neural tube (Figure 4.4K, K’, L) compared to 
controls (Figure 4.4G, G’, I, J, J’, L). Quantification of the number of CC3-positive 
nuclei per one hundred total nuclei (apoptotic index) is significantly increased in 
both the first PhA (**, p=0.0038; Figure 4.4I) and the neural tube (*, p=0.028; 
Figure 4.4L). 
Given that there is a shift away from proliferation towards apoptosis in 




molecular changes underlying this shift. Hence, we performed qPCR on an array 
of cyclin-dependent kinases, using the neural-crest derived first PhAs dissected 
from Wnt1;1KO2KO and Wnt1;1Het2Het embryos at E9.5. Our analysis revealed 
significant upregulation of Cdkn2b (Figure 4.4M, *, p=0.043), Cdkn2c (Figure 
4.4N, *, p=0.032), Cdkn1a (Figure 4.4O, ***, p=0.0008), Cdkn1b (Figure 4.4P, *, 
p=0.035), Tp53 (Figure 4.4Q, ***, p=0.0001), and Cdkn1c (Figure 4.4R, **, 




Disruption of the pharyngeal arches and their corresponding arteries are a 
common source of congenital defects and syndromes with a multitude of etiologies 
and clinical courses[159, 199, 207, 465]. While much of the cellular, molecular, and 
genetic basis of these defects is understood, the role of epigenetic regulators in 
development and congenital disease is just starting to be elucidated[474]. HDACs 
are a group of enzymes that regulate the epigenome[275]. HDACs are divided into 
five classes with class I HDACs (HDAC1, 2, 3, and 8) being structurally similar and 
having the most intrinsically active enzymatic domains[341, 467]. Hdac1 and Hdac2 
have already been implicated in congenital craniofacial defects seen in humans[227, 
228, 345], yet no causal link has been drawn. Here we show that Hdac1 and Hdac2 
regulate neural crest progenitor cell pluripotency, pharyngeal arch development, 




strengthens the association between these critical enzymes and human congenital 
defects. In contrast, Hdac3 and Hdac8, other class I HDACs, regulate neural crest-
derived skull morphogenesis during late-gestation[363, 475], suggesting a unique role 
of Hdac1 and Hdac2 within neural crest progenitor cells. 
The cephalic neural crest has an established role in brain development, in 
addition to its critical role in craniofacial morphogenesis[180]. Interestingly, Hdac1 
and Hdac2 have also been found to regulate brain development and function[25, 363, 
404, 476]. Specifically, Hdac1 and Hdac2 were found to regulate cerebellar foliation 
and cortical neuron organization in GFAP-Cre+ neuronal progenitor cells during 
development with loss of Hdac1 and Hdac2 resulting in postnatal lethality[394]. 
While PhA defects in Wnt1;1KO2KO embryos suggest disrupted craniofacial 
development, defects in the formation of neuronal structures, such as the 
telencephalic vesicle, suggest that brain development may also be affected, which 
is an exciting area for future investigation. 
Proliferation and self-renewal are essential to any progenitor cell population 
and when genetic or epigenetic insult disrupts these processes, progenitor cells 
have a choice: differentiate into an end-linage or undergo apoptosis. In this case, 
we observed that neural crest progenitor cells lacking Hdac1 and Hdac2 
experienced arrested proliferation and apoptosis, indicating a depletion of this 
critical population. Working through what seems to be emerging as a common 
mechanism across multiple progenitor cell populations[276, 341, 381, 404, 467], Hdac1 




neural crest progenitor cells. Increased expression of cyclin-dependent kinase 
inhibitors places a brake on the cell cycle while decreased expression induces 
proliferation[477-482]. Numerous reports have shown that Tp53 mediates cell cycle 
arrest and apoptosis through a variety of pathways[483-487]. The significant 
upregulation of Tp53 in Wnt1;1KO2KO embryos, increased apoptosis, and resultant 
depletion of NC progenitor cells align with these reports. There is also evidence 
that inhibition of HDACs can result in increased p53 activity, resulting in elevated 
p21 (leading to cell cycle arrest) and Bax translocation and activation of apoptotic 
pathways[488]. These results integrate the significant upregulation of Tp53 
observed in Wnt1;1KO2KO embryos, decreased proliferation, and increased 
apoptosis. Hdac1 and Hdac2 function in NC progenitor cells to suppress Tp53 and 
other cyclin dependent kinase inhibitors, maintain a proliferative progenitor cell 
phenotype, and moderate NC progenitor contribution to craniofacial and PhA 
development. 
A long-held assumption about HDACs, including Hdac1, is that they are 
ubiquitously expressed. However, recent studies demonstrate that HDACs are 
expressed in tissue and temporal specific manner during development. Hdac7, a 
class II HDAC, is endothelial specific and loss results in vascular defects[318]. 
Hdac8, specifically expressed in fore and midbrain regions at E10 and E11.5, is 
critical for skull development[363]. Similarly, murine embryos show restricted, 
distinct, and non-overlapping Hdac1 mRNA expression areas between E10 and 




in the spinal cord of E10 murine embryos. Similarly, rhombic fossa expresses 
Hdac1 mRNA at E10, but not at E13, suggesting spatiotemporal regulation of 
Hdac1 expression during murine development. Hence, the expression pattern of 
Hdac1, at both the gene-level and protein-level, is crucial to understanding how 
this highly conserved class I HDAC functions during mammalian development. To 
date, there are no models or reports that use a genetic approach to evaluate the 
endogenous Hdac1 expression under the control of native Hdac1 promoter and 
enhancer elements at the earliest stages of neural crest development. Using the 
Hdac1LacZ knock-in allele (Figure 4.1A), we show that Hdac1 is broadly expressed 
in all embryonic lineages at E7.5, E8.5, and E9.5 (Figure 4.1B-D). Additionally, 
overlapping Hdac1LacZ and Hdac1 protein expression confirmed the specificity of 
the Hdac1LacZ knock-in allele. This allele will enable dissection of the 
spatiotemporally specific expression patterning of Hdac1 in development and 
disease. HDAC1 expression variance is important in a number of human diseases, 
including several cancers[346, 489, 490]. With this allele, the spatiotemporal expression 
dynamics of Hdac1 can be explored in mouse models of these diseases. 
Additionally, whether the expression pattern of Hdac1 changes later in 
development or beyond the neonatal period remains unknown and a topic for 
future investigation using the Hdac1LacZ knock-in allele. 
 Wnt1;1KO2KO embryos exhibited areas of extravascular pooling of blood in 
the cranial vesicles and primitive gut suggesting defective formation of NC derived 




staining intensity in developing craniofacial structures. Additionally, there was 
decreased LacZ staining intensity within the first and second PhAs and absent 
LacZ staining within the third PhA at both E9.5 and E10.5. At E9.5, the first PhA 
was significantly smaller in the double knockouts than its counterpart in controls. 
Despite the reduced intensity in the cranial and pharyngeal regions, there was no 
observed change in the craniocaudal migration of neural crest cells, seen by 
comparable LacZ staining patterns in the primitive gut and developing tail region. 
These results suggest that loss of Hdac1 and Hdac2 in the neural crest reduced 
the proliferation or increase apoptosis of neural crest cells after they migrate along 
the craniocaudal axis. Further morphologic evaluation identified that the 
developing network of cranial vesicles is abnormal in Wnt1;1KO2KO samples when 
compared to controls (Figure 4.3D). The telencephalic vesicle is misshapen, 
narrow, and exhibits a disconnect between its cranial and caudal components, 
reinforcing the observation of disrupted craniofacial development in these 
samples. Additionally, we were unable to locate a sixth pharyngeal arch or PhAA 
in Wnt1;1KO2KO embryos (Figure 4.3E). The remaining PhAs and their 
corresponding arteries were visualized in double knockout embryos and, despite 
being smaller than comparable structures in controls, have similar early pockets of 
α-smooth muscle actin staining suggesting that at least initial specification of these 
structures proceeded normally. Whether the sixth arch never forms, is so small it 
is unrecognizable, or forms and then regresses cannot be determined yet the result 




with the other frank craniofacial and pharyngeal abnormalities (mainly the atrophic 
first and second PhAAs) would lead to defective formation of the maxillary artery 
and stapedial artery and is a likely cause of the pooling blood observed at E11.5. 
Our findings demonstrate that Hdac1 and Hdac2 function within the neural crest to 
support craniofacial and PhA development necessary to sustain mammalian 
embryonic development past E11.5. 
 Reinforcing the idea that epigenetic homeostasis is critical to developing 
cell populations, a single allele of either Hdac1 or Hdac2 was able to rescue 
Wnt1;1KO2KO embryos to birth, but was not sufficient to sustain them much further. 
There are several other reports of either partial or complete rescue of an Hdac1 
and Hdac2 double knockout phenotype with the reintroduction of a single allele of 
either Hdac1 or Hdac2. In both the epidermis and in T-cells a single copy of Hdac1 
was sufficient to rescue (fully or partially) the double knockout phenotype[375, 385] 
while Hdac2 was not. In contrast, a single copy of Hdac2 was sufficient to rescue 
the Hdac1/2 double knockout phenotype in the brain[404] yet Hdac1 was unable to 
rescue. In addition, Hdac1 and Hdac2 redundantly regulate cardiac 
morphogenesis, neuron development, oligodendrocyte differentiation, 
adipogenesis, and skeletal muscle homeostasis[382, 394, 401, 470, 491]. These results 
suggest that Hdac1 and Hdac2 have a complex array of co-dependent, semi-
independent, and truly independent roles during development[342]. In this case, it 
appears that Hdac1 and Hdac2 are both able to partially rescue the double 




distension, cyanosis, pulmonary distress (demonstrated by increased work of 
breathing and intercostal retractions), or perinatal lethality (Table 4.1, Figure 
4.2O-Q). Interestingly, all examined neural-crest derived structures appeared 
normal including the palate (Figure 4.2R-T), cardiac outflow tract and thymus 
(Figure 4.2U-Z), aortic valve (Figure 4.2AA,AC,AE), pulmonic valve (Figure 
4.2AB,AD,AF), and peri-arterial morphology in the outflow tract (Figure 4.2AG-
AI). Hence, the dose-sensitive nature of Hdac1 and Hdac2 coupled with their 
potent ability to modulate progenitor cell behavior aligns them at a crossroads from 
which they may play a causal or contributory role in a variety of human congenital 
defects, including those arising from defective neural crest function and pharyngeal 
arch disruption. Work understanding the genetic basis of congenital defects in 
humans is only just now maturing and in the coming years we can expect to see a 
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CHAPTER V – Discussion and Future Directions 
 
 Although outcomes for infants born with congenital heart defects are 
improving, our understanding of the mechanisms governing normal and abnormal 
mammalian cardiac development are lacking[7]. During cardiogenesis, cardiac 
progenitor cells undergo ordered differentiation, proliferation, and migration to craft 
a mature four-chambered heart[16]. Increasingly, the importance of chromatin 
dynamics and histone modifications during cardiogenesis have been recognized. 
Recent studies highlight that mutation in, or pharmacologic inhibition of histone 
modifying enzymes are associated with congenital heart defects in humans[223, 227-
234]. This dissertation aimed to define the role of Hdac1 and Hdac2, two highly 
homologous class I histone deacetylases, in the first heart field, second heart field, 
and cardiac neural crest during early cardiac development. 
 Hdac1 and Hdac2 have a web of independent, redundant, and dose-
sensitive functions in normal physiology and development that have been 
elucidated through studies in humans, model organisms, and in vitro[275, 276, 342]. 
Although causal mutations in HDAC1 or HDAC2 have not been identified in human 
congenital syndromes, copy number variation at chromosomal locations 
containing HDAC1 (1p35) or HDAC2 (6q21-22) cause congenital defects, 
including cardiac defects[227, 228, 345]. Additionally, treatment with HDAC inhibitors, 
such as trichostatin A and valproic acid, increase the incidence of congenital heart 




role in the pathogenesis of congenital heart disease. Murine models illustrate 
Hdac1 and Hdac2 have independent and redundant roles in the neonatal and 
maturing heart. Hdac2-null mice are resistant to cardiac hypertrophy while Hdac2-
overexpressing mice are overly responsive to hypertrophic stimuli[357, 366]. 
Simultaneous deletion of Hdac1 and Hdac2 in mature cardiomyocytes causes 
lethality within two weeks of birth[382]. Despite this evidence, the roles of Hdac1 and 
Hdac2 in early cardiogenesis remain unexplored. 
Here we define three novel, spatiotemporally specific roles for Hdac1 and 
Hdac2 during cardiogenesis. Within the first heart field, Hdac1/Hdac2 redundantly 
facilitate bioenergetic maturation of early cardiomyocytes. Embryos lacking Hdac1 
and Hdac2 in the first heart field display abnormally thin myocardium, contractile 
network fragmentation, reduced mitochondrial mass, cytosolic lipid accumulation, 
and complete lethality shortly after E10.5. Hdac1 and Hdac2 cooperatively enforce 
canonical transcription of key metabolic genes by suppressing cryptic 
transcription. In the second heart field, Hdac1 and Hdac2 have distinct redundant 
and dose-sensitive functions. Specifically within the posterior second heart field, 
Hdac1 and Hdac2 cooperate to promote progenitor receptivity to coordinating 
signals from critical signaling hubs in a dose-sensitive manner. A single allele of 
Hdac1 or Hdac2 is unable to support outflow tract elongation, leading to persistent 
truncus arteriosus, interrupted aortic arch, ventricular septal defect, neonatal 
cyanosis, and perinatal lethality. Finally, within the cardiac neural crest, Hdac1 and 




Hdac2 causes severe craniofacial defects, incompetent craniofacial vasculature, 
and embryonic lethality around E11.5. Hdac1 and Hdac2 redundantly suppress 
cyclin-dependent kinase inhibitor expression, promoting progenitor cell 
proliferation. These findings demonstrate that Hdac1 and Hdac2 function to 
regulate diverse cell types and behaviors through distinct molecular mechanisms. 
Additionally, they expand our understanding of how Hdac1 and Hdac2 cooperate 
to regulate progenitor cell proliferation. Critically, these studies define a 
mechanism that reconciles the repressive mechanism of action of class I HDACs 
and their experimentally determined roles as transcriptional activators.  
 
Spatiotemporally Specific Functions of Hdac1 and Hdac2 
 
 Germline ablation of Hdac1 causes severe proliferation defects and early 
embryonic lethality, while germline deletion of Hdac2 can cause perinatal 
lethality[381, 382]. Consequently, tissue-specific knockouts are required to elucidate 
the roles of Hdac1 and Hdac2 beyond the earliest stages of development. 
Interestingly, no tissue-specific Hdac1 knockout has recapitulated the early 
lethality of Hdac1-null embryos. Tissue specific loss of Hdac1 in the cardiac 
crescent (Mesp1-Cre)[83], first heart field (Nkx2.5IRES-Cre)[427], second heart field 
(Isl1-Cre)[447], anterior second heart field (Mef2C-Cre)[150], neural crest (Wnt1-
Cre2), vascular progenitors (Tie2-Cre[100], Cdh5-Cre[492]), fibroblasts (Thy1-




or observable phenotypes (Appendix C). These results suggest, that beyond the 
earliest stages of embryogenesis Hdac2 can compensate for loss of Hdac1. 
Indeed, Hdac2 expression increases following ablation of Hdac1 and Hdac1 
expression increases following Hdac2 ablation[375, 376]. These results confirm, 
owing to their similarity and redundancy, both Hdac1 and Hdac2 must be 
manipulated to explore their tissue specific roles during development. Indeed, as 
described above, disruption both of Hdac1 and Hdac2 reveal novel, tissue-specific, 
redundant, and dose-sensitive functions of both genes.  
Combined ablation of Hdac1/Hdac2 does not necessarily cause a 
phenotype, suggesting that Hdac1 and Hdac2 have spatiotemporally specific 
functions. Preliminary analysis of mice lacking Hdac1/Hdac2 within fibroblasts (via 
Thy1-Cre) suggests that Hdac1 and Hdac2 are dispensable for fibroblasts 
development, maturation, and function (data not shown). Adding to the concept of 
spatiotemporally specificity for Hdac1 and Hdac2, phenotypes resulting from 
Hdac1/Hdac2 ablation are not necessarily lethal. Based on preliminary analysis of 
Hdac1/Hdac2 in smooth muscle and myocardium (via Tagln-Cre), mice lacking 
both Hdac1 and Hdac2 have hypertrophic septal myocardium at birth. Surprisingly, 
these mice exhibit no survival defects, suggesting that the degree of cardiac 
hypertrophy is below the threshold for causing damage (Appendix A). Here we 
show that, far from ablation invariably causing apoptosis, precocious 




Hdac1 and Hdac2 function through an array of spatiotemporally specific cellular 
and molecular mechanisms. 
Hdac1 and Hdac2 appear to have distinct spatiotemporal functions when 
compared to other class I HDACs, including Hdac3. Hdac1/Hdac2 are found 
primarily in the NuRD, Sin3, and Co-REST complexes while Hdac3 functions as a 
member of the N-CoR/SMRT complex, suggesting that they are functionally 
independent[283, 287, 291-298 302-305]. Additionally, Hdac3 diverged much earlier than 
Hdac1/Hdac2 during evolution, implying functional diversification[495, 496]. This is 
supported by the distinct and independent functions of Hdac1/Hdac2 and Hdac3. 
While Hdac1 and Hdac2 can compensate for paralog loss, Hdac3 is unable to 
rescue defects observed following ablation of Hdac1 and Hdac2[276]. Additionally, 
Hdac3 ablation does not phenocopy loss of Hdac1/Hdac2 in the first heart field, 
second heart field, and neural crest[358, 372, 390, 475]. Despite their differences, 
Hdac1/Hdac2 and Hdac3 both regulate murine cardiac metabolism. However, loss 
of Hdac1/Hdac2 disrupts the transition from anaerobic to aerobic metabolism 
during embryogenesis due to mitochondrial insufficiency while cardiac-specific 
ablation of Hdac3 inappropriately activates PPARα, inducing lipid accumulation 
and lethality within the first 4 months of life[359]. Consequently, while all Class I 
HDACs have similar structure, murine studies show distinct functional divergence 
between Hdac1/Hdac2 and Hdac3. 
To better understand the roles of Hdac1/Hdac2 in development and 




modulate normal and abnormal physiology in individual cell types and time points. 
Future studies in mice using tissue-specific constitutively active Cre-recombinase 
alleles, inducible Cre-recombinases, or emerging genome editing technology will 
be critical to elucidate and understand the functions of Hdac1 and Hdac2. 
 
HDACs and Control of Progenitor Proliferation 
 
Despite their intricacy and disparate functions, Hdac1 and Hdac2 have 
consistently been shown to oversee the balance of proliferation and 
differentiation[263, 278, 339, 356, 374, 376, 378, 381, 388, 450, 455, 497]. One of the areas where 
their oversight is best defined is in human malignancy[450]. Mutations of HDAC1 or 
HDAC2 are found in a variety of cancers including colorectal cancer, prostate 
cancer, ovarian cancer, gastric cancer, Hogdkin’s Lymphoma, and endometrial 
cancers[346-353]. Almost universally, these mutations increased proliferation by 
activating HDAC1 and HDAC2. The role of HDAC1 and HDAC2 in cancer is 
mirrored by their role in early embryogenesis and embryonic stem cells. Germline 
deletion of Hdac1 impairs proliferation through de-repression of cyclin dependent 
kinase inhibitors, including Cdkn1a[381, 455]. Loss of either Hdac1 or Hdac2 alone 
does not alter embryonic stem cell proliferation. However, loss of both enhances 
differentiation at the cost of proliferation[374, 378, 498]. 
Here we demonstrate that Hdac1 and Hdac2 redundantly regulate 




Hdac1 and Hdac2 suppress Cdkn1a and Cdkn1b. Ablation of Hdac1/Hdac2 
reduces neural crest proliferation, disrupting patterning of the craniofacial 
vasculature. Here, Hdac1 and Hdac2 function similarly to their roles in early murine 
development, suggesting this may be a conserved role of the highly related class 
I HDACs. Additionally, Hdac1/Hdac2 control of neural crest proliferation has 
interesting implications for the 1p35 and 6q21-22 copy number variations 
syndromes because ‘neural crest’ defects, including syndromic facies and 
cardiovascular anomalies, are typically present in these syndromes[227, 228, 345]. 
Specifically, HDAC1 or HDAC2 might be central to their pathogenesis through 
limiting proliferation, in the case of microdeletion, or misregulated proliferation, in 
the case of microduplication. Therefore, it is important continue studying how 
Hdac1 and Hdac2 regulate proliferation in development and malignancy. The 
specific epigenetic mechanism by which Hdac1 and Hdac2 repress cyclin 
dependent kinase inhibitors remains undefined and is an important target of future 
investigations. Critical questions include whether Hdac1/Hdac2 regulate 
proliferation in a deacetylase dependent or independent manner and how 
Hdac1/Hdac2 are specifically targeted to regulate cyclin dependent kinase 
inhibitors in vivo. 
 





 Consistent with previously studies, we demonstrate Hdac1 and Hdac2 have 
a complex array of dose-sensitive and overlapping functions. It is thought Hdac2 
arose due to a gene duplication event relatively recently in evolution and therefore 
has limited functional divergence from Hdac1[495, 496]. This is supported by 
redundancy demonstrated by singular Hdac1 or Hdac2 knockouts. Following loss 
of its paralog, compensatory overexpression of Hdac1 or Hdac2 is observed. 
Interestingly, a single allele of Hdac1 or Hdac2 is unable to moderate a similar 
overexpression following paralog ablation, suggesting that this is critical for 
compensation. In certain contexts, a single allele of Hdac1 or Hdac2 cannot rescue 
the double knockout phenotype, suggesting that certain biological functions are 
sensitive to the dose of Hdac1/Hdac1. Additionally, there are contexts where a 
single allele of Hdac1 (but not Hdac2) or Hdac2 (but not Hdac1) rescues double 
knockout defects, indicating specific biologic processes prefer one paralog over 
the other[375, 376, 385, 404]. Here, we demonstrate a single allele of Hdac1 or Hdac2 in 
the neural crest and posterior second heart field partially rescues the double 
knockout phenotype, but by doing so exposes additional dose-sensitive 
processes. 
The mechanisms by which Hdac1/Hdac2 dose affect biology remains 
undefined. There is growing evidence that Hdac1 and Hdac2 preferentially and 
cooperatively regulate distinct developmental processes. Hdac1/2 containing 
complexes have a catalytic core containing either Hdac1/Hdac1 or Hdac2/Hdac2 




appear to have distinct molecular functions, targets, and regulatory potential. 
Indeed, a large portion of Hdac1 is dissociated from Hdac2 and likewise a large 
percentage of Hdac2 is dissociated from Hdac1, suggesting that Hdac1/Hdac1, 
Hdac1/Hdac2, and Hdac2/Hdac2 catalytic cores have different substrate 
affinities[383]. Although not extensively discussed here, preliminary observations 
suggest that Tie2;1KO2Het embryos exhibit complete embryonic lethality while their 
Tie2;1Het2KO counterparts are born in expected mendelian ratios, providing a 
system to study these different interactions (Appendix B). Combined with the 
additional potential diversity arising from permutations of other subcomponents of 
Sin3, NuRD, and CoREST, HDAC1/HDAC2 complexes are well-positioned to 
mediated a wide array of functions in diverse progenitor populations and mature 
tissues. Future experiments targeted at elucidating the different sensitivity, 
specificity, and affinity of Hdac1 and Hdac2 complexes across the genome are 
critical for understanding Hdac1/Hdac2 dose-sensitivity and continuing to define 
their critical roles in development and beyond. 
 
Repressors as Activators 
 
 Owing to their repressive mechanism of action, class I HDACs were 
originally defined as transcriptional repressors[277]. This association also drove the 
definition of Hdac1/Hdac2 containing compounds as co-repressor complexes[445, 
499]. Despite this, growing experimental evidence suggests that class I HDACs play 




null tissues reveals a mix of up- and down-regulated transcripts (Chapter 2)[275, 374, 
378, 407]. While many of these changes are secondary effects, it is impossible to 
discard all of these changes as secondary. If Hdac1/Hdac2 were solely repressive 
repression, they would likely reside on inactive loci. Instead, genome-wide studies 
revealed that Hdac1/hdac2 preferentially associate with the coding regions actively 
transcribed loci Interestingly, the Saccharomyces cerevisiae class I HDAC, 
Rpd3promotes transcription through the well-defined Rpd3(S)/Set2 axis[409-415]. In 
this axis, Set2 deposits H3K36 trimethylation in the wake of elongating RNA 
polymerase II, recruiting Rprd3(S) via Eaf2’s chromodomain to actively transcribed 
loci, and directing histone deacetylation at actively transcribed genes. Critically, 
deacetylation of actively transcribed loci reforms basal chromatin conformations, 
enabling successive rounds of transcription[411, 499]. Indeed, disruption of this axis 
via HDAC or DNA methyltransferase inhibition reduces transcriptional efficiency, 
increases chromatin accessibility, and induces cryptic transcription[437]. These data 
suggest that, much like condensed chromatin inhibits transcription, excessively 
permissive chromatin inappropriately exposes intragenic sequences that serve as 
transcription start sites for non-productive mRNA synthesis[410, 411, 437, 440, 500]. 
Despite results indicating that Hdac1 and Hdac2 promote transcription during 
mammalian development, no mechanism has been defined. 
 Here we provide the first evidence that Hdac1 and Hdac2 promote ordered 
transcription through suppressing cryptic transcription during vertebrate 




the metabolic maturation of cardiomyocytes by deacetylating of histones within 
actively transcribed loci, restoring basal chromatin structure, and suppressing 
cryptic transcription. Our results reconcile the repressive mechanism of Class I 
HDACs and their experimentally established roles as transcriptional activators. 
Hdac1 and Hdac2 cooperate to maintain epigenomic homeostasis, inhibiting 
cryptic transcription and promoting canonical transcription. This suggests that 
rather than functioning as a binary regulator of gene expression, chromatin 
carefully balances transcriptional activation and silencing during mammalian 
cardiogenesis. The evidence that Hdac1/Hdac2 cooperatively regulate cryptic 
transcription during vertebrate development opens numerous avenues for future 
investigation, including: How broadly applicable is this mechanism? And, do other 




 This thesis describes an array of spatiotemporally specific, redundant, and 
dose-dependent functions for Hdac1 and Hdac2 in early cardiac progenitor cells. 
These findings build upon previous work, demonstrating the wide-ranging and 
multifaceted roles of Hdac1/Hdac2 with critical implications for human 





 Beyond continuing to explore the phenotypes and mechanisms described 
above, future directions broadly include: investigating the roles of Hdac1 and 
Hdac2 in related and novel cardiac progenitor cell populations, testing how 
Hdac1/Hdac2 may cooperatively regulate adult cardiac physiology, and probing 
the role of Hdac1/2 in progenitors versus differentiated cells. Here we define roles 
for Hdac1 and Hdac2 in the first heart field, second heart field, anterior second 
heart field, and cardiac neural crest. Preliminary evidence suggests that 
Hdac1/Hdac2 have an undefined role in vascular progenitors and the function of 
Hdac1/Hdac2 in epicardial progenitors remains unexplored. Additionally, whether 
Hdac1/Hdac2 are required differentiated cardiac lineages has not been thoroughly 
explored. Using both established techniques and new genomic editing tools, future 
studies on how Hdac1/Hdac2 interact to control the differentiation and function of 
both progenitors and mature cardiac lineages will help to elucidate mechanisms 
driving normal and abnormal cardiac physiology. Finally, the studies described 
above utilized active Cre-recombinases. Employing inducible Cre-recombinases 
to explore additional spatiotemporal roles for Hdac1 and Hdac2 in the mammalian 
cardiovascular system is an important area of future investigation. Defining the 
spatiotemporally specific roles of Hdac1/Hdac2 in both cardiac progenitors and 
differentiated cardiac lineages will provide critical insight into the role of epigenetics 
during cardiogenesis and have direct implications for understanding and treating 




 One of the most important questions raised by this thesis is: What 
mechanisms drive the redundancy of Hdac1/Hdac2 during mammalian 
development? Examining how genome-wide residency of Hdac1/Hdac2 varies 
with paralog loss is an important step towards understanding redundant and dose-
sensitive roles for Hdac1 and Hdac1. Additionally, characterizing the different 
developmental function of Sin3/NuRD/CoREST complex permutations may 
illuminate the different regulatory networks governing Hdac1/Hdac2 redundancy, 
independence, and dose-sensitivity. Using available biological, biochemical, and 
computational tools to carefully delineate the distinct interactions of each 
independent Hdac1/Hdac2 containing complex is critical to understanding their 
diverse roles in physiology and pathology. 
Fully understanding the impact of Hdac1 and Hdac2 during mammalian 
development requires systematically exploring all potential functions of 
Hdac1/Hdac2. To guide this investigation, it is helpful to consider four major 
domains of Hdac1/Hdac2 mechanisms. The first are both deacetylase and 
chromatin-dependent interactions. These interactions encompass enzymatic roles 
for Hdac1 and Hdac2 as part of their regulatory complexes. The second group of 
interactions are deacetylase-dependent but chromatin-independent while the third 
contains deacetylase-independent, chromatin dependent interactions. Other class 
I HDACs regulate transcription through deacetylating non-histone substrates or 
mediating transcription factor binding[372, 373]. Whether Hdac1 and Hdac2 regulate 




contains deacetylase-independent and chromatin-independent interactions. To 
date, no study has demonstrated a role for Hdac1 or Hdac2 that is both 
independent of their regulatory complexes and the deacetylase domain, however 
it is important to consider all potential interactions when designing experiments. 
Limited in vivo experiments demonstrated that the deacetylase activity of Hdac1 
and Hdac2 is required during mammalian development, however the 
spatiotemporally specific and dose-sensitive requirements remain undefined[406]. 
Establishing murine models of deacetylase-inactive, chromatin-inactive, and 
combined deacetylase/chromatin-independent Hdac1/Hdac2 is critical to exploring 
these interactions. Deacetylase-inactive Hdac1 (Hdac1H141A) and Hdac2 
(Hdac2H142A) mutants are established and some of their functions have been 
investigated, yet their role in cardiac development remains unexplored[406]. 
Modulating Hdac1/Hdac2 interacting with chromatin will focus on the core Hdac1/2 
containing complexes Sin3, NuRD, and CoREST. As Hdac1 and Hdac2 have no 
intrinsic DNA binding ability, abolishing interaction with these complexes should 
isolate them from DNA, thus enabling the study of their chromatin-independent 
interactions. Additionally, removing the ability of Hdac1 and Hdac2 to assemble 
into homo- or hetero-dimers, potentially through altering their HDAC interaction 
domain, will provide invaluable insight into the dynamics of these critical class I 
HDACs. By using this framework to explore Hdac1/Hdac2 interactions, we can 




 Finally, we define a novel mechanism by which Hdac1 and Hdac2 
cooperate to promote ordered transcription of critical metabolic genes by 
suppressing cryptic transcriptional activity. Several major questions about 
Hdac1/Hdac2, cardiac metabolism, and cryptic transcription remain: Are 
Hdac1/Hdac2 required to maintain expression of oxidative cardiac metabolic gene 
programs throughout development and beyond? How does cryptic transcription 
influence local chromatin regulation and gene expression? How broadly applicable 
is this method of gene regulation in mammalian biology? 
The embryonic heart generates energy through glycolysis while the mature 
heart derives energy from fatty acid β-oxidation, indicating that a transition must 
occur during development[417]. Pathologic reactivation of fetal cardiac metabolism 
in myocardial ischemia or heart failure increases usage of carbohydrate fuels, 
perpetuating cardiovascular damage[33, 221, 420-422]. Reactivation of this gene 
program suggests it is epigenetically regulated[221, 422]. We demonstrate the 
developmental transition from early anaerobic metabolism to mature oxidative 
metabolism depends on Hdac1 and Hdac2. However, the role of Hdac1/Hdac2 in 
reactivation of this program is unknown. Exploring cardiac expression levels of 
HDAC1 and HDAC2 in human populations with reactivated fetal metabolism would 
help elucidate their role in this process. Additionally, genetic ablation of Hdac1 and 
Hdac2 in murine models of myocardial infarction or heart failure will help define 




cardiac metabolism, it would present an important therapeutic target to address 
this under treated part of cardiac pathology. 
While our data defines local changes in histone modifications following 
reactivation of cryptic transcription in Hdac1/Hdac2-null cardiomyocytes, the 
impact on global chromatin conformations are not explored. There is a growing 
appreciation for the impact of chromatin organization, rather than just histone 
modifications, in regulating gene expression. Specifically, the recent discovery of 
CTCF-mediated topologically associating domains and other organization-based 
methods of gene regulation have expanded the study of epigenetics beyond simply 
presence or absence of chromatin modifications[256, 257]. Studies have 
demonstrated that pharmacologic inhibition of HDACs results in widespread 
changes in transcript expression, suggesting corollary widespread epigenetic 
changes[437]. Therefore, it is important to characterize how loss of Hdac1/Hdac2 
alters chromatin conformation and gene expression during cardiac development. 
Specifically, defining organizational changes that modulate cryptic transcription 
using ATAC-Seq and chromosome conformation capture (Hi-C) in Hdac1/Hdac2-
null cardiomyocytes will help define the mechanisms regulating ordered 
transcription during cardiogenesis. Elucidating how Hdac1 and Hdac2 regulate 
local and global chromatin architecture during cardiac development will provide an 
important window into how chromatin can influence physiology and disease. 
Here we define a novel, albeit specific, role for Hdac1 and Hdac2 in 




mechanism reconciles experimentally defined roles of HDACs as transcriptional 
activators with their repressive mechanism of action. Perhaps the most natural 
extension of this work is to investigate whether this mechanism drives HDAC-
dependent transcriptional activation more broadly. First, it will be important to 
define whether Hdac1 and Hdac2 globally regulate cryptic transcription in E10.5 
cardiomyocytes. Preliminary evidence presented above suggests that this is the 
case, however this analysis can be supported and extended by globally defining 
transcription start sites by CAGE or GRO-Seq. Correlating these results with 
transcriptome analysis will help to delineate if Hdac1/Hdac2 mediated suppression 
of cryptic transcription regulates transcriptional activation more broadly within 
developing cardiomyocytes. Beyond early cardiac development, investigating 
whether Hdac1/Hdac2 control cryptic transcription in other developmental contexts 
will help define the broadly applicability of this mechanism. If Hdac1/Hdac2 broadly 
regulate cryptic transcription, this will define a highly conserved function of HDACs 
and serve as a critical foundation for understanding the relationship between 







 Broadly, the work presented here advances our understanding of Class I 
histone deacetylases, specifically Hdac1 and Hdac2, during early mammalian 
cardiogenesis. We demonstrate roles for Hdac1 and Hdac2 in multiple early 
cardiac progenitor populations with implications for a range of developmental 
disorders. Hdac1 and Hdac2 cooperate to regulate neural crest proliferation, 
potentially contributing to the pathogenesis of a multitude of neural-crest derived 
disorders. Additionally, we show that Hdac1 and Hdac2 are required for proper 
septation of the mammalian outflow tract, opening new avenues of investigation to 
better understand and treat congenital outflow tract anomalies. Finally, we 
describe that Hdac1 and Hdac2 regulate early cardiac bioenergetics and establish 
a novel mechanism that potentially alters the framework for understanding 
Hdac1/Hdac2 interactions during development and disease. Further studies with a 
focus on understanding the specific dynamics of Hdac1/Hdac2 are required to 
continue defining the independent, redundant, and dose-sensitive roles of Hdac1 
and Hdac2 in cardiogenesis and beyond. Ongoing study of Hdac1 and Hdac2 will 
provide insights into their critical roles in mammalian development and further 




APPENDIX A: Loss of Hdac1 and Hdac2 in myocardium and smooth muscle 
causes septal and valvular hypertrophy at birth 
 Smooth muscle cells are an important component of the mammalian 
vasculature[14]. Derived from the first heart field, second heart field, and cardiac 
neural crest, smooth muscle resides in the walls of the coronary vasculature and 
mammalian outflow tract[51]. Critically, vascular smooth muscle deposition in the 
aorta and pulmonary artery is required to support the systolic pressure generated 
while perfusing the mature vasculature. Class I HDACs have demonstrated roles 
in cardiomyocytes, yet their roles in other end cardiac lineages remains 
unexplored[276]. To investigate the role of epigenetics, smooth muscle progenitor 
cells, and mammalian outflow tract development, we genetically ablated Hdac1 
and Hdac2 using Tagln-Cre, a transgenic Cre-recombinase under the promoter of 
smooth muscle protein 22-alpha (Sm22α) that is robust expressed in smooth 
muscle with some expression in myocardium[494]. We recovered Tagln-
Cre;Hdac1F/F Hdac2F/F mice in expected Mendelian ratios at birth (Table A.1). 
Hearts from Tagln-Cre;Hdac1F/F Hdac2F/F mice were comparable to hearts from 
Hdac1F/F Hdac2F/F mice at P0 (Figure A.1). Both Hdac1 and Hdac2 staining was 
decreased within the myocardium (Figure A.2) and outflow tract smooth muscle 
(data not shown), consistent with efficient recombination by Tagln-Cre. Preliminary 
results suggest that loss of Hdac1/Hdac2 in smooth muscle and myocardium 
results in thickening of the interventricular septum and aortic valve leaflets at birth 




 Observed (Expected) 
Genotype P0 
Hdac1F/F, Hdac2F/+ 11 (9.75) 
Hdac1F/F, Hdac2F/F 14 (9.75) 
Tagln-Cre; Hdac1F/F, Hdac2F/+ 8 (9.75) 
Tagln-Cre; Hdac1F/F, Hdac2F/F 6 (9.75) 
Total (p value): 39 (p=0.287) 
 
Table A.1 - Genotypes of Tagln-Cre samples at birth. Tagln-Cre; Hdac1F/F; 
Hdac2F/+ mice were crossed with Hdac1F/F; Hdac2F/F mice and samples were 
collected at birth. 
 
Figure A.1 - Tagln-Cre; Hdac1F/F Hdac2F/F hearts appear normal at birth. Gross 
images of dissected and isolated P0 Hdac1F/F Hdac2f/F and Tagln-Cre;Hdac1F/F 
Hdac2F/F hearts. RA, right atrium; LA, left atrium; RV, right ventricle; LV, left 





Figure A.2 - Immunostaining reveals loss of Hdac1 and Hdac2 in Tagln-Cre; 
Hdac1F/F Hdac2F/F hearts at birth. Hdac1 immunostaining (brown, top) or Hdac2 
immunostaining (brown, bottom) on Hdac1F/F Hdac2F/F (left) or Tagln-Cre; Hdac1F/F 






Figure A.3 - Loss of Hdac1 and Hdac2 by Tagln-Cre leads to a thickened 
aortic valve and interventricular septum at birth. Hematoxylin (pink) and Eosin 
(purple) stained frontal sections of Hdac1F/F Hdac2F/F and Tagln-Cre;Hdac1F/F 
Hdac2F/F hearts at the level of the pulmonic valve (top) or aortic valve (bottom). 
RA, right atrium; LA left atrium; RV right ventricle; LV, left ventricle; IVS, 
interventricular septum; AO, aorta; AV, aortic valve; PA, pulmonary artery; PV, 





Figure A.4 - Tagln-Cre;Hdac1F/F Hdac2F/F heats have a thickened 
interventricular septum but normal left ventricle at P0. Quantification of 
interventricular septum (IVS, left) or left ventricle (LV) thickness at 3 different levels 
in Hdac1F/F Hdac2F/F (black) and Tagln-Cre;Hdac1F/F Hdac2F/F (gray) across at 





Appendix B: Loss of Hdac1/Hdac2 in vascular progenitors has timing-
dependent effects on survival 
The mammalian vascular system consists of centralized pump, the heart, 
and a hierarchical distribution network lined by endothelium: the arteries, veins, 
and lymphatic vessels[14]. During development, vascular progenitor cells 
differentiate from the mesoderm and pattern a primitive vasculature through a 
complex process termed vasculogenesis. Recent evidence from our lab defined 
that the class I HDAC Hdac3 plays a critical role in vascular development, 
specifically the development and maintenance of blood-lymph separation[373]. 
Despite this evidence, the roles of other class I HDACs, specifically Hdac1 and 
Hdac2, in vasculogenesis are undefined. To investigate the role of Hdac1/Hdac2 
in vascular development, we genetically ablated them in vascular progenitor cell 
using Tie2-Cre[100] and Cdh5-Cre[492]. Although evidence is preliminary, we 
recovered Cdh5-Cre; Hdac1F/F Hdac2F/F mice at birth in expected mendelian ratios, 
suggesting that Hdac1 and Hdac2 are dispensable in the Cdh5-Cre cell lineage for 
embryogenesis (Table B.1). With a different breeding strategy, we observed that 
Cdh5-Cre; Hdac1F/F Hdac2F/F mice were born in a lower than expected ratio, 
indicating further investigation is required (Table B.2). Additionally, preliminary 
results suggest that Hdac1/Hdac2 have redundant and dose-sensitive functions in 
vascular progenitors, as we didn’t recover Tie2-Cre; Hdac1F/F Hdac2F/F or Tie2-
Cre; Hdac1F/F Hdac2F/+ pups at birth (Table B.3). Further experiments are required 




 Observed (Expected) 
Genotype P0 
Hdac1F/F, Hdac2F/+ 5 (6.875) 
Hdac1F/+, Hdac2F/F 9 (6.875) 
Hdac1F/F, Hdac2F/+ 9 (6.875) 
Hdac1F/F, Hdac2F/F 7 (6.875) 
Cdh5-Cre; Hdac1F/+, Hdac2F/+ 2 (6.875) 
Cdh5-Cre; Hdac1F/+, Hdac2F/F 8 (6.875) 
Cdh5-Cre; Hdac1F/F, Hdac2F/+ 14 (6.875) 
Cdh5-Cre; Hdac1F/F, Hdac2F/F 6 (6.875) 
Total (p value): 55 (p=0.012) 
 
Table B.1 - Genotypes of samples lacking Hdac1/Hdac2 in endothelial cells, 
collected at birth. Cdh5-Cre; Hdac1F/+; Hdac2F/+ mice were crossed with 
Hdac1F/F; Hdac2F/F mice and samples were collected at birth. 
 
 Observed (Expected) 
Genotype P0 
Hdac1F/F, Hdac2F/+ 12 (9.75) 
Hdac1F/F, Hdac2F/F 15 (9.75) 
Cdh5-Cre; Hdac1F/F, Hdac2F/+ 10 (9.75) 
Cdh5-Cre; Hdac1F/F, Hdac2F/F 2 (9.75) 
Total (p value): 39 (p=0.023) 
 
Table B.2 - Genotypes of samples lacking Hdac1/Hdac2 in endothelial cells, 
collected at birth. Cdh5-Cre; Hdac1F/F; Hdac2F/+ mice were crossed with 






 Observed (Expected) 
Genotype P0 E9.5 
Hdac1F/F, Hdac2F/+ 13 (8) 5 (3) 
Hdac1F/+, Hdac2F/F 8 (8) 1 (3) 
Hdac1F/F, Hdac2F/+ 6 (8) 3 (3) 
Hdac1F/F, Hdac2F/F 16 (8) 4 (3) 
Tie2-Cre; Hdac1F/+, Hdac2F/+ 11 (8) 4 (3) 
Tie2-Cre; Hdac1F/+, Hdac2F/F 10 (8) 1 (3) 
Tie2-Cre; Hdac1F/F, Hdac2F/+ 0 (8) 4 (3) 
Tie2-Cre; Hdac1F/F, Hdac2F/F 0 (8) 2 (3) 
Total (p value): 64 (p<0.001) 24 (p=0.619) 
 
Table B.3 - Genotypes of samples lacking Hdac1/Hdac2 in vascular 
progenitors, collected at various developmental stages. Tie2-Cre; Hdac1F/+; 
Hdac2F/+ mice were crossed with Hdac1F/F; Hdac2F/F mice and samples were 





Appendix C: Loss of Hdac1 in cardiac progenitor populations does not 
affect survival 
Germline ablation of Hdac1 results in complete embryonic lethality early in 
development due to severe proliferation defects[382, 387, 455]. It has been repeatedly 
claimed that no spatiotemporally specific knockout of Hdac1 has been described 
with similar lethality, suggesting that Hdac2 can fully compensate for Hdac1 
beyond the earliest stages of mammalian development[275, 276, 342]. Unfortunately, 
experimental data to support this conclusion is limited. To explore and verify these 
claims, we genetically ablated Hdac1 in a variety of cell lineages. Specifically, we 
ablated Hdac1 in mesodermal progenitors (Mesp1-Cre, Table C.1)[83], the first 
heart field (Nkx2.5IRES-Cre, Table C.2)[427] the second heart field (Isl1-Cre, Table 
C.3; Mef2C-Cre, Table C.4)[150, 447], neural crest progenitor cells (Wnt1-Cre2, 
Table C.5)[472], fibroblasts (Thy1-Cre, Table C.6), and vascular progenitor cells 
(Tie2-Cre, Table C.7; Cdh5-Cre, Table C.8)[100, 492] and collected pups at birth. 
Consistent with previous reports, we did not observe any survival defects following 
ablation of Hdac1 in any of these lineages. Overall, these results provide evidence 
to support previous literature claims that Hdac1 and Hdac2 function redundantly 





 Observed (Expected) 
Genotype P0 
Hdac1+/+ 23 (16) 
Hdac1F/+ 30 (32) 
Hdac1F/F 14 (16) 
MesP1-Cre; Hdac1+/+ 22 (16) 
MesP1-Cre; Hdac1F/+ 29 (32) 
MesP1-Cre; Hdac1F/F 10 (16) 
Total (p value): 128 (p=0.145) 
 
Table C.1 - Genotypes of samples lacking Hdac1 in the cardiogenic 
mesoderm, collected at birth. MesP1-Cre; Hdac1F/+ mice were crossed with 
Hdac1F/+ mice and samples were collected at birth. 
 
 Observed (Expected) 
Genotype P0 
Hdac1F/+ 10 (7.5) 
Hdac1F/F 4 (7.5) 
Nkx2.5IRES-Cre; Hdac1F/+ 11 (7.5) 
Nkx2.5IRES-Cre; Hdac1F/F 5 (7.5) 
Total (p value): 30 (p=0.177) 
 
Table C.2 - Genotypes of samples lacking Hdac1 in the first heart field, 
collected at birth. Nkx2.5IRES-Cre; Hdac1F/+ mice were crossed with Hdac1F/F mice 
and samples were collected at birth. 
 
 Observed (Expected) 
Genotype P0 
Hdac1+/+ 11 (11.25) 
Hdac1F/+ 32 (22.5) 
Hdac1F/F 13 (11.25) 
Isl1-Cre; Hdac1+/+ 7 (11.25) 
Isl1-Cre; Hdac1F/+ 21 (22.5) 
Isl1-Cre; Hdac1F/F 6 (11.25) 
Total (p value): 90 (p=0.133) 
 
Table C.3 - Genotypes of samples lacking Hdac1 in the second heart field, 
collected at birth. Isl1-Cre; Hdac1F/+ mice were crossed with Hdac1F/+ mice and 






 Observed (Expected) 
Genotype P0 
Hdac1F/+ 7 (8.5) 
Hdac1F/F 9 (8.5) 
Mef2C-Cre; Hdac1F/+ 8 (8.5) 
Mef2C-Cre; Hdac1F/F 10 (8.5) 
Total (p value): 34 (p=0.899) 
 
Table C.4 - Genotypes of samples lacking Hdac1 in the anterior second heart 
field, collected at birth. Mef2C-Cre; Hdac1F/+ mice were crossed with Hdac1F/F 
mice and samples were collected at birth. 
 
 Observed (Expected) 
Genotype P0 
Hdac1F/+ 47 (40) 
Hdac1F/F 36 (40) 
Wnt1-Cre2; Hdac1F/+ 45 (40) 
Wnt1-Cre2; Hdac1F/F 32 (40) 
Total (p value): 160 (p=0.278) 
 
Table C.5 - Genotypes of samples lacking Hdac1 in neural crest progenitors, 
collected at birth. Wnt1-Cre2; Hdac1F/+ mice were crossed with Hdac1F/F mice 
and samples were collected at birth. 
 
 Observed (Expected) 
Genotype P0 
Hdac1F/+ 8 (5) 
Hdac1F/F 6 (5) 
Thy1-Cre; Hdac1F/+ 3 (5) 
Thy1-Cre; Hdac1F/F 3 (5) 
Total (p value): 20 (p=0.308) 
 
Table C.6 - Genotypes of samples lacking Hdac1 in fibroblasts, collected at 
birth. Thy1-Cre; Hdac1F/+ mice were crossed with Hdac1F/F mice and samples 




 Observed (Expected) 
Genotype P0 
Hdac1F/+ 13 (9.5) 
Hdac1F/F 8 (9.5) 
Tie2-Cre; Hdac1F/+ 7 (9.5) 
Tie2-Cre; Hdac1F/F 10 (9.5) 
Total (p value): 38 (p=0.530) 
 
Table C.7 - Genotypes of samples lacking Hdac1 in vascular progenitors, 
collected at birth. Tie2-Cre; Hdac1F/+ mice were crossed with Hdac1F/F mice and 
samples were collected at birth. 
 
 Observed (Expected) 
Genotype P0 
Hdac1F/+ 8 (8) 
Hdac1F/F 8 (8) 
Cdh5-Cre; Hdac1F/+ 8 (8) 
Cdh5-Cre; Hdac1F/F 8 (8) 
Total (p value): 32 (p=1.00) 
 
Table C.8 - Genotypes of samples lacking Hdac1 in endothelial cells, 
collected at birth. Cdh5-Cre; Hdac1F/+ mice were crossed with Hdac1F/F mice and 
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